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IN VITRO ANALYSIS OF POTENTIAL ANTICANCER EFFECTS ASSOCIATED 
WITH WATERCRESS  
 
by Breeze Erin Cavell 
 
Epidemiological studies indicate that there is an inverse relationship between 
consumption of cruciferous vegetables and risk of cancer. As a result there is much 
interest in understanding the anticancer potential not only of cruciferous vegetables 
themselves but also of the key phytochemicals contained in them. This project focuses 
on the potential anticancer properties of watercress, a cruciferous vegetable which is 
cultivated around the world and eaten raw as a salad vegetable as well as in cooked 
dishes. Watercress is the most abundant source of gluconasturtiin, a precursor to the 
phytochemical phenethyl isothiocyanate (PEITC), and is also a rich source of indole-3-
carbinol (I3C) and quercetin. 
This project addressed the hypothesis that the in vitro anticancer activity of 
watercress can be enhanced by altering the growth environment. To investigate this it 
was necessary to develop assays that can be used to assess the in vitro anticancer 
activity of watercress-derived compounds, to explore the mechanisms by which PEITC 
exhibits its anticancer effects, and to determine potential effects of altered growth 
conditions on in vitro anticancer properties. 
The activity of watercress-derived phytochemicals was analysed in a series of 
in vitro assays. Based on these results, inhibition of MCF7 cell growth and activation of 
Nrf2-dependent transcription were selected as potential assays for subsequent 
analysis of watercress extracts. Mechanistic studies demonstrated that PEITC inhibited 
the transcriptional activity of hypoxia inducible factor (HIF), a key positive regulator of 
angiogenesis in malignant cells. Inhibition of HIF function was associated with 
inhibition of mammalian target of rapamycin complex 1 (mTORC1) activity and 
decreased HIF1α mRNA translation, and was dependent on the presence of the 
mTORC1 regulator, tuberous sclerosis complex 2 (TSC2). I also demonstrated that, in 
addition to effects on HIF1α mRNA translation, PEITC inhibited general protein 
synthesis and modulated two other key regulators of translation, eukaryotic initiation 
factor 2 (eIF2) and eukaryotic elongation factor 2 (eEF2). In proof-of-principle 
experiments, I demonstrated that growth inhibition and Nrf2 activation assays were 
suitable for the analysis of crude watercress extracts and that a natural variety of “red” 
watercress displayed approximately 10-fold more potent in vitro anticancer activity than 
standard, commercial “green” watercress. However, in a series of field trials, 
modulation of time of harvest, water availability or sulfur fertilisation did not alter the in 
vitro effects of watercress extracts in growth inhibition/Nrf2 activation assays. 
In conclusion, this study suggests that, rather than altering environmental 
factors, selective breeding might be a better approach to increase the in vitro 
anticancer activity of watercress. Moreover, my findings have increased our 
understanding of the mechanisms underlying the anticancer activity of PEITC, 
uncovering a novel role for PEITC in inhibiting HIF1α and total protein synthesis, and 
identifying several key regulators of these processes that are modulated by PEITC.    
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PDK1    Phosphoinositide dependent kinase 1  
PEITC   Phenethyl isothiocyanate 
PERK    PKR-like endoplasmic reticulum kinase 
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PHD    Proyl hydroxylase domain  
PI3K   Phosphatidylinositol  3-kinase 
PIP2     Phosphatidylinositol (4,5)-bisphosphate 
PIP3     Phosphatidylinositol (3,4,5)-trisphosphate 
PKR     Protein kinase RNA-dependent 
PR   Progesterone  receptor   
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Qn   Quercetin 
QTL    Quantitative trait locus 
Raptor   Regulatory associated protein of mTOR 
REDD1  Regulated in development and DNA damage response 1    
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ROS    Reactive oxygen species 
RTK    Receptor tyrosine kinase  
S6K   S6  kinase 
SAHA    Suberoylanilide hydroxamic acid 
SD   Standard  deviation 
SFN   Sulforaphane 
SOD   Superoxide  dismutase   
tRNA   Transfer  RNA 
TSA   Trichostatin  A 
TSC1/2  Tuberous sclerosis complex 1/2  
UPR    Unfolded protein response 
VEGFA  Vascular endothelial growth factor A  
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1.1  Overview of introduction 
 
The work described in this thesis was performed as part of an Industrial CASE 
studentship with Vitacress Salad Leaves Ltd, a major grower of watercress in the UK.  
Although the potential health benefits of consumption of a diet rich in watercress and 
other cruciferous vegetables remain unproven, extensive data demonstrate that 
aqueous extracts of watercress, as well as its key phytochemical constituents, inhibit 
the growth of human cancer cells in vitro and in experimental animals. The primary 
goal of the project was to investigate molecular mechanisms by which watercress 
extracts/phytochemicals inhibited cancer cell growth in vitro. The secondary goal was 
to use this knowledge to investigate potential enhancement of the in vitro anticancer 
effects of watercress through manipulation of the crop. The project focused on breast 
cancer cell lines as a well validated model to investigate effects on human cancer 
cells. 
 
In this introduction, an overview of the cancer process is provided before the 
epidemiology and characterisation of human breast cancer is described. Some 
molecules and pathways that contribute to breast cancer development and 
progression, and are potential targets for modulation by watercress compounds, 
including histone deacetylases (HDACs), hypoxia inducible factor (HIF), mammalian 
target of rapamycin (mTOR) and the phosphatidylinositol 3-kinase (PI3K)/Akt and 
mitogen activated protein kinase (MAPK) pathways, are then described. A background 
on the cultivation of watercress in the UK, and the potential strategies that could be 
used to manipulate its potential anticancer properties are also described. Finally, the 
key phytochemicals of watercress and their known molecular effects, focusing on 
phenethyl isothiocyanate (PEITC) are detailed. 
    
1.2  Molecular genetics of cancer 
 
Cancer results from genetic and/or epigenetic changes within a cell. Oncogenic 
mutations occur in two different types of genes, both of which are required for normal 
cell homeostasis. Gain-of-function mutations in oncogenes act to promote cell division 
and survival, whereas loss-of-function mutations in tumour suppressor genes 
inactivate negative regulatory proteins which normally prevent inappropriate cell 
division and survival. Tumourigenesis is a multistep process whereby normal cells 
accumulate multiple mutations to acquire a fully malignant phenotype. This is                                                 Chapter 1: Introduction                        
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consistent with the idea that, whilst cancer incidence is high within human populations, 
the frequency of conversion to a fully malignant phenotype is extremely low for any 
given cell within an individual. It has been proposed that there are six essential 
hallmarks that need to be acquired by all cancers, although these may be achieved 
through different mechanistic strategies; independence from growth signals, 
insensitivity to growth-inhibitory signals, resistance to apoptosis, limitless replicative 
potential, angiogenesis, and finally tissue invasion and metastasis (Hanahan and 
Weinberg, 2000). Several other hallmarks have since emerged, notably the ability to 
evade the immune system and dysregulate metabolism. In addition, genomic instability 
and inflammation have been highlighted as enabling characteristics which promote 
tumour progression (Hanahan and Weinberg, 2011).    
 
1.3 Breast  cancer 
 
1.3.1 Epidemiology 
 
In 2008, 48,034 new cases of breast cancer were diagnosed in the UK, with >99% of 
these being in women (Cancer Research UK, accessed February 2011). Breast cancer 
is the second most common cause of death from cancer in women following lung 
cancer. The highest rates of breast cancer occur in the developed world, particularly in 
Northern and Western Europe, as well as Australia and North America, whereas the 
lowest rates are found in Asia and parts of Africa.  
 
In the UK the lifetime risk for women of developing breast cancer is 1 in 8. The onset of 
breast cancer is strongly associated with age and more than 80% of breast cancer 
cases occur in women over the age of 50, with the highest number of cases diagnosed 
in the 50-69 age range. Approximately 10-15% of patients with breast cancer develop 
distant metastasis within 3 years of detection of the primary tumour (Weigelt et al., 
2005). Despite a continued increase in the incidence of breast cancer, the number of 
women dying from breast cancer has steadily declined since 1989. This is likely due to 
better drug treatments such as tamoxifen, which has been widely used since 1992, 
and the introduction of the national screening program in the UK in 1988. Current 5-
year survival rates for women with breast cancer in the UK are approximately 80% 
(Cancer Research UK, accessed February 2011).  
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1.3.2  Familial genetic risk 
 
A predisposition to breast cancer has been identified in people that inherit mutations in 
the high-risk BRCA1, BRCA2 and TP53 genes (Lalloo et al., 2006). However, these 
genes account for only a minority, approximately 5%, of all breast cancers in the 
population (Key et al., 2001). Most cases of breast cancers are therefore sporadic and 
more the result of environmental and lifestyle factors. 
 
1.3.3 Subtypes 
 
Breast cancer is a complex and highly heterogeneous disease and as a result there 
are many different subtypes. The majority of all invasive breast cancers are 
adenocarcinomas and tend to be either ductal (85%) or lobular (15%) (see Figure 1.1 
for structure of the human breast), and both can be further divided according to 
histological appearance (Table 1.1). In addition to this there are also two types of non-
invasive in situ breast cancers, Ductal Carcinoma In Situ (DCIS) and Lobular 
Carcinoma In Situ (LCIS). LCIS is relatively rare and is believed to be a high risk factor 
for invasive breast cancer rather than a direct precursor. On the other hand DCIS is 
the most common type of non-invasive breast cancer and accounts for 20% of all 
breast cancers detected (Page et al., 1995).  
 
Various markers have also been identified to further characterise breast cancer with an 
aim to predict prognosis and response to therapy. The most established biomarkers 
are oestrogen receptor α (ERα) status, progesterone receptor (PR) status and human 
epidermal growth factor receptor 2 (HER2) expression. Breast cancers that are ERα- 
and PR-positive are generally associated with a good prognosis and are more likely to 
respond to endocrine therapy. Alternatively HER2 overexpression is indicative of a 
poor clinical outcome in patients with axillary-lymph-node metastasis. HER2 
expression is particularly important in assessing the potential response to trastuzumab 
(Herceptin), an antibody directly targeted to HER2 (Weigelt et al., 2005). 
 
Gene expression arrays have expanded upon characterisation of breast cancer and 
identified various subtypes of breast cancer based on the presence of several 
prognostic markers together. ERα negative tumours can be further divided into basal-
like group which exhibit high expression of basal epithelial markers such as basal 
keratins 5/6, HER2 positive group which overexpresses HER2, and                                                  Chapter 1: Introduction                        
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Figure 1.1: Structure of the normal adult human breast.  
The ducts connect the milk-producing lobules to the nipple. The lobules and ducts are 
surrounded by fatty connective tissue and ligaments (Adams, 2008).  
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Table 1.1: Histopathological subtypes of invasive breast cancer, frequency of 
occurrence and 10-year survival rates.  
Information from Weigelt et al. (2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histopathological type of invasive breast 
cancer 
Frequency  10-year survival rate 
Invasive ductal carcinoma of no special type  50-80%  35-50% 
Invasive lobular carcinoma  5-15%  35-50% 
Mixed type, lobular and ductal features  4-5%  35-50% 
Tubular/invasive cribiform carcinoma  1-6%  90-100% 
Mucinous carcinoma  <5%  80-100% 
Medullary carcinoma  1-7%  50-90% 
Invasive papillary carcinoma  <1-2%  60% 
Invasive micropapillary carcinoma  <3%  Unknown 
Metaplastic carcinoma  <5%  Unknown 
Adenoid cystic carcinoma  0.1%  Unknown 
Invasive aprocrine carcinoma  0.3-4%  Unknown 
Neuroendocrine carcinoma  2-5%  Unknown 
Secretory carcinoma  0.01-0.15%  Unknown 
Lipid-rich carcinoma  <1-6%  Unknown 
Acinic-cell carcinoma  7 cases  Unknown 
Glycogen-rich, clear-cell carcinoma  1-3%  Unknown 
Sebaceous carcinoma  4 cases  Unknown                                                 Chapter 1: Introduction                        
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normal breast like group which resemble the normal breast, expressing genes of 
adipose-cell and other non-epithelial-cell origin (Perou et al., 2000). Nearly all basal-
like breast cancers are triple-negative in that they are negative for both ERα and PR, 
and do not overexpress HER2. This type of breast cancer has been reported to be 
particularly aggressive and less responsive to treatment resulting in poor prognosis 
(Dent et al., 2007). Perou et al. (2000) classified all ERα positive tumours in a luminal-
type group as they all overexpressed breast luminal cell markers, however, this group 
has since been divided into luminal A which overexpress HER2 and luminal B which 
do not (Sorlie et al., 2003). 
 
1.3.4 Oestrogen  receptor 
 
Oestrogen receptor α (ERα) positive breast cancer is seen in a third of patients  under 
50, and this rises to approximately 80% in women over 50 (Clarke et al., 1998 and see 
Table 1.2). ERs are transcription factors which mediate the response to the hormone 
oestrogen. In humans there are two ER subtypes, ERα and ERβ, which exhibit 
different expression patterns in specific tissues. Both receptors share a high level of 
homology and belong to the nuclear hormone receptor superfamily. Although ERα and 
ERβ bind to oestrogen with equal affinity, other ligands preferentially bind to one or the 
other (Enmark and Gustafsson, 1999). In the context of breast cancer ERα is thought 
to be the most important and it is the status of this subtype that is assessed in clinical 
practice (Badve and Nakshatri, 2009). However, there is increasing interest in the 
potential clinical significance of ERβ. Homna et al. (2008) found ERβ1-positive breast 
cancers treated with adjuvant tamoxifen were associated with significantly better 
survival independent of ERα expression. This is of particular interest when considering 
triple-negative breast cancer (negative for ERα, PR, and HER2), that might still be 
positive for ERβ.  
 
     
ERα+ve/PR+ve ERα-ve/PR-ve ERα+ve/PR-ve ERα-ve/PR+ve 
54.8% 22.1% 19.8% 3.2% 
Table 1.2: Frequency of progesterone and oestrogen receptor α phenotypes in 
breast cancer.  
Information from Rhodes et al. (2000). 
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Oestrogen is a lipophilic steroid and able to diffuse through the phospholipid plasma 
membrane to the cytoplasm where it can bind to intracellular ERα or ERβ. The binding 
of oestrogen to these receptors induces phosphorylation, dissociation from chaperones 
such as heat shock protein 90 (Hsp90), and a change in protein conformation, 
ultimately allowing the ERs to dimerise and recruit co-activators to enhance 
transcription. The ligand bound receptor complex activates transcription either through 
direct binding to ERE (oestrogen response elements) in the promoter region of ER-
dependent genes or through interactions with other transcription factors such as SP1 
(Salvatori et al., 2003). It has also been reported that ERs at the cell membrane can 
mediate non-genomic effects of oestrogen, termed membrane-initiated steroid 
signalling (MISS), which results in the activation of a variety of cell signalling cascades 
such as the MAPK pathway (discussed later) (Song et al., 2002) .   
 
In women oestrogen is primarily produced in the ovaries and is responsible for 
controlling sexual development. One role of oestrogen is to promote the growth of 
breasts by stimulating cell division. ER positive breast cancers are dependent on 
oestrogen to grow and as a result this pathway is an important target for therapeutic 
therapy (Anderson, 2002). 
 
1.3.4.1 Tamoxifen 
 
Tamoxifen is the most widely used treatment of ERα-positive breast cancer, and when 
given as adjuvant therapy in early stage breast cancer it has been shown to improve 
survival rates (Clarke et al., 1998). Tamoxifen is a selective oestrogen receptor 
modulator (SERM) in that it acts as an antagonist in breast tissue, but partial-agonist in 
the uterus and bone. Through direct binding with ERs in breast tissue tamoxifen 
induces a conformational change which, in contrast to oestrogen, favours recruitment 
of co-repressors to the ER, inhibiting transcriptional activity (Shou et al., 2004).  
 
1.3.4.2 Aromatase inhibitors 
 
A second class of drugs, aromatase inhibitors (AIs), prevent the synthesis of oestrogen 
by inhibiting the enzyme aromatase that catalyses the conversion of androgens to 
oestrogens. This therapy is only used in postmenopausal women whose main source 
of oestrogen comes from converted androgens in the periphery tissues, not the 
ovaries. Examples of AIs include anastrozole, letrozole, and exemestane, and they                                                 Chapter 1: Introduction                        
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tend to be used in preference to tamoxifen in postmenopausal women with ERα 
positive breast cancer due to better efficacy and less adverse effects (Mokbel, 2002).  
 
1.3.5  Human epidermal growth factor receptor 2 
 
Aberrant expression of epidermal growth factor (EGF) receptors has been linked to 
many cancers. In particular, human epidermal growth factor receptor 2 (HER2; also 
known as HER2/neu and ErbB2) gene amplification or protein overexpression is found 
in 20-30% of human breast cancers and is indicative of poor prognosis (Slamon et al., 
1987; Slamon et al., 1989). HER2 along with HER1 (EGFR, ErbB2), HER3 (ErbB3), 
and HER4 (ErbB4) form the human epidermal growth factor receptor (HER) family of 
tyrosine kinase receptors. Activation of these receptors by ligands such as EGF 
causes homo- or heterodimerisation and subsequent phosphorylation. This initiates a 
signal cascade through activation of both the PI3K/Akt and MAPK pathways 
(discussed later) that ultimately results in altered gene expression, with biological 
responses ranging from proliferation to migration (Bazley and Gullick, 2005). No ligand 
has yet been identified to bind HER2 directly, although the receptor has been shown to 
act as the preferred heterodimerisation partner to all other ligand-bound members of 
the HER family (Graus-Porta et al., 1997). It seems HER2 overexpression causes 
transformation of malignant breast cancer cells by amplifying the signals of other 
receptors, with Akt phosphorylation being shown in HER1 and HER2 overexpressing 
cells even in the absence of ligands (Longva et al., 2005). 
 
1.3.5.1 Herceptin 
 
The humanised monoclonal antibody Trastuzumab (more commonly known as 
Herceptin) is used as a treatment for patients with breast cancer that overexpress 
HER2. Herceptin is targeted to the extracellular domain of HER2 with treatment being 
shown to induce regression of HER2 overexpressing breast cancers (Vogel et al., 
2002). Although the mechanism is not fully understood it is thought to involve inhibition 
of Akt phosphorylation, a target of the PI3K pathway activated by HER2 that regulates 
many processes including cell proliferation, apoptosis, and glycogen metabolism 
(Longva et al., 2005; Yakes et al., 2002). In particular, Herceptin treated cells have 
been shown to arrest in the G1 phase of the cell cycle, believed to be the result of Akt 
inhibition stabilising the cyclin-dependent kinase 2 (CDK2) inhibitor p27 (Le et al., 
2005; Yakes et al., 2002).                                                  Chapter 1: Introduction                        
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1.4  Key molecular pathways in breast cancer 
 
1.4.1  Hypoxia inducible factor pathway 
 
Tumours are only able to grow to approximately 1-2 mm
2 in size before they outgrow 
the existing vasculature and lack of oxygen and nutrients become a limiting factor. 
Therefore, in order for solid tumours to progress they must adapt to hypoxic conditions, 
or increase vascularisation, or both. Hypoxia inducible factors (HIFs) are transcription 
factors that are critical for this adaptation as they increase expression of genes that 
enable cells to survive in hypoxic conditions and promote angiogenesis (the growth of 
new blood vessels), such as glucose transporter 1 (GLUT-1) and vascular endothelial 
growth factor-A (VEGF-A) (Carmeliet and Jain, 2000).  
 
HIFs are heterodimeric complexes composed of an α-subunit and a β-subunit and are 
members of the basic helix-loop-helix (bHLH)-PER-ARNT-Sim (PAS) family of 
transcription factors. Both subunits are constitutively expressed. However, while HIF1β 
is maintained at relatively constant levels, the HIF1α protein has a very short half life 
(T1/2 ∼ 5 min) in normoxia, due to oxygen-dependent proteolysis (Figure 1.2). In an 
oxygen rich environment, proline residues 402 and 577 of HIF1α are hydroxylated by 
prolyl hydroxylase domain-containing (PHD) proteins. This hydroxylation triggers 
association with the von Hippel-Lindau tumour suppressor protein (pVHL), a member 
of the E3 ubiquitination complex, which subsequently ubiquitinates HIF1α and targets it 
for degradation by the 26S proteasome. The significance of this tumour suppressor 
protein and importance of normal HIF regulation is evident in individuals who inherit a 
defective VHL allele. VHL disease is characterised by the presence of hypervascular 
tumours in multiple organs, although kidney cancer is the primary cause of death (Ohh, 
2006). The PHD proteins, which contain iron, require oxygen as a co-factor for activity. 
In hypoxia when there is a low availability of oxygen the activity of the prolyl 
hydroxylases is inhibited, HIF1α is no longer targeted for ubiquitination and is 
stabilised. HIF1α is translocated to the nucleus where it dimerises with HIF1β. The 
transcriptionally active HIF complex binds to hypoxic response elements (HRE) in the 
promoter region of hypoxia regulated genes such as those involved in angiogenesis 
(VEGF-A) and pH regulation (carbonic anhydrase IX; CAIX) (Ke and Costa, 2006; Lee 
et al., 2004).  
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Figure 1.2: Oxygen-dependent regulation of hypoxia inducible factor 1α.   
In normoxia where there is an abundance of oxygen (O2) HIF1α is hydroxylated by 
proyl hydroxylases (PHDs). This triggers association with von Hippel-Lindau tumour 
suppressor protein (pVHL) which acts to polyubiquitinate HIF1α and subsequently 
targets it for degradation by the 26S proteasome. However, in hypoxia PHDs are 
unable to hydroxylate HIF1α. Consequently it is no longer targeted for degradation and 
is free to translocate to the nucleus. In the nucleus HIF1α forms heterodimers with 
HIF1β and the active transcription factor complex can then bind to hypoxia response 
elements (HRE) in the promoter region of target genes to initiate transcription. BNIP3 
(Bcl2/adenovirus E1B 19kDa interacting protein 3), CAIX (carbonic anhydrase IX), 
GLUT-1 (glucose transporter 1), VEGF-A (vascular endothelial growth factor A); U 
(ubiquitin).  
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While only one β-subunit has been identified (HIF1β, also known as aryl hydrocarbon 
nuclear translocator; ARNT), three α-subunits have been identified; HIF1α, HIF2α (also 
termed endothelial PAS protein; EPAS1/HIF-like factor; HRF/HIF-related factor; 
HRF/member of PAS superfamily 2; MOP2) and HIF3α. HIF1α and HIF2α are 
implicated in the induction of hypoxia responsive genes. HIF1α is ubiquitously 
expressed whereas HIF2α has been found to be predominantly expressed in the lung, 
endothelium and carotid body (Ke and Costa, 2006; Wiesener et al., 2003). Little is 
known about HIF3α but it is known to act as a dominant-negative regulator of HIF1 
(Makino et al., 2002).  
 
Due to the importance of hypoxia adaption in the progression of tumour development, 
HIF1α and HIF2α have been found to be overexpressed in a variety of cancers, 
including breast cancer (Zhong et al., 1999), and are often associated with resistance 
to cancer therapies (Teicher, 1994) 
 
1.4.2  Histone deacetylases  
 
DNA is not free within the nucleus but is present in the form of chromatin, where 
sections of DNA are wrapped around nucleosomes. These nucleosomes are 
composed of two molecules each of the core histones, H2A, H2B, H3, and H4 that 
initially form two heterodimers, H2A-H2B and H3-H4, which then combine to produce 
an octamer barrel structure that the DNA wraps around twice. The fifth class of 
histone, H1, is the largest with a molecular weight of 23-kDa, and is believed to link the 
nucleosomes together. In total 200bp of DNA are associated with each nucleosome, 
with approximately 146bp making up two turns of the DNA around the histone core, 
with the remaining DNA acting as a linker, connecting the nucleosomes. All the histone 
proteins exhibit a net positive charge, as approximately 20-30% of their amino acid 
sequence comprises of the basic amino acids arginine and lysine. This characteristic 
enables the histones to have a strong charge attraction to the negatively charged 
phosphate groups in the backbone of DNA. This not only results in the DNA being 
tightly associated with nucleosomes, but by neutralising the negative charge on DNA 
the histones also facilitate DNA folding (Geiman and Robertson, 2002; Hames, 2000; 
Latchman, 2005). 
 
How tightly chromatin is organised correlates with the extent of transcriptional activity 
in that region of the genome as a result of changes to the accessibility of                                                 Chapter 1: Introduction                        
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transcriptional machinery to the DNA. Therefore tightly packaged chromatin, 
heterochromatin, is associated with transcriptional repression, and loosely packaged 
chromatin, euchromatin, is indicative of transcriptional activity. This more relaxed state 
of chromatin is the result of modifications to either the DNA or histones that decrease 
the ionic bond between the negatively charged DNA and the positively charged 
histones (Latchman, 2005).  
 
There are various forms of histone modification that can alter transcriptional activity in 
different ways and they predominantly occur on the amino tails of the histones that 
extend out from the nucleosome, typically the amino-terminal tails of the core histones 
H3 and H4. Methylation, phosphorylation and ubiquitination, are all known 
modifications that alter transcriptional activity, but perhaps the most characterised form 
is acetylation (Latchman, 2005). Patterns of acetylation are determined by the 
opposing activities of histone acetyltransferases (HATs) and histone deacetylases 
(HDACs). HATs transfer an acetyl group to lysines present on the  
amino-terminal tails of histones, neutralising the positively charged histones and thus 
resulting in a decreased affinity of the nucleosomes to the DNA (Figure 1.3). As a 
result acetylation of histones H3 and H4 correlates with transcriptional activity with 
acetylation positions including K9, K14, K18, and K27 on histone H3, and K5, K8, K12, 
and K16 on histone H4 (Salozhin et al., 2005). Conversely HDACs remove the acetyl 
group, restoring the ionic interaction between the histones and the DNA promoting 
heterochromatinisation. 
 
Aberrant histone acetylation is found in many cancers and results in irregular gene 
expression patterns. As a result molecules that are able to inhibit HDACs are providing 
a promising new way to treat cancer (Ropero and Esteller, 2007).  
 
1.4.3 PI3K/Akt  pathway 
 
As already touched upon, the phosphatidylinositol (PI3K)/Akt pathway lies downstream 
of HER2 signalling. However, PI3K can also be activated by other receptor tyrosine 
kinases (RTKs) as well as G protein-coupled receptors (GPCR) in response to a broad 
range of stimuli including growth factors and hormones. PI3K catalyses the addition of 
a phosphate group to phosphatidylinositol (4,5)-bisphosphate (PIP2) giving rise to 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3).  PIP3 is required to recruit pleckstrin 
homology (PH) domain-containing proteins, such as Akt and phosphoinositide                                                  Chapter 1: Introduction                        
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Figure 1.3: Balance between HDACs and HATs in chromatin modelling.  
Histone acetyl transferases (HATs) transfer acetyl groups (ac) to lysines on the tails of 
histones in the nucleosome, decreasing the ionic bond between DNA and the histones. 
This results in more loosely packaged chromatin that is accessible to transcriptional 
machinery. Conversely histone deacetylases (HDACs) remove acetyl groups, returning 
the chromatin to a tightly packaged and transcriptionally inactive state.  
 
 
 
dependent kinase 1 (PDK1) to the cell membrane. This acts to colocalise enzymes and 
their substrates. The tumour suppressor protein phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN) reverses this action by dephosphorylating PIP3, 
inhibiting the PI3K/Akt signalling pathway. Aberrant activation of Akt as a result of PI3K 
or Akt gene amplification, or mutation/loss of PTEN is commonly seen in a variety of 
cancers (Osaki et al., 2004). Once at the cell membrane Akt (also known as protein 
kinase B; PKB) is phosphorylated at multiple sites, threonine 308 (Thr308) located in 
the activation loop by PDK1 (Alessi et al., 1997) and serine 473 (Ser473) present in 
the hydrophobic motif by mammalian target of rapamycin complex 2 (mTORC2) 
(Sarbassov et al., 2005). While it seems phosphorylation at both sites is required for 
full activation of Akt (Alessi et al., 1996), the disruption of mTORC2 stability and 
subsequent loss of Ser473 phosphorylation of Akt has been seen to only effect a small 
number of Akt targets, namely the forkhead box (FOX) family of transcription factors 
(Jacinto et al., 2006). 
 
There are numerous downstream targets of Akt that are involved in the regulation of 
cell survival and proliferation (Figure 1.4) (Osaki et al., 2004). For example, Akt exerts 
its anti-apoptotic effects by inhibiting the FOX transcription factors, FOXO1, FOXO3a, 
and FOXO4, preventing expression of pro-apoptotic proteins such as Fas ligand                                                  Chapter 1: Introduction                        
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Figure 1.4: Overview of the PI3K/Akt pathway. 
PI3K (phosphatidylinositol 3-kinase) can be activated directly by binding to phospho-
sites on activated tyrosine kinase receptors or indirectly through adaptor proteins 
activating small G protein Ras. PI3K converts PIP2 (phosphatidylinositol (4,5)-
bisphosphate) to PIP3 (phosphatidylinositol (3,4,5)-trisphosphate), which can recruit 
proteins such as Akt and PDK1 (phosphoinositide dependent kinase 1) to the cell 
membrane. Akt is activated following phosphorylation by PDK1 and mTORC2 
(mammalian target of rapamycin complex 2) and has many downstream effectors 
involved in the regulation of cell survival and proliferation. PTEN (phosphatase and 
tensin homolog deleted on chromosome 10) reverses the action of PI3K. EGFR 
(epidermal growth factor receptor), FOX3a (forkhead box transcription factor 3a), GSK-
3 (glycogen synthase kinase 3), Rheb (Ras homolog enriched in brain), TSC1/2 
(tuberous sclerosis complex 1/2).                                                 Chapter 1: Introduction                        
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(FasL) (Brunet et al., 1999) . Whereas, the phosphorylation and inactivation of 
tuberous sclerosis complex 1/2 (TSC1/2) by Akt enhances protein synthesis via the 
mammalian target of rapamycin complex 1 (mTORC1) pathway (Cai et al., 2006).  
 
1.4.4 MAPK  pathway 
 
There are multiple mitogen activated protein (MAP) kinases which are activated 
downstream of protein kinase cascades in response to distinct stimuli including growth 
factors, inflammatory cytokines and environmental stresses. Activation of these 
pathways mediates diverse cellular responses such as cell proliferation, apoptosis, and 
the inflammatory response. The signal is transmitted via a series of sequentially 
activated kinases; MAP kinase kinase kinase (M3K), MAP kinase kinase (MKK) and 
MAP kinase (MAPK). There are three main MAPK families, the extracellular-signal 
regulated kinases (ERK1/2, also known as classical MAPK), the C-Jun N-terminal 
kinase (JNK, also known as stress-activated protein kinase; SAPK), and p38 kinases 
(Krishna and Narang, 2008).  
 
The ERK1/2 pathway is the most characterised and is preferentially activated by 
growth factors (Figure 1.5). Signalling is typically initiated by activation of RTKs, 
resulting in activation of the small G protein Ras. Activated Ras triggers the protein 
kinase activity of M3K, Raf, which then phosphorylates and activates the MKK, 
MEK1/2. MEK1/2 then phosphorylate ERK1/2 at two sites, a threonine and a tyrosine 
residue. Once active, ERK1/2 can translocate to the nucleus and activate transcription 
factors such as Elk1, resulting in the elevated expression of a variety of proteins 
associated with proliferation and differentiation. Other downstream targets of ERK1/2 
include cytoskeletal and scaffold proteins, and protein kinases such as 90 kDa 
ribosomal S6 kinases (p90RSK) which further propagate the signal (Yoon and Seger, 
2006). Both ERK1/2 and p90RSK can also increase protein synthesis via the 
phosphorylation of several proteins involved in translational regulation such as 
negative regulator of mTORC1, TSC2, and eukaryotic elongation factor 2 kinase 
(eEF2K) (Ma et al., 2005; Wang et al., 2001).    
 
Aberrant activity of the ERK1/2 pathway is observed in multiple cancers, and can be 
the result of activating mutations in the ras or raf oncogenes, and overexpression or 
activating mutations in EGFRs. Consequently many inhibitors of the ERK pathway are 
currently in clinical trials (Kohno and Pouyssegur, 2006).                                                 Chapter 1: Introduction                        
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Figure 1.5: Overview of the ERK pathway. 
Activation of the small G protein Ras, activates the protein kinase activity of Raf 
initiating the protein kinase cascade. Raf phosphorylates MEK1/2 (MAP kinase kinase 
1/2), which in turn phosphorylates ERK1/2 (extracellular-signal regulated kinases 1/2). 
ERK1/2 also phosphorylates another protein kinase, p90RSK (90 kDa ribosomal S6 
kinase). Both ERK1/2 and p90RSK can translocate to the nucleus and activate several 
transcription factors, as well as phosphorylating multiple translational regulators to 
increase protein synthesis. eEF2K (eukaryotic elongation factor 2 kinase), EGFR 
(epidermal growth factor receptor), mTORC1 (mammalian target of rapamycin 
complex), SRF (serum response factor), Rheb (Ras homolog enriched in brain), SRE 
(serum response element), TSC1/2 (tuberous sclerosis complex 1/2).                                                 Chapter 1: Introduction                        
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1.4.5 mTOR 
 
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that forms 
the catalytic domain of two distinct complexes; mTORC1 and mTORC2. In addition to 
mTOR, mTORC1 is composed of mLST8 (mammalian lethal with Sec13 protein 8, also 
known as GβL) and Raptor (regulatory associated protein of mTOR). Two further 
proteins have also been found to interact with mTORC1, PRAS40 (proline-rich Akt 
substrate 40 kDa), and Deptor (DEP-domain containing mTOR interacting protein), 
both of which are believed to have an inhibitory influence on mTORC1 (Haar et al., 
2007; Peterson et al., 2009). mTORC2 is less studied than mTORC1 and contains 
mTOR, mLST8, Rictor (rapamycin-insensitive companion of mTOR), Sin1 (stress-
activated protein kinase interacting protein 1) and Proctor. Deptor has also been 
shown to interact with and inhibit mTORC2 (Peterson et al., 2009). Notably, mTORC1 
and mTORC2 can be distinguished by their sensitivity to the immunosuppressant drug, 
rapamycin. Rapamycin binds to the intracellular protein FKBP12 and together interacts 
with mTOR only within mTORC1, specifically inhibiting mTORC1 activity (Jacinto et al., 
2004; Sarbassov et al., 2004). However, it should be noted that some rapamycin-
insensitive functions of mTORC1 have been identified, examples will be given below.  
As reviewed by Menen and Manning (2008), mTORC1 activity is frequently 
upregulated in a number of cancers, including breast cancer, and as a result there is 
much interest in furthering our understanding of this pathway.  
 
1.4.5.1 mTORC1 substrates 
 
The best known substrates of mTORC1 are the eIF4E binding proteins (4E-BP) and 70 
kDa ribosomal S6 protein kinases (p70 S6K), both of which are involved in the control 
of mRNA translation. It seems that these substrates are directed to mTOR by Raptor 
via Tor signalling motifs (TOS) (Nojima et al., 2003). The 4E-BP family are key 
negative regulators of the eukaryotic initiation factor 4F (eIF4F) complex required for 
cap-dependent translation. eIF4F complexes form at the 5’ end of mRNA and are 
composed of three subunits, the scaffold protein eukaryotic initiation factor 4G (eIF4G), 
the RNA-helicase eukaryotic initiation factor 4A (eIF4A) and the cap-binding protein 
eukaryotic initiation factor 4E (eIF4E). Specifically, the 4E-BPs, of which 4E-BP1 is the 
most prominent, tightly regulates the availability of eIF4E by competing with eIF4G for 
an overlapping binding site on eIF4E in a phosphorylation-dependent manner. 
Hypophosphorylated 4E-BP1 binds strongly to eIF4E thus preventing the assembly of  
the eIF4F complex (Haghighat et al., 1995; Lin et al., 1994). mTORC1 phosphorylates                                                 Chapter 1: Introduction                        
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4E-BP1 at multiple sites in a hierarchical manner. Phosphorylation of Thr37 and Thr46 
occur first, in response to amino acids, and although these modifications are not 
sufficient to inhibit the interaction between 4E-BP1 and eIF4E, they act as a priming 
step for the phosphorylation of Thr70 and then Ser65 when mTORC1 is further 
stimulated by growth factors (Gingras et al., 2001). However, while phosphorylation of 
all 4E-BP1 sites is mediated by mTORC1, phosphorylation of Thr37 and Thr46 are 
insensitive to rapamycin (Wang et al., 2005).  
 
The other main mTORC1 substrate, p70 S6K, is itself a serine/threonine protein 
kinase, and phosphorylation by mTORC1 increases its activity. Targets of p70 S6K 
include the S6 ribosomal protein, which forms part of the 40S ribosomal subunit, 
eukaryotic initiation factor 4B (eIF4B) (Raught et al., 2004) and programmed cell death 
protein 4 (Pdcd4) (Dorrello et al., 2006), which respectively enhance and impair mRNA 
helicase eIF4A, and the eukaryotic elongation factor 2 kinase (eEF2K), which inhibits 
eEF2 (Wang et al., 2001). p70 S6K is known to be an important regulator of cell size 
(Shima et al., 1998) and considering the known targets of the kinase it seems p70 S6K 
has a positive influence on ribosome biogenesis and protein synthesis. However, as 
several p70 S6K targets are also phosphorylated by downstream effectors of the 
MAPK pathway, its impact on the overall control of protein synthesis is not clear 
(Shahbazian et al., 2006; Wang et al., 2001).  
 
mTORC1 can also increase the protein synthesis capacity of cells by upregulating 
specific mRNAs such as those encoding ribosomal proteins. Many of these mRNAs 
contain a tract of pyrimidines in their 5’ untranslated regions (5’UTR) that ordinarily 
impair translation. The ability of mTORC1 to control translation of 5’ tract 
oligopyrimidine (5’TOP) mRNAs was originally attributed to p70 S6K however, this has 
since been found not to be the case (Pende et al., 2004). Therefore, despite this 
process being sensitive to rapamycin, the exact mechanism by which mTORC1 
increases translation of these mRNAs remains unknown.      
 
1.4.5.2 Upstream control of mTORC1 
 
The PI3K/Akt and MAPK pathways both converge on mTORC1 to increase protein 
synthesis in response to hormones and growth factors. mTORC1 is also regulated by 
other pathways that sense whether or not conditions are favorable for cell growth and 
proliferation, such as nutrient availability, cellular energy levels and oxygen levels, 
activating or inhibiting mTORC1 accordingly (Figure 1.6). The response of mTORC1 to 
many of these cellular stresses and growth factors is orchestrated by the tuberous                                                 Chapter 1: Introduction                        
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sclerosis complex 1/2 (TSC1/2) (Dibble and Manning, 2010). Although it should be 
noted that mTORC1 can also be regulated independently of TSC1/2, as observed in 
amino acid mediated activation of mTORC1 (Smith et al., 2005).TSC1/2 is a 
heterodimeric complex composed of TSC1 (also known as hamartin) and TSC2 which 
acts as a negative regulator of mTORC1. Genetic mutations in either gene can cause 
the genetic disorder of the same name, TSC, with patients presenting with multiple 
benign tumours (hamartomas) in various organs including the brain and kidneys 
(Kwiatkowski, 2003). TSC2 acts as a guanosine triphosphatase activating protein 
(GAP), stimulating the intrinsic GTPase activity of Ras homolog enriched in brain 
(Rheb), and catalysing its conversion from GTP to GDP bound state. It has been 
shown that Rheb-GTP activates mTORC1, although the precise mechanism behind 
this is unknown (Inoki et al., 2003a; Tee et al., 2003). 
 
Many of the pathways shown to act via TSC1/2 to control mTORC1 signalling can also 
influence mTORC1 in a TSC1/2-independent manner by phosphorylating Raptor 
(Carrière et al., 2008; Gwinn et al., 2008). In addition, Akt can phosphorylate PRAS40, 
another protein known to associate with the mTORC1 complex (Haar et al., 2007). 
Interestingly, PRAS40 has also been identified as a substrate for mTORC1 and it 
seems that phosphorylation by both Akt and mTOR is required for its dissociation from 
the mTORC1 complex. However, the functional role of this is not fully understood, as 
while PRAS40 dissociation has been shown to increase 4E-BP1 binding to mTORC1, 
it does not promote mTORC1 signalling (Rapley et al., 2011). 
 
1.4.5.3 mTORC2 
 
Although mTORC2 activity is enhanced by growth factors little is known about the 
signalling events involved in mTORC2 regulation (García-martínez and Alessi, 2008). 
One of the main functions of mTORC2 is to phosphorylate Akt on Ser473, which along 
with phosphorylation on Thr308 by PDK1 is required for full Akt activation (Sarbassov 
et al., 2005). However, while this would suggest mTORC2 acts upstream of mTORC1, 
the disruption of mTORC2 stability and subsequent loss of Ser473 phosphorylation on 
Akt did not attenuate phosphorylation of TSC2 (Jacinto et al., 2006). mTORC2 also 
phosphorylates and activates serum- and glucocorticoid-induced protein kinase 1 
(SGK1) which is involved in activating various sodium and potassium channels 
(García-martínez and Alessi, 2008), and protein kinase Cα (PKCα) which has a role in 
multiple cellular processes including apoptosis, cell cycle control and regulation of cell 
shape and mobility (Sarbassov et al., 2004).                                                 Chapter 1: Introduction                        
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Figure 1.6: Outline of the mTORC1 pathway.   
mTORC1 (mammalian target of rapamycin complex 1) is regulated by multiple 
pathways that sense whether or not conditions are favorable for cell growth and 
proliferation, such as nutrient availability, cellular energy levels and oxygen levels and 
the presence of growth factors, activating or inhibiting mTORC1 accordingly. p70 S6K 
(70 kDa S6 ribosomal protein kinase) p90RSK (90 kDa ribosomal protein kinase), 
AMPK (5’ adenosine monophosphate-activated kinase), 4E-BP1 (eIF4E binding 
protein 1), ERK (extracellular-signal regulated kinase), PKCα (protein kinase C α),  
PTEN (phosphatase and tensin homolog deleted on chromosome 10), PI3K 
(phosphoinositide 3-kinase), PDK1 (phosphoinositide dependent kinase 1), PRAS40 
(proline-rich Akt substrate 40 kDa), mLST8 (mammalian lethal with Sec13 protein 8), 
MEK (mitogen activated protein kinase kinase), Raptor (regulatory associated protein 
of mTOR), Rheb (Ras homolog enriched in brain), REDD1 (regulated in development 
and DNA damage response 1), Rictor (rapamycin-insensitive companion of mTOR), 
SGK1 (Serum- and glucocorticoid-induced protein kinase 1), Sin1 (stress-activated 
protein kinase interacting protein 1), TSC1/2 (tuberous sclerosis complex 1/2).                                                 Chapter 1: Introduction                        
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1.5  Regulation of mRNA translation 
 
In eukaryotes the majority of mRNAs are translated via cap-dependent translation, 
which involves three steps; initiation, elongation and termination. This is a tightly 
controlled process with multiple factors regulating both initiation and elongation. 
Notably, many of the factors involved in the regulation of mRNA translation have been 
implicated in downstream oncogenic signalling (Rajasekhar and Holland, 2004). 
 
Initiation begins with the formation of a eukaryotic initiation factor 4F (eIF4F) complex 
at the 7-methyl guanosine cap at the 5’ end of mRNA (Figure 1.7). eIF4F is composed 
of three subunits, the scaffold protein eIF4G, the cap-binding protein eIF4E, and the 
RNA-helicase eIF4A which is thought to unwind secondary structure in the 5’UTR. The 
small 40S ribosomal subunit and associated eIF2-GTP-Met-tRNAi complex is recruited 
to the eIF4F complex by ribosome-associated protein eIF3 which interacts with the 
eIF4G scaffold protein. eIF4G also interacts with the poly(A)-binding protein (PABP) 
which binds to the poly-A tail present in most eukaryotic mRNAs, resulting in the 
circularisation of the mRNA molecule (Cormier et al., 2003). A further eukaryotic 
initiation factor, eIF4B, binds to eIF4A and eIF3, enhancing the helicase activity of 
eIF4A. eIF4B is a target for p70 S6K phosphorylation which increases its affinity to 
eIF3 (Raught et al., 2004). Binding of eIF4E to the mRNA 5’-cap is the rate limiting 
step of cap dependent translation and as a result is tightly regulated. As already 
mentioned, the availability of eIF4E is controlled by 4E-BPs, which when 
hypophosphorylated sequester eIF4E away from the eIF4F complex. However, eIF4E 
can also be regulated by MAPK-signal integrating kinases 1 and 2 (Mnk1/2; also 
known as MAPK-interacting kinases), which lie downstream of ERK and p38 MAPK, 
and interact with eIF4G. Phosphorylated eIF4E displays a decreased affinity for the 5’-
cap structure, despite the fact signalling pathways that lead to its phosphorylation are 
associated with increased protein synthesis (Scheper et al., 2002). It is proposed that 
this facilitated dissociation of eIF4E from 5’-cap of an mRNA molecule already being 
translated allows eIF4E to bind other mRNAs.    
 
As reviewed in Kimball (1999), after the formation of eIF4F complex at the 5’ end of the 
mRNA molecule and recruitment of the 40S ribosomal subunit, this pre-initiation 
complex (PIC) scans along the mRNA in the 5’ to 3’ direction until it locates the AUG 
start codon. The Met-tRNAi is then transferred to the 40S ribosomal subunit by 
hydrolysis of eIF2-GTP to eIF2-GDP facilitated by the GTPase activating protein eIF5.                                                 Chapter 1: Introduction                        
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Figure 1.7: Eukaryotic translation: initiation. 
Briefly, various eukaryotic initiation factors (eIFs) form a complex at the 5’ cap of 
mRNA and recruit the 40S ribosome. When the start codon is identified Met-tRNAi is 
transferred to the 40S ribosomal subunit by hydrolysis of eIF2-GTP to eIF2-GDP 
facilitated by eIF5. The 60S ribosome then binds and elongation can begin. See text 
for more details. 4E-BP1, eIF4E binding protein 1; mTORC1, mammalian target of 
rapamycin 1; PABP, poly(A)-binding protein.                                                 Chapter 1: Introduction                        
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The 60S ribosomal subunit is then recruited to form the functional 80S ribosome and 
elongation of the polypeptide chain can begin.  The guanine nucleotide exchange 
factor (GEF) eIF2B is required for the regeneration of eIF2-GDP to its active eIF2-GTP 
state and continued initiation of translation and protein synthesis. Regulation of this 
step provides an important mechanism by which the rate of translation can be 
controlled. eIF2 is comprised of three subunits, α, β and γ,  and when Ser51 on the α 
subunit is phosphorylated it acts as a competitive inhibitor for eIF2B, displaying a 
higher affinity than unphosphorylated eIF2 (Webb and Proud, 1997).   
 
Elongation requires three eukaryotic elongation factors, eEF1α, eEF2β and eEF2 
(Figure 1.8). The aminoacyl-tRNA corresponding to the next codon in the mRNA is 
recruited by GTP bound eEF1α and transferred to the A (aminoacyl) site of the 80S 
ribosome by hydrolysis of eEF1α -GTP to eEF1α-GDP. However, before eEF1α can 
recruit another aminoacyl-tRNA it must first be regenerated to its active eEF1α-GTP 
state. This is catalysed by the GEF, eEF2β. Once positioned, a peptide bond is formed 
between the two amino acids, catalysed by the ribosome, and eEF2 is required for the 
translocation of the peptidyl chain along the ribosome from the A site to the P (peptidyl) 
site (Proud, 2007). Phosphorylation of eEF2 at Thr56 by eEF2K disrupts eEF2 binding 
to the ribosome effectively inhibiting its activity and thus translation (Carlberg et al., 
1990). eEF2K is a calcium/calmodulin (CAM)-dependent kinase also regulated by 
multiple phosphorylation sites which have both activatory (e.g. cAMP-dependent 
protein kinase; PKA) and inhibitory (e.g. p70 S6K) influences (Diggle et al., 2001; 
Wang et al., 2001).  
 
1.6 Benefits  of  healthy  diet 
 
In 1989, following numerous epidemiological studies that reported diets rich in fruit and 
vegetables reduced incidence of cancer and heart disease, the National Academy of 
Sciences’ report on diet and health made the recommendation to eat 5 or more 
servings of a variety of fruit or vegetables every day (National Academy of Sciences, 
1989). The 5-a-Day program was subsequently initiated to encourage the consumption 
of at least five 80 g servings of fruit or vegetables daily, and promote public awareness 
of the potential health benefits (Liu, 2004). Although it should be noted Boffetta et al. 
(2010) recently reported that while there is an inverse correlation between fruit and 
vegetable consumption and cancer risk, the effect is not as great as once thought.                                                  Chapter 1: Introduction                        
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Figure 1.8: Eukaryotic translation: elongation.  
Briefly, hydrolysis of eukaryotic elongation factor 1α (eEF1α) transfers the next aminoacyl-
tRNA to the aminoacyl (A) site of the ribosome. Following peptide bond formation eEF2 
aids in translocation of the tRNA with the peptidyl chain from the A site to the peptidyl (P) 
site, and the deacylated tRNA moves to the exit (E) site and exits the ribosome. The 
process can then be repeated. See text for more details.                                                 Chapter 1: Introduction                        
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Specifically, cruciferous vegetable intake has been associated with reduced cancer 
risk (Verhoeven et al., 1996). In one study, subtype analysis of specific groups of 
vegetables identified a stronger inverse association with consumption of cruciferous 
vegetable and reduced risk of colorectal cancer, than overall consumption of fruit and 
vegetables (Voorrips et al., 2000). 
 
1.7 Watercress 
 
1.7.1 Cultivation 
 
Watercress (Nasturtium officinale, formerly Rorippa nasturtium-aquaticum) belongs to 
the Brassicaceae (Cruciferae) family along with Brussels sprouts, broccoli, and 
cabbage (Figure 1.9). Originating in Europe, watercress has been used since the first 
century AD for medicinal purposes and consumption as a raw leaf crop. Watercress is 
now cultivated around the world and, as well as being eaten raw as a salad vegetable, 
is becoming a popular addition to a variety of cooked dishes (Palaniswamy and 
McAvoy, 2001).  
 
Watercress is a perennial semi-aquatic crop, thriving in alkaline waters, and can often 
be found growing wild in and around open-running waterways in chalk or limestone 
areas. The first recorded commercial cultivation of watercress in Britain dates back to 
the early 1800s when it was grown along the River Ebbsfleet at Springfield, Kent. In 
the last 80 years it has been common practice to cultivate watercress in purpose built 
gravel lined beds that are fed by a constant flow of natural spring water. The 
temperature of the water is important as it provides a source of heat in the colder 
months, maintaining growth, and ideally should be 10-11°C. Due to an abundance of 
uncontaminated alkaline water with a constant temperature at source of 10°C or 11°C, 
watercress production in Britain tends to be concentrated in Hampshire, Wiltshire and 
Dorset (Stevens, 1983).   
 
Although watercress can be vegetatively propagated from cuttings this limits genetic 
variation and means the crop becomes susceptible to diseases, such as fungal crook 
root disease. As a result watercress is now typically propagated from seed.  
Commercially, seeds are germinated in polytunnels on a thin layer of soil and at 7-10 
days old are transplanted into gravel lined concrete beds. Watercress grows best in 
spring and autumn, and during this time has a growing period of approximately 4-6                                                   Chapter 1: Introduction                        
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Figure 1.9: Image of green watercress growing in a commercial bed.  
 
 
weeks from transplanted seedling to mature crop. Watercress flowers under long day 
conditions, appearing as small white clusters, traditionally meaning that watercress 
was not sold in the summer months. However, this has now been largely overcome by 
selecting for late flowering cultivars (Stevens, 1983). In the colder winter months 
watercress grows much more slowly and in order to maintain annual supply in Britain, 
the crop is grown abroad in warmer climates and imported back. For example, 
Vitacress Salad Leaves Ltd. supply the UK with British grown watercress from March 
through to November, but grows watercress in farms in the USA from November to 
April to provide watercress over the winter months. In addition, Vitacress Salad Leaves 
Ltd. grow watercress throughout the year in farms in Portugal. 
 
Up until the Second World War there were two species of watercress being cultivated, 
the typical green watercress seen cultivated today and brown watercress. Brown 
watercress, characterised by brown/purple leaves, is a sterile hybrid between 
Nasturtium officinale and a wild watercress, Nasturtium microphyllum (formally Rorippa 
microphylla). Although, as brown watercress could only be propagated vegetatively it 
was susceptible to disease and now green watercress is the only species currently 
cultivated commercially. Nonetheless, within this species there are multiple cultivars. 
Most of the commercially available watercress can be characterised by their dark                                                 Chapter 1: Introduction                        
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green circular leaves and are believed to be genetically very similar. However, as 
every commercial grower carries out their own selections for desirable characteristics 
each have their own unique cultivar (Stevens, 1983). Interestingly, an American red 
variety of watercress has recently been commercially cultivated. It is characterised by 
red/purple leaves and is also sterile so perhaps has similar origins to brown 
watercress.  
 
1.7.2  Increasing the anticancer activity of watercress 
 
Given the public interest in healthy diet, it might be considered a commercial and 
health benefit to generate crops with enhanced anticancer activity. Indeed, previous 
studies have manipulated both genetics and environmental factors to increase 
glucosinolate concentration in a variety of cruciferous vegetables.    
 
1.7.2.1 Genetics 
 
Conventional breeding involves cross-pollination of two related plants to produce a 
new variety with favourable genetic traits from both and an absence of any negative 
traits. This is a laborious process. As per the nature of sexual recombination, progeny 
inherit a random mix of genes, and hence further selection and cross breeding over 
several generations is required to identify a variety with all the desired traits. On the 
other hand, genetic engineering of crops allows for the insertion of a single gene or 
genes associated with a specific trait into the genome of another plant. This produces 
a crop with the desired trait without altering the parent genotype. However, there is still 
public concern on the long term effects of consuming genetically modified (GM) crops 
and as a result they are often avoided by consumers (Harlander, 2002).  
   
Using plant genomics to identify genetic markers linked to desired traits allows for 
improved selection of progeny generated from conventional breeding programs, 
speeding up the process. This marker-assisted breeding was utilised in the generation 
of an isothiocyanate-enriched variety of broccoli (Mithen et al., 2003). The 
introgression of three genomic segments from the Brassica villosa, a wild relative of 
broccoli, into the genetic background of commercial broccoli (B. oleracea var. italica) 
was shown to increase glucosinolate levels. These three segments were identified as 
being responsible for the increased glucosinolate content of wild broccoli and while 
each contains a quantitative trait locus (QTL), the exact function of the gene or genes                                                 Chapter 1: Introduction                        
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remain unknown. Compared to commercial broccoli, the broccoli hybrid was 80-fold 
more potent at inducing quinone reductase activity. This effect was attributed not only 
to an increase in 3-methylsulphinylpropyl and 4-methylsulphinylbutyl glucosinolates, 
but also a greater conversion of the glucosinolate precursors to their respective 
isothiocyanates, iberin and sulforaphane. 
 
1.7.2.2 Environment 
 
Previous groups have reported that glucosinolate concentration in a variety of 
cruciferous vegetables was effected by temperature, photoperiod, light quality, water 
availability, and sulfur and nitrogen fertilisation (Bouchereau et al., 1996; Engelen-
Eigles et al., 2006; Rosen et al., 2005). 
 
In studies looking at watercress, crops grown under long days (16 h), low night  
temperatures (10°C or 15°C), and supplemented with red light (light quality)  were 
found to have higher gluconasturtiin concentrations, the glucosinolate precursor of 
PEITC, compared to those grown under short days (8 h), higher night temperatures 
(20°C or 25°C), and far-red light supplementation (Engelen-Eigles et al., 2006). 
Increasing either sulfur or nitrogen fertilisation in watercress was also found to 
enhance glucosinolate concentration. However, while sulfur fertilisation increased 
glucosinolate levels in a linear manner, there was an optimal concentration of nitrogen 
with the highest nitrogen concentration causing a drop in glucosinolate content 
(Kopsell et al., 2007). 
 
1.7.3  Key active components in watercress 
 
1.7.3.1 Glucosinolates 
 
Cruciferous vegetables are characteristically rich in glucosinolates, nitrogen and sulfur 
containing glycosides, which make up a class of relatively inert phytochemicals. 
However, upon tissue damage, such as bruising, cutting or mastication, glucosinolates 
are hydrolysed by the plant β-thioglucosidase enzyme, myrosinase, to generate 
various bioactive compounds. The disruption to the tissue acts to break the physical 
barrier between the glucosinolates and myrosinase, with the latter being sequestered 
within aqueous vacuoles (Fahey et al., 2001; Holst and Williamson, 2004). Microflora 
present in the gut also have myrosinase activity although it is relatively limited. Thus,                                                 Chapter 1: Introduction                        
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individuals consuming watercress that has been cooked to completely denature all the 
plant myrosinase have considerably less glucosinolate metabolites in their urine 
(Getahun and Chung, 1999).  
 
1.7.3.1.1 Glucosinolate metabolism 
 
Structurally, glucosinolates are (cis)-N-hydroximinosulphate esters with a sulfur-linked 
β-[D]-glucopyranose group and a highly variable side chain (R) that may include 
aliphatic, aromatic or heterocyclic groups. Myrosinase cleaves off the β-glucosyl 
moiety by hydrolysing the thioglycosidic bond to generate glucose, sulfate and the 
unstable aglycone, thiohydroxamate-O-sulfonate (Fahey et al., 2001). Depending on 
the R side chain, reaction conditions and the presence of specifier proteins, 
thiohydroxamate-O-sulfonate rapidly converts to a series of hydrolysis products, 
principally isothiocyanates, nitriles, or thiocyanates (Figure 1.10). The generation of 
isothiocyanates from glucosinolates is believed to be adapted as a defence 
mechanism, making the plant bitter and unpalatable to predators (Rask et al., 2000).   
 
1.7.3.1.2 Isothiocyanates  
 
Watercress contains several glucosinolates which can be subsequently converted to 
their constituent isothiocyanate (Table 1.3). The most abundant isothiocyanate derived 
from watercress is phenethyl isothiocyanate (PEITC), with watercress being the richest 
dietary source of this compound.  
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Figure 1.10: General schematic of the hydrolysis of a glucosinolate to an 
isothiocyanate, a nitrile or a thiocyanate by myrosinase.  
The exact product of hydrolysis depends on the R side chain of the glucosinolate. 
Adapted from Fahey et al. (2001).  
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Table 1.3: The isothiocyanate and glucosinolate content of watercress.  
Information taken from 
1Gill et al. (2007) and 
2Rose et al. (2000)
Glucosinolate Isothiocyanate 
Chemical Name  Common Name  Chemical Name  µmol/g fresh weight  µmol/g dry weight 
2-Phenylethyl-GLS 
 
Gluconasturtiin   2-Phenylethyl-ITC   1.53
1  17.98
1, 23.7
2 
6-Methylsulfinylhexyl-GLS Glucohesperin 
 
6-Methylsulfinylhexyl-ITC   0.2
2 
7-Methylsulfinylheptyl-GLS Glucoibarin 
 
7-Methylsulfinylheptyl-ITC 0.1
1  1.07
1, 3.9
2 
8-Methylsulfinyloctyl-GLS Glucohirsutin 
 
8-Methylsulfinyloctyl-ITC 0.06
1 0.68
1, 2.1
2 
7-Methylthioheptyl-GLS 
 
- 7-Methylthioheptyl-ITC    1.8
2 
8-Methylthiooctyl-GLS 
 
- 8-Methylthiooctyl-ITC    0.8
2 
4-Methoxy-3-indolylmethyl-GLS 
 
4-Methoxyglucobrassin 4-Methoxy-3-indolylmethyl-ITC 0.065
1  0.791
1 
3-Indolylmethyl-GLS 
 
Glucobrassin Indole-3-carbinol 0.04
1  0.43
1 
 
0.7
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Isothiocyanates are generally very electrophilic and as a result rapidly conjugate with 
thiols. This can occur either via enzymatic or non-enzymatic processes, and 
subsequently the issue of enzyme availability is not rate-limiting for the formation of 
thiol conjugates. As the most abundant thiol in cells is glutathione (GSH), most 
isothiocyanates after diffusion into cells form S-(N-phenylethylthiocarbamoyl) 
glutathione. These dithiocarbamate conjugates can then be exported out of the cell by 
various transporters such as multidrug resistance protein 1 (MRP1) and enter the 
mercapturic acid pathway. Here they are metabolised to cysteine conjugates and 
finally acetylated to mercapturic acids, which are isothiocyanate-N-acetylcysteine 
conjugates (ITC-NAC) in the kidney and excreted in the urine (see Figure 1.11 for 
metabolism pathway). ITC-NACs are the main ITC metabolite excreted by humans in 
the urine, and have been used to study the bioavailability of ITCs (Callaway et al., 
2004). Chung et al. (1992) determined that after consumption of 30 g watercress, 
containing 21.6 mg gluconasturtiin, 30-67% of the gluconasturtiin was recovered as the 
mercapturic acid metabolite NAC-PEITC in the urine. Assuming that there was 
quantitative hydrolysis to PEITC, 21.6 mg gluconasturtiin would yield 7.6 mg PEITC. 
Furthermore, the excretion of NAC-PEITC in the urine peaked between 2-4 h and was 
completely absent by 24 h, suggesting PEITC is rapidly metabolised.  
 
Glutathione  +  Isothiocyanate
CYS-NAC
C NH R S
CYS
C NH R S
CYS-GLY 
C NH R S
γ-GLU-CYS-GLY 
S H
GGTP CG NAT
Isothiocyanate-
glycine-cysteine
conjugate
Isothiocyanate-
cysteine conjugate
Isothiocyanate-N-
acetylcysteine
conjugate
CYS-GLY 
C NH R S
Glutathione
dithiocarbamate
GST
C N R S
 
Figure 1.11: The metabolism of isothiocyanates.   
After conjugation of glutathione and isothiocyanate to form glutathione 
dithiocarbamate, glutathione dithiocarbamate enters the mercapturic acid pathway ([ ]) 
to generate an isothiocyanate-N-acetylcysteine (GST, glutathione-S-transferase; 
GGTP, γ-glutamyltransferase; CG, cysteinylglycinase; NAT, N-acetyltransferases). 
Adapted from Holst and Williamson (2004).                                                 Chapter 1: Introduction                        
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However, following export of GSH-ITC conjugates out of the cell, extracellular 
hydrolysis can also occur, releasing free ITCs which are able to re-enter the cell and 
again react with GSH. This results in cellular depletion of GSH and rapid accumulation 
of intracellular ITCs, 100-200-fold over extracellular concentrations (Zhang, 2001). 
Once GSH levels are depleted, ITCs can conjugate to other protein cysteinyl thiols and 
this is thought to be important in ITC-mediated apoptosis and cell cycle arrest (Figure 
1.12). In human non-small lung cancer A549 cells treated with PEITC, intracellular 
levels of PEITC–GSH conjugates reached a maximum at 30 min post treatment and 
dropped rapidly thereafter. By contrast, PEITC–protein content gradually increased, 
accounting for 87% of total cellular content by 4 h. Interestingly, SFN–protein 
conjugates accounted for only 12% of total SFN uptake at the same time point. PEITC 
appears to bind to proteins more readily than SFN, perhaps accounting for its more 
potent apoptosis promoting activity (Mi et al., 2007). However, the critical targets 
involved in growth inhibition by ITCs are not known and only a few proteins have been 
shown to be direct targets for ITCs, including negative regulator of Nrf2, Keap1, 
cytoskeletal protein α-tubulin and protein kinase MEKK1 (Brown and Hampton, 2011). 
 
Furthermore, as GSH is a major antioxidant its depletion by ITCs reduces the redox 
buffering capacity of the cell and causes an increase in intracellular reactive oxygen 
species (ROS). Generation of ROS is thought to contribute to ITC-mediated apoptosis, 
as the addition of hydrogen peroxide-scavenging enzyme catalase attenuated PEITC-
induced cell death (Trachootham et al., 2006). 
 
Interestingly, the indole glucosinolates such as glucobrassin, which is present in 
watercress, generate very unstable isothiocyanates that readily undergo hydrolysis 
leaving the subsequent alcohol indole-3-carbinol (I3C), in the case of glucobrassin, 
and a thiocyanate ion. Furthermore, I3C can further condense, and in an acidic pH 
such as that provided by the gut, form various condensation products including 3,3’-
diindoylmethane (DIM) that can then form dimers, trimers and tetramers (Grose and 
Bjeldanes, 1992).  
 
1.7.4 Carotenoids 
 
Carotenoids are another class of photochemical that can be further split into two 
groups of compounds, the carotenes such as β-carotene and α-carotene that are 
unoxygenated, and the xanthophylls like lutein and zeaxanthin that contain oxygen.  
Watercress contains relatively high concentrations of β-carotene, a precursor to                                                  Chapter 1: Introduction                        
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protein
thiocarbamoylation
extracellular
intracellular
(3)
(1)
(2)
(4)
(5)
  
Figure 1.12: Intracellular accumulation of isothiocyanates.  
Following their initial diffusion into cells (1), isothiocyanates (ITCs) are rapidly 
conjugated to glutathione (GSH) via the action of glutathione-S-transferases (GST) (2). 
The GSH conjugates are exported from the cells via efflux pumps (3). Extracellular 
hydrolysis of the GSH conjugate (4) gives rise to the free ITC which is able to re-enter 
the cell. The net effect of this cycle is the rapid (1–3 h) and profound (100- to 200-fold) 
accumulation of ITC and the concomitant depletion of GSH. Once GSH levels are 
reduced, ITCs are able to conjugate to intracellular protein cysteinyl thiols. From Cavell 
et al. (2011). 
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vitamin A, and lutein. Despite there being variation between sources on the exact 
content of both β-carotene and lutein in watercress the amount of lutein is generally 
twice that of β-carotene (Table 1.4). Following the consumption of 85g of raw 
watercress daily for a period of 8 weeks, plasma concentration of β-carotene increased 
by 33% and that of lutein increased by 100% (Gill et al., 2007). 
 
1.7.5 Phenolics 
 
Flavonoids are antioxidant polyphenolics consisting of five subclasses of which 
watercress contains compounds present in two, the flavones and the flavonols (Table 
1.5). In plants these compounds are typically glycosylated, the majority thought to be 
converted to the more active aglycone by cleavage of the glycoside in the 
gastrointestinal tract.  Of particular interest is quercetin which is present in 
considerably higher amounts than any of the other flavonoids. Quercetin is present in 
watercress in the form of various glycosides such as rutin, consisting of quercetin and 
the disaccharide rutinose (Rice-Evans et al., 1996). Watercress also contains a 
relatively large concentration of the phenolics, hydroxycinamic acid derivatives (Gill et 
al., 2007). 
 
1.8  Anticancer effects of PEITC 
 
The breakdown products of glucosinolates were initially recognised as potential agents 
in preventing cancer by their ability to alter the activity of phase I and phase II drug 
metabolising enzymes. More recent studies point to there being a direct anticancer role 
for ITCs, by inducing apoptosis and inhibiting cell cycle progression, angiogenesis and 
metastasis. However, despite this, the upstream triggering events remain largely 
unknown.  
 
The anticancer activity of ITCs has been the topic of multiple reviews (Cavell et al., 
2011; Cheung and Kong, 2010; Zhang et al., 2006). As a result, this introduction will 
focus on the effects of ITCs on Nrf2 activity and angiogenesis as this relates 
specifically to the work within this study. Nonetheless, a brief overview of the potential 
mechanisms contributing to the anticancer effects of PEITC will be given in order to 
provide an insight into the scope of downstream effectors. 
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Carotenoid  μg/100g fresh weight 
β-carotene 4777
1, 2520
2 
Lutein 10713
1, 5767
2 (lutein and zeaxanthin) 
Table 1.4: The carotenoid content of watercress.  
Information taken from 
1Hart and Scott (1995) and 
2Food Standards Agency (2002). 
 
 
Flavonoids µg/100g  fresh  weight 
Flavones   
Apigenin 10 
Luteolin 20 
Flavonols   
Kaempferol 1400 
Myricetin 200 
Quercetin 7440 
Table 1.5: The flavonoid content of watercress.  
Information from the USDA Database for the Flavonoid Content of Selected Foods, 
Release 2 (2006). 
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1.8.1 Chemopreventive  effects 
 
Phase I enzymes include cytochrome P-450 enzymes (CYP), reductases, and 
hydrolases, the former being the most influential, which are involved in the 
biotransformation and subsequent activation of many chemical carcinogens. On the 
other hand phase II enzymes like glutathione-S-transferase (GST), N-acetyltransferase 
(NAT) and NAD(P)H:quinone oxidoreductase 1 (NQO1) are detoxification enzymes 
that convert carcinogens to polar conjugates so that they can be easily excreted in the 
urine or bile and therefore removed from the body (Conaway et al., 2002).  
 
Inhibition of carcinogen-induced tumourigenesis in rodents by PEITC has been 
demonstrated in a variety of tissues and is associated with a reduction of DNA adducts 
and carcinogen metabolism, as well as increase in carcinogen excretion (Huang et al., 
1993; Morse et al., 1989; Stoner et al., 1991). For example, PEITC has been shown to 
inhibit lung tumourigenesis induced by key tobacco carcinogen 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK) in rats. F344 rats were fed approximately 49 μM/d 
PEITC for 1 week prior and for the following 111 weeks during which NNK was also 
given. An increase in NNK metabolites, NNAL and NNAL-Gluc, in the urine of rats 
treated with PEITC and NNK compared to just NNK, suggests that PEITC not only 
enhances detoxification but also interferes with the metabolic activation of NNK that 
otherwise would give rise to more harmful intermediates (Hecht et al., 1996). As a 
result these chemopreventive effects of PEITC are believed to be due to modulation of 
the activity of phase I and II drug metabolising enzymes.  
 
Indeed, PEITC has been shown to induce activity of several phase II drug metabolising 
enzymes including GST and NQO1 in vitro and in vivo (Dingley et al., 2003; Rose et 
al., 2000). GST catalyses the conjugation of GSH to electrophilic moieties on a variety 
of substrates (Armstrong, 1991), while NQO1 catalyses two electron reduction of 
quinones, effectively preventing one electron reduction that would give rise to harmful 
radical species (Li et al., 1995). Observations that PEITC caused an increase in the 
mRNA levels of GST, NQO1 and antioxidant enzyme heme oxygenase 1 (HO1) 
indicates that PEITC acts at the level of transcription (Ernst et al., 2011; Keum et al., 
2003; Xu et al., 2006b).  
 
Phase II metabolising and antioxidant enzymes are transcriptionally upregulated by the 
transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) binding to 
antioxidant response elements (ARE) present in their promoter regions. Nrf2 is                                                 Chapter 1: Introduction                        
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negatively regulated by Kelch-like ECH-associated protein 1 (Keap1), which binds to 
Nrf2 and prevents it from translocating to the nucleus as well as targeting Nrf2 for 
degradation via the ubiquitin-proteasome pathway (Itoh et al., 2003). Keap-1 
dissociates from Nrf2 in response to ROS and electrophiles, allowing Nrf2 to 
translocate to the nucleus where along with small Maf proteins it can bind to AREs and 
enhance transcription of responsive genes (Figure 1.13). In mice genetically ablated 
for Nrf2, protection against benzo(a)pyrene-induced gastric tumour formation by 
sulforaphane (SFN), an isothiocyanate found in broccoli, was lost (Fahey et al., 2002). 
Furthermore, induction of NQO1 gene expression by SFN was abolished in Nrf2 null 
MEFs (Nioi et al., 2003). These studies demonstrate the importance of Nrf2 in ITC-
mediated induction of phase II drug metabolising enzymes and protection from 
carcinogen-induced tumourigenesis.  
 
ITCs have been shown to induce transcription of phase II drug metabolising enzyme 
by binding directly to several key cysteine residues in Keap1 (Ahn et al., 2010; 
Dinkova-Kostova et al., 2002). Conjugation of Keap1 with ITCs was initially thought to 
trigger the release of Nrf2, however it is now believed that ITCs inhibit Keap-1 
dependent ubiquitination and proteasome mediated degradation of Nrf2 (Zhang and 
Hannink, 2003). As ROS can also react with Keap1 to activate Nrf2, PEITC may also 
be able to activate Nrf2 indirectly. However, while Ernst et al. (2011) found induction of 
ARE-driven expression by hydrogen peroxide to be attenuated by the antioxidant 
catalase, induction by allyl isothiocyanate (AITC) was not. This suggests that 
thiocarbamoylation rather than ROS generation is responsible for ITC-induced Nrf2 
dependent transcription. Although, activation of the MAPK pathway by ITCs may also 
contribute to the upregulation of phase II drug metabolising enzymes, via downstream 
phosphorylation of Nrf2 (Keum et al., 2003; Xu et al., 2006b). Indeed, loss of PEITC-
induced ERK phosphorylation by an inhibitor of the MAPK pathway was found to 
attenuate the rise in mRNA levels of drug metabolising enzyme HQO1 (Ernst et al., 
2011).  
 
1.8.2 Anticancer  effects 
 
The potential mechanisms contributing to the anticancer effects of PEITC are outlined 
in Table 1.6. While the underlying mechanisms are unknown, inhibition of cancer cell 
proliferation has been shown to be due to the ability of isothiocyanates to induce 
apoptosis and/or cause cell cycle arrest, and an overview of the signalling pathways 
implicated is provided in Figure 1.14.                                                 Chapter 1: Introduction                        
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Figure 1.13: Activation of Nrf2. 
Keap1 (Kelch-like ECH-associated protein 1) binds to Nrf2 (nuclear factor erythroid 2-
related factor 2), targeting it for ubiquitination (U) by Cul3 (Cullin 3)-based E3 ligase. 
Electrophiles, such as isothiocyanates, and pro-oxidants, like ROS, attack ( ) the thiol 
group (S-H) of several key cysteine residues on Keap-1, allowing accumulation of Nrf2.  
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Biological response  Effect  Concentration
1 
Cell cycle arrest  Inhibition of cell cycle progression has been observed in a wide variety of cell lines 
derived from both solid and haematological malignancies. Arrest in S or G2/M 
phases of the cell cycle has been described.  
5 µM (Xiao et al., 2004) 
10 µM (Mi et al., 2008) 
1-5 µM (Hwang and Lee, 2010) 
5-10 µM (Wu et al., 2011) 
7.5 µM (Tang and Zhang, 2004) 
 
Induction of apoptosis  Induction of both the intrinsic and the extrinsic pathways has been observed in a 
wide variety of cell lines derived from both solid and haematological malignancies. 
20 µM (Satyan et al., 2006) 
5-10 µM (Huong et al., 2011) 
15 µM (Tang and Zhang, 2005) 
5 µM (Trachootham et al., 2008) 
5 µM (Xiao and Singh, 2002) 
 
In vivo tumour growth  PEITC inhibits tumour growth in a variety of xenograft models.   9-12 µM/d (Monday to Friday) by oral 
gavage for up to 31 days (Xiao et al., 2006) 
50 mg/kg (five days a week) given 
intraperitoneally for up to 60 days 
(Trachootham et al., 2006) 
50 mg/kg given intraperitoneally for 20 days 
(Gao et al., 2011) 
 
Angiogenesis   ITCs inhibit angiogenesis in in vitro and in vivo models.  1 µM (Xiao and Singh, 2007) 
5 µg/ml AITC (Thejass and Kuttan, 2007a) 
0.1-1 µM SFN (Bertl et al., 2006) 
 
Metastasis  ITCs inhibit cell adhesion, invasion and migration in vitro, and metastasis in vivo.  5 µM (Hwang and Lee, 2006)  
2 µM (Xiao and Singh, 2007) 
10 µM (Wu et al., 2010a) 
 
Table 1.6: Potential mechanisms contributing to the anticancer effects of PEITC. 
In the interests of space, only selected references are provided. 
1 Typical effective concentration. Note that differences in assay design 
preclude direct comparison between studies. Due to limited studies on the anti-angiogenic activity of PEITC, I have included data collected on 
additional ITCs, namely allyl isothiocyanate (AITC) and sulforaphane (SFN).                                                Chapter 1: Introduction 
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Figure 1.14: The various signalling pathways, known or suggested, in which 
PEITC can induce apoptosis and cell cycle arrest.  
DR (death receptor), FADD (Fas-associated protein with death domain), GSH 
(glutathione), X (thiol compounds, such as GSH), Bid (BH3 interacting domain death 
agonist), Bcl-2 (B cell lymphoma 2), Apaf1 (apoptosis protease activation factor 1), Cyt. 
C (cytochrome C), MRP1 (multidrug resistance-associated protein 1), ROS (reactive 
oxygen species), MAPK (mitogen-activated protein kinase), HDAC (histone 
deacetylase), CDK1 (cyclin dependent kinase 1), Cdc25C (cell division cycle 25C). 
Adapted from Zhang et al. (2006). 
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1.8.2.1 Induction of cell cycle arrest 
 
Cell cycle arrest as a result of PEITC treatment predominantly occurs in the G2/M 
phase, this is associated with a downregulation of cyclin dependent kinase 1 (CDK1), 
cyclin B1 and/or cell division cycle 25C (cdc25C) (Hwang and Lee, 2010; Xiao et al., 
2004). Ordinarily CDK1 forms complexes with cyclin B and is then activated by cdc25C 
which targets it for dephosphorylation. The activated CDK1-cyclin B complex is 
required for transition into mitosis and cell cycle arrest occurs by decreasing levels of 
CDK1 or cyclin B1 or preventing CDK1 phosphorylation. PEITC has also been reported 
to cause mitotic arrest by disrupting tubulin polymerisation and spindle assembly (Mi et 
al., 2008). Notably, Mi et al. (2008) demonstrated that PEITC disrupted tubulin 
polymerisation by directly conjugating to α-tubulin, later this was shown to induce 
proteasome-mediated degradation of tubulin (Mi et al., 2009). In some cell lines, arrest 
in the S phase is also observed, and is associated with a reduction in protein levels of 
S phase regulator cyclin A (Wu et al., 2011). 
 
1.8.2.2 Influence on apoptotic machinery 
 
Satyan et al. (2006) demonstrated that PEITC induces apoptosis exclusively via 
activation of the intrinsic pathway in the ovarian OVCAR3 cancer cell line. This was 
associated with a reduction in anti-apoptotic Bcl-2 protein levels and an increase in 
pro-apoptotic Bax levels, as well as activation of the MAPKs, JNK and p38.  
Furthermore, in UM-UC-3 bladder cancer cells, PEITC was found to increase Bcl-2 
phosphorylation and promote translocation of Bak to the mitochondria (Tang and 
Zhang, 2005). Therefore it seems PEITC ultimately induces apoptosis through the 
transcriptional or post-translational modulation of multiple Bcl-2 family members. 
Although, PEITC-mediated apoptosis has also been shown to occur via the extrinsic 
pathway through increased expression of death receptors 4 and 5 (DR4, DR5) (Huong 
et al., 2011).  
 
1.8.2.3 Inhibition of angiogenesis 
 
Studies on the anti-angiogenic and anti-metastatic activity of PEITC are limited. 
However, several groups have found that other isothiocyanates can also inhibit 
angiogenesis and metastasis. Both PEITC and SFN have independently been shown 
to inhibit the growth of cultured human umbilical vein endothelial (HUVEC) cells and 
prevent tube formation of these cells on matrigel, a well recognised technique for                                                 Chapter 1: Introduction 
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determining in vitro angiogenesis (Asakage et al., 2006; Xiao and Singh, 2007).  
Similar results have been shown for SFN using the immortalised human microvascular 
endothelial cell line, HMEC-1, whereby treatment prevented tube formation of these 
cells on basement membrane (Bertl et al., 2006).  
 
In ex vivo tissue culture models, SFN caused a dose dependent reduction of 
microcapillary density in a placental vessel fragment outgrowth assay (Bertl et al., 
2006) and PEITC decreased vascular density in chicken egg chorioallantoic membrane 
assays (Xiao and Singh, 2007). AITC demonstrated both in vitro and in vivo anti-
angiogenic activity by decreasing outgrowth of microvessels from rat aortic rings, and 
inhibiting in vivo tumour directed capillary formation in the mouse B16F-10 melanoma 
model (Thejass and Kuttan, 2007a). Furthermore, intravenous administration of SFN 
decreased in vivo angiogenesis in VEGF-impregnated matrigel plugs in female Balb/C 
mice (Jackson et al., 2007). SFN also reduced blood vessel density in vivo in MIA-
PaCa2 xenografts (Kallifatidis et al., 2009). 
 
Inhibition of angiogenesis by ITCs in vivo has been associated with reduced production 
of multiple pro-angiogenic factors including VEGF, nitric oxide and tumour necrosis 
factor α (Thejass and Kuttan, 2007a; Thejass and Kuttan, 2007b). Bertl et al. (2006) 
also observed a decrease in HIF1α accumulation, and VEGF production in HUMEC-1 
cells, an in vitro model of angiogenesis, following SFN treatment. HIF1α is a major 
regulator of angiogenesis which promotes transcription of VEGF. PEITC and SFN have 
been shown by both our lab and other groups to reduce HIF1α accumulation and 
VEGF expression in a variety of cancer cell lines (Wang et al., 2009; Yao et al., 2008). 
 
1.8.2.4 Inhibition of metastasis 
 
Xiao and Singh (2007) demonstrated that PEITC inhibited the in vitro migration of 
endothelial HUVEC cells and prostate cancer PC3 cells. PEITC has also been shown 
to inhibit adhesion, invasion and migration of human hepatoma SK-Hep1 cells and 
highly metastatic human lung cancer L9981 cells (Hwang and Lee, 2006; Wu et al., 
2010a). This activity was associated with a decrease in matrix metalloproteinase 
(MMP) 2 and 9, and membrane type 1 matrix metalloproteinase (MT-MMP) expression, 
and an increase in expression of tissue inhibitors of matrix metalloproteinase (TIMPs) 1 
and 2, which inhibit the activity of the MMPs (Hwang and Lee, 2006). In vivo, oral 
administration of SFN reduced pulmonary metastasis in TRAMP mice, a transgenic 
mouse model of prostate cancer (Singh et al., 2009b).                                                     Chapter 1: Introduction 
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1.9  Anticancer effects of watercress 
 
In addition to studies of isolated phytochemicals, a number of studies have 
investigated potential anti-cancer effects of watercress extracts (referred to as 
“watercress juice”), predominantly focusing on chemopreventive capabilities. Boyd et 
al. (2006) demonstrated that watercress extract protects colon cancer HT29 cells from 
oxidative DNA damage induced by various genotoxins, 4-Hydroxy Nonenal (4-HNE), 
hydrogen peroxide, and fecal water. Furthermore, the addition of watercress juice  to 
human hepatoma Hep G2 cells has been shown to protect against benzo(a)pyrene 
(B(a)P) induced DNA damage. However, this effect appears not to be due to PEITC 
alone, as when it was added in concentrations similar to that present in the juice, it was 
unable to protect the Hep G2 cells against the DNA damage induced by B(a)P. The 
watercress juice also increased the activities of the drug metabolising enzymes, GST 
and CYP1A1, although this action alone was unlikely to be responsible for the 
protection against the genotoxic effect of B(a)P, as garden cress juice showed similar 
protection against B(a)P-induced DNA damage in Hep G2 cells but the activity of GST 
and CYP1A1 was not affected (Kassie et al., 2003). Overall, this indicates that there 
are phytochemicals present in watercress, other than PEITC, that seem to be having 
an effect and that these effects are not limited to modifying drug metabolising 
enzymes.  
 
Indeed, Rose et al. (2000) discovered that despite being present in watercress at 
concentrations approximately 3 times less than PEITC, the methylsulfinylalkyl 
isothiocyanates, 7-methylthioheptyl-ITC and 8-methylthiooctyl-ITC were far more 
potent at inducing NQO1 activity in murine heptatoma Hepa 1c1c7 cells. While only 0.2 
µM of 7-methylthioheptyl-ITC and 0.5 µM of 8-methylthiooctyl-ITC were required to 
induce a two-fold increase in NQO1 activity, 5 µM of PEITC was needed to produce 
the same results. The PEITC glutathione conjugate, S-(N-β-phenylethylthiocarbomyl) 
glutathione (PECG) was also found to have a similar potency to PEITC in regards to 
increasing quinine reductase activity.   
 
These chemopreventive actions have also been demonstrated in human consumption 
studies. Hecht et al. (1995) reported that the consumption of watercress, 56.8 g with 
every meal for 3 days, inhibited the metabolic activation of a key tobacco carcinogen  
NNK in smokers. The reduction in NNK carcinogenicity is thought to be the result of 
PEITC, as changes in the excretion of PEITC metabolite PEITC-NAC in the urine 
correlated with the increased urinary detoxification metabolites used to measure                                                 Chapter 1: Introduction 
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oxidative metabolism of NNK. Furthermore consumption of 85 g of raw watercress 
once a day for eight weeks decreased several measures of DNA damage in 
lymphocytes, a cancer biomarker, and increased plasma levels of the antioxidants, β-
carotene and lutein. There was a statistically significant decrease in basal DNA 
damage, basal plus oxidative purine DNA damage, and basal DNA damage in 
response to hydrogen peroxide challenge. In addition to this there was a greater and 
more significant change in those subjects who were smokers, indicating that their 
increased exposure to toxins resulted in their observed lower antioxidant status, and 
therefore they benefited more from a boost in antioxidants than non-smokers (Gill et 
al., 2007).  
 
Interestingly Gill et al. (2007) also examined the activity of the detoxifying enzymes, 
superoxide dismutase (SOD) and glutathione peroxidase (GPX), with little change 
being observed between the watercress and control phase. Similar to what was 
concluded from the in vivo studies, this suggests that there are other mechanisms at 
work, which may be attributed to PEITC or even to other compounds present in 
watercress. When these data were later subdivided according to the genetic profile of 
the subjects, an increase in the activity of SOD and GPX in individuals with a GST Mu 
1 (GSTM1) null genotype was identified (Hofmann et al., 2009). GST is responsible for 
the conjugation of ITCs with GSH, and individuals with GSTM1 or GST theta 1 
(GSTT1) null genotypes have been previously reported to benefit more than those that 
are GSTM1 or T1 positive from the protective effects of cruciferous vegetables (Seow 
et al., 2005). As ITC-GSH conjugates are rapidly exported from the cell, it is proposed 
that loss of GST enzyme activity in these individuals slows the metabolism of ITCs 
prolonging their presence in the body. However, a recent study found that irrespective 
of the GSTM1 or T1 null genotype, there was no difference in excretion rates of 
PEITC-NAC in the urine of subjects who drank 200 ml watercress juice (Dyba et al., 
2010). While ITCs are known to initially form conjugates with GSH, one mechanism by 
which ITCs are thought to exert their anticancer effects is through conjugation with 
other cellular proteins once GSH has been depleted. It is possible that ITCs 
preferentially conjugate with GSH because of the activity of GST, and loss of that 
activity would allow ITCs to conjugate more readily with other cellular thiols, accounting 
for the enhanced protective effect seen in GSTM1 or T1 null individuals.   
 
Some studies have begun to investigate the anti-proliferation and anti-metastatic 
activity of watercress, for the first time looking not only at a chemopreventive role for 
watercress but more wholly as an anti-cancer agent. Watercress extract was found to                                                 Chapter 1: Introduction 
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inhibit cell cycle progression of colon cancer HT29 cells, specifically halting them in S 
phase, as well as inhibiting the invasion of HT115, a particularly invasive colon cancer 
cell line, through matrigel (Boyd et al., 2006). Rose et al. (2005) demonstrated that 
watercress extract, although more specifically the non-volatile 7-methylsulphinylheptyl 
isothiocyanate component, reduced MMP9 activity in the human breast cancer MDA-
MB-231 cell-line. MMP9 is a proteolytic enzyme whose activity is essential for cell 
invasion and is often upregulated in cancer cells. Subsequently treatment of 12-O-
tetradecanoylphorbol-13-acetate (TPA) stimulated MDA-MB-231 cells with either 
watercress extract or simply a fraction containing methylsulfinylheptyl-ITC resulted in 
inhibition of their invasiveness. Due to the volatility of the other ITCs present in 
watercress they where not tested in this study but Rose et al. (2005) also looked at 
broccoli extract in which they identified 4-methylsulphinylbutyl (sulforaphane) which 
demonstrated similar anti-invasive and anti-metalloproteinase activity, suggesting that 
this activity is not specific to particular ITCs.  
 
1.10 Aims 
 
Epidemiological studies indicate that there is an inverse relationship between the 
consumption of cruciferous vegetables and the risk of cancer development (Verhoeven 
et al., 1996; Voorrips et al., 2000). As a result there is much interest in understanding 
the anticancer potential not only of cruciferous vegetables themselves but also of the 
key phytochemicals contained in them. I hypothesise that the in vitro anticancer activity 
of watercress can be enhanced by altering environmental factors. To address this, the 
following aims will be investigated: 
 
i)  Select assays to assess the in vitro anticancer effects of watercress-derived 
compounds.  
ii)  Explore the mechanisms by which PEITC exhibits its anticancer effects.  
iii)  Carry out proof-of-principle experiments to discover the suitability of the assays 
selected for the analysis of crude watercress extracts.  
iv)  Investigate whether altering growth environment can increase the in vitro 
anticancer activity of watercress. 
 
 
 
 
Chapter 2
 
Materials and methods 
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2.1 Cell  culture 
 
2.1.1 Cell  lines 
 
Human breast cancer cell lines, MCF7 and SK-BR-3 (Table 2.1) were purchased from 
American Type Culture Collection (ATCC; Manasses, USA). MCF7 cells stably 
transfected with antioxidant response element (ARE) plasmid (Wang et al., 2006) were 
a generous gift of Professor Roland Wolf (University of Dundee, Scotland).  
 
Mouse embryonic fibroblasts (MEFs) lacking tuberin (TSC2-/-TP53-/-) and wild type 
control MEFs (TSC2+/+TP53-/-) (Zhang et al., 2003a) were a kind gift of Professor 
Christopher Proud (University of Southampton, UK) who obtained them from Dr David 
Kwiatkowski (Harvard Medical School, Boston, USA). MEFs that homozygously 
express the eukaryotic elongation factor 2α Ser51Ala mutation (eIF2α AA) and wild 
type control MEFs (eIF2α SS) (Scheuner et al., 2001) were a generous gift of 
Professor Randal Kaufman (University of Michigan Medical Center, Ann Arbor, USA). 
MEFs both homozygous and heterozygous for knockout of the phosphatase and tensin 
homolog deleted on chromosome 10 gene (PTEN -/-; PTEN +/-) along with wild type 
control (PTEN +/+) (Stambolic et al., 1998) were a kind gift of Dr. Vuk Stambolic 
(University of Toronto, Canada).   
 
All cell lines were maintained in complete Dulbecco’s modified Eagle’s Medium 
(DMEM; Lonza Group Ltd, Basel, Switzerland) (i.e. supplemented with 10% (v/v) fetal 
bovine serum (FBS; PAA Laboratories, Yeovil, UK), 2 mM glutamine, 50 U/ml penicillin 
and 50 U/ml streptomycin (Lonza Group Ltd). Cells were grown in a 37ºC incubator 
supplied with 10% (v/v) CO2 (Hera cell, Heraeus). 
 
 
Cell Line  Characteristics  References 
MCF7  Malignant pleural effusion secondary to breast 
carcinoma. Retains characteristics of 
differentiated mammary epithelium including 
oestrogen receptor expression. 
 
Tong et al. (1999), 
ATCC 
SK-BR-3  Malignant pleural effusion secondary to breast 
carcinoma. Overexpresses the HER2 gene 
product. Negative for oestrogen receptor 
expression. 
 
Kallioniemi et al. 
(1992), Tong et al. 
(1999), ATCC 
Table 2.1: Cell lines and characteristics.                                                                                        Chapter 2: Materials and methods 
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2.1.2 Cell  culture 
 
Cells were maintained in 175 cm
2 tissue culture flasks (Greiner Bio-One Ltd., 
Gloucestershire, UK) and routinely passaged at 60-70% confluence. Media was 
aspirated from flasks and Trypsin-Versene
® (EDTA) Mixture (3 ml; 0.05% (w/v) trypsin 
and 0.02% (w/v) versene (EDTA); Lonza Group Ltd.) was used to rinse away any 
remaining cell debris before being discarded. Trypsin-Versene
® (EDTA) Mixture (4 ml) 
was added to the flask and incubated at 37ºC/10% CO2 for a minimum of 3 min to 
detach cells. Following this complete DMEM (8 ml) was added to the flask to inactivate 
the trypsin and collect the cells. The required volume of cell suspension to produce the 
desired dilution was removed and either discarded or transferred to a 15 ml centrifuge 
tube (Greiner Bio-One Ltd.) where the cells were then counted and used for an 
experiment. Complete DMEM (25 ml) was added to the remaining cells in the flask and 
incubated at 37ºC/10% (v/v) CO2.  
 
2.1.3 Hypoxia 
 
To expose cells to hypoxia, cells were sealed in a modulator incubator chamber 
(Billups-Rothenberg, Inc.; Del Mar, USA) which was flushed for 2 min with 1% (v/v) O2, 
5% (v/v) CO2, 94% (v/v) N2 (BOC, Surrey, UK) and placed in a 37ºC/5% (v/v) CO2 
incubator (Galaxy S, RSBiotech) alongside the normoxia control. After 1 h the chamber 
was re-flushed for 2 min with 1% (v/v) O2, 5% (v/v) CO2, 94% (v/v) N2 and placed back 
in the incubator for the desired length of time. For some experiments hypoxic 
responses were induced using the hypoxia mimetics cobalt chloride (CoCl2; Sigma, 
Poole, UK) or desferrioxamine (DFO; Sigma). Both stabilise HIF1α by preventing 
binding of the pVHL; CoCl2 by directly binding to HIF1α and blocking the pVHL binding 
site (Yuan et al., 2003), and DFO by acting as an iron chelator and inhibiting the 
activity of the iron-dependent proyl hydroxylases which hydroxylate HIF1α required for 
pVHL recognition (Wang and Semenza, 1993). Cells were pretreated with 100 μM 
CoCl2 or DFO immediately prior to treatment with the test compound. 
 
2.1.4  Freezing cells for long term storage 
 
Freezing media was prepared by adding 10% dimethyl sulphoxide (DMSO; Sigma) to 
90% FBS. Cells were trypsinised as described in Section 2.1.2 and counted before 
being centrifuged at 1300 rpm for 3 min in a Sorvall
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50 
(360 g). The cell pellet was resuspended in freezing media to at a concentration of 
2x10
6 – 6x10
6 cells per ml. Aliquots (1 ml) were transferred to labelled Cryo.s
™ 1.0 ml 
cyrovial (Greiner Bio-One Ltd.) and frozen in a NALGENE
® Mr Frosty (Thermo Fisher 
Scientific) filled with isopropanol (250 ml; Thermo Fisher Scientific) at -80ºC overnight 
and transferred to liquid nitrogen for long term storage. 
 
2.1.5  Thawing cells for culture 
 
Cells were quickly thawed by hand, to maintain cell viability, whilst the cryovial lid was 
loosened gently. Thawed cells were transferred to a 1.5 ml microcentrifuge tube and 
centrifuged at 2000 rpm for 3 min in a Heraeus
® Biofuge
® fresco microfuge (380 g) to 
remove DMSO. The supernatant was discarded and the cell pellet resuspended in 
complete DMEM (1 ml) that was then further added to more complete DMEM (9 ml) in 
a 25 cm
2 tissue culture flask (Greiner Bio-One Ltd.) and incubated at 37ºC/10% (v/v) 
CO2. 
 
2.2 Compounds  and  extracts 
 
2.2.1  Analytical grade compounds 
 
Phenethyl isothiocyanate (PEITC), indole-3-carbinol (I3C) and quercetin dihydrate 
were all purchased from Sigma. 10 mM PEITC, 100 mM I3C and 100 mM quercetin 
stock solutions were made in DMSO fresh on the day of use.   
 
2.2.2 Watercress  extracts 
 
Green and red watercress samples were obtained directly from Vitacress Salads Ltd. 
(Andover, UK). Samples were snap frozen in liquid nitrogen and stored at -80ºC.  2 g 
of leaf and 2 g of stem were weighed and placed in a 20 ml syringe (BD Biosciences, 
Oxford, UK) that had had the plunger removed and a circular 25 mm glass microfibre 
filter (Whatman, Dassel, Germany) placed at the bottom. The syringe was then placed 
inside a 50 ml centrifuge tube without the lid and centrifuged at 2641 rpm for 30 min in 
a Sorvall
® Legend RT bench top centrifuge (1500 g) to collect the extract. This crude 
watercress extract was then filtered through a 0.22 µm filter (Whatman) and used 
immediately.  
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2.3 Cell  proliferation   
 
2.3.1  Preparation of assays 
 
MCF7 cells and MEFs were seeded at a density of 1000 cells per well of a 96 well 
plate (Greiner Bio-One Ltd.) in complete DMEM (50 µl). SK-BR-3 cells were seeded at 
a density of 5000 cells per well of a 96 well plate in complete DMEM (50 µl). The 
outside wells of the 96 well plate were not used and were instead filled with phosphate 
buffered saline (100 µl; PBS; see Section 2.11) to avoid the cells drying out and to 
allow for no cell blank controls. Cells were incubated at 37ºC/10% (v/v) CO2 overnight. 
The following day cells were treated with watercress-derived compounds, watercress 
juice or solvent controls. The non-specific protein kinase inhibitor staurosporine (50 
nM; Sigma) was used as a positive control (Jacobson et al., 1996). For compounds, a 
DMSO solvent control was carried out equivalent to the largest volume of compound 
added. Dilutions were made in a 24 well plate (Greiner Bio-One Ltd.) at 2x final 
concentration and added to the cells in complete DMEM (50 µl) to give a total volume 
of 100 µl. Breast cancer cell lines were incubated at 37ºC/10% (v/v) CO2 for a further 
six days, while the MEFs were only incubated for a further four days due to their faster 
rate of proliferation.   
 
2.3.2 MTS  assay 
 
Metabolically active cells convert the tetrazolium compound 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(-4-sulfophenyl-2H-tetrazolium inner salt (MTS) that 
is contained in the CellTiter 96
® AQueous One Solution Reagent (Promega, 
Southampton, UK) to the coloured product formazan. The colour intensity of the 
formazan dye is widely used as a measure of the number of viable cells.  However, it 
should be noted that whilst this assay provides a simple method to measure the effect 
of compounds on cells, it does not provide a direct measure of cell division. Apparent 
cell number will be influenced by both cell division and cell death, and changes in 
metabolic activity may also affect the amount of formazan generated.  
 
At the end of the culture period, growth media was removed from the wells of the 96-
well plate and discarded. Roswell Park Memorial Institute 1640 media (100 µl; RPMI; 
Lonza Group Ltd) and CellTiter 96
® AQueous One Solution Reagent (5 µl) was added per 
well. The 96 well plate was placed in a 37ºC incubator supplied with 5% (v/v) CO2 for                                                                                        Chapter 2: Materials and methods 
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90 min to allow for the colorimetric reaction to occur. Changes in absorbance were 
measured by a Varioskan Flash plate reader (Thermo Fisher Scientific Inc, Rockford, 
USA) at 490 nm. An average value obtained from the blanks was subtracted from all 
other values to allow for any background absorbance of the RPMI and these 
normalised values were set as a percent of the average from the untreated wells. 
 
2.3.3 Analysis 
 
Data obtained from the simple growth inhibition experiments was analysed by the 
software program GraphPad Prism 4 (GraphPad Software Inc.) to produce survival 
curves and calculate the IC50 value.  
 
2.4  SDS-PAGE and western blotting 
 
2.4.1  Preparation of cell lysates 
 
Cells were seeded at a density of 1x10
6 cells per 60 mm dish (Greiner Bio-One Ltd.) in 
complete DMEM (4 ml) and incubated overnight. The following day cells were treated 
with the watercress derived compounds, DMSO as a solvent control, or were left 
untreated and incubated for the desired length of time. For serum starvation cells were 
plated in complete DMEM overnight, washed (3 x 1 ml) with serum free DMEM and 
incubated for 24 h in serum free DMEM (4 ml). For those cells that were re-stimulated 
with serum, the serum free DMEM was replaced with complete DMEM for 2 h.  
 
To prepare protein lysates, the growth media was decanted from the tissue culture 
dishes and the cells were rinsed with ice cold PBS (1 ml). Ice cold PBS (1 ml) was then 
added and the cells were detached using a plastic cell scraper (Greiner Bio-One Ltd.) 
and collected in a 1.5 ml microcentrifuge tube. This protocol was carried out for all cell 
lines with the exception of TSC2 null and wild type MEFs as PEITC seemed to 
interfere with the adherence of the former cells. It was observed that after 3 h PEITC at 
as low as 5 µM resulted in a large number of the cells detaching, however if left 
incubated overnight re-adhered. Therefore in the case of TSC2 null and wild type 
MEFs, these cells were scraped on ice in their media before the whole volume was 
transferred to a 15 ml centrifuge tube and centrifuged at 4ºC and 1500 rpm in a 
Sorvall
® Legend RT bench top centrifuge (500 g) for 5 min. The supernatant was                                                                                        Chapter 2: Materials and methods 
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discarded and the cell pellet resuspended in ice-cold PBS (1 ml) before being 
transferred to a 1.5 ml microcentrifuge tube. 
 
Cells were centrifuged at 4ºC and 3000 rpm for 1 min in a Heraeus
® Biofuge
® 
microfuge (860 g) and the supernatant discarded. Cell pellets were resuspended in 1x 
RIPA buffer (see Section 2.11) plus 1:100 dilution of protease inhibitor cocktail (Sigma; 
see Section 2.11) and phosphatase inhibitor cocktail 1 (Sigma) as required. Cell 
lysates were left on ice for 30 min and centrifuged at 4ºC and 13000 rpm for 15 min in 
a Heraeus
® Biofuge
® fresco microfuge (16100 g). The lysate supernatant was 
removed, aliquoted into a fresh microcentrifuge tube and kept on ice. Protein lysates 
were quantified on a Varioskan Flash plate reader spectrophotometer at 595 nm using 
the BSA protein assay described below. 
 
2.4.2  BSA protein assay 
 
BioRad protein assay dye concentrate (BioRad Laboratories, Hercules, USA) was 
diluted 1:5 with PBS and aliquoted (250 µl) into 96 well plate. 1 µl of each sample or 
desired amount of bovine serum albumin (BSA; Promega) was added and mixed. BSA 
standards were made up in the following concentrations by adding various volumes of 
1mg/ml BSA, adding the appropriate volume of distilled H2O to give a total volume of 5 
µl each time:  
 
0: 0 mg/ml: 0 µl (Blank) 
1: 0.2 mg/ml: 1 µl 
2. 0.4 mg/ml: 2 µl 
3. 0.6 mg/ml: 3 µl 
4. 0.8 mg/ml: 4 µl 
5. 1 mg/ml: 5 µl 
 
Wells were mixed thoroughly, left for 5 min at room temperature and absorbance 
measured at 595 nm on a Varioskan Flash plate reader spectrophotometer.  
 
2.4.3  Making Tris-HCl gels 
 
Tris-HCl gels were prepared reusing the BioRad Mini-PROTEAN 3 system in 
accordance to the recipes detailed in Table 2.2 and Table 2.3. 10% gels were used in                                                                                        Chapter 2: Materials and methods 
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the majority of cases except when probing for extremely large proteins (i.e. TSC2) 
where 6% gels were used.  
 
 
Resolving Gel  Reagents 
6% gel 
 
10% gel 
H2O  5.3 ml  4 ml 
30% (v/v) acrylamide  2 ml  3.3 ml 
1.5 M Tris pH 8.8  2.5 ml  2.5 ml 
10% (w/v) SDS  100 µl  100 µl 
10% (w/v) ammonium persulphate (APS)  100 µl  100 µl 
TEMED (N, N, N’, N’-tetramethylenediamine)  10 µl  10 µl 
Table 2.2: Recipe for 10 ml 6% and 10% Tris-HCl resolving gels. 
 
 
Reagents Stacking  Gel 
 
H2O 2.7  ml 
30% (v/v) acrylamide  670 µl  
1.5 M Tris pH 8.8  500 µl 
10% (w/v) SDS  40 µl 
10% (w/v) APS  40 µl 
TEMED   5 µl 
Table 2.3: Recipe for 8 ml Tris-HCl stacking gel. 
 
 
2.4.4 Western  blotting 
 
Tris-HCl gels were placed in a BioRad Mini-PROTEAN 3 Cell containing approximately 
500 ml 1x running buffer (see Section 2.11).  Equal amounts (15-30 µg) of protein from 
each sample was made up to 10 µl with distilled H2O and mixed with 5 µl 3x SDS 
Sample Buffer Red (Cell Signaling Technology, Danvers, USA; see Section 2.11) 
supplemented with 0.1 M dithiothreitol (DTT; Cell Signaling Technology) to give a final 
volume of 15 µl. The samples along with the protein marker (New England BioLabs, 
Ipswich, USA) were heated at 95ºC for 5 min before being spun briefly up to 13000 
rpm in a Heraeus
® Biofuge
® microfuge (16100 g).  Protein marker (5 µl) was loaded 
into the first well and the samples (15 µl) loaded into subsequent wells. The gel was 
resolved at 150 V for a minimum of 60 min. The gel was removed and placed between 
transfer filter paper and membrane in a ‘sandwich’ consisting of 1 sponge (BioRad 
Laboratories), 1 filter paper, nitrocellulose blotting membrane (Whatman), a further 1                                                                                        Chapter 2: Materials and methods 
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filter paper and 1 sponge in a  BioRad Mini-Trans Blot Cell as per manufacturers 
instructions. Approximately 500 ml transfer buffer (see Section 2.11) was added to the 
BioRad Mini-Trans Blot Cell before being transferred at 100 V for 1 h.  This is with the 
exception of the 6% gel used when looking at large proteins (i.e. tuberin) where the gel 
was transferred at 30 V overnight at 4°C followed by 70 V for 1 h at room temperature 
the following day.  
 
Membranes were blocked with 5% (w/v) milk (dried non-fat Marvel) made in 0.1% (w/v) 
TBS-Tween (5 ml; TBS-TW; see Section 2.11) for 1 h at room temperature on an 
automatic roller before being stained with primary antibody (see Table 2.4) overnight at 
4°C. The following day membranes were then washed (3x 5 min) with 0.1% TBS-TW 
(5 ml) and stained with the appropriate secondary horseradish peroxidase-conjugated 
(HRP) antibody (see Table 2.4) for 1 h at room temperature. Membranes were again 
washed (3x 5 min) with 0.1% TBS-TW (5 ml). 1:1 mixture of stable peroxide solution 
and luminol enhancer that form the Supersignal West Pico Chemilluminescent 
substrate reagent (Thermo Fisher Scientific) was applied to the membrane for 1 min. 
Chemilluminescence was detected on a ChemiDoc-It
® Imaging System (Ultra-Violet 
Products Ltd., Cambridge, UK) using VisionWorks
®LS Image Acquisition and Analysis 
Software (UVP Ltd). Protein band quantification was carried out using ImageJ software 
(http://rsb.info.nih.gov/ij/). Protein expression values were normalised to expression of 
β-actin and then to untreated control. For phospho-specific antibodies, expression 
values were expressed relative to total protein. For 4E-BP1, phosphorylation was 
detected as a decrease in the migration of 4E-BP1 detected using non-phospho-
specific antibody and phosphorylated forms were quantified as a proportion of total 4E-
BP1 expression. 
 
2.4.5 Stripping  of  membranes 
 
Membranes were washed for 5 min in stripping buffer (5 ml; see Section 2.11) to strip 
off the antibody complexes prior to re-probing. Blots were further washed (3x 5 min 
and 2x 10 min) with 0.1% TBS-TW (5 ml) to restore pH and finally re-blocked in 5% 
(w/v) milk in 0.1% TBS-TW (5 ml) for 1 h at room temperature before being re-probed. 
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Primary antibody 
Species 
raised in 
Blocking 
step 
 
Supplier 
 
Dilution 
4E-BP1  rabbit  BSA  Cell Signaling Technology   1:1000 
Akt   rabbit  BSA  Cell Signaling Technology  1:1000 
AMPK  rabbit  BSA  Cell Signaling Technology  1:1000 
β-actin rabbit  milk  Sigma  1:1000 
eEF2  rabbit  BSA  Cell Signaling Technology  1:1000 
eIF2α  rabbit  BSA  Cell Signaling Technology  1:1000 
ERK1/2  mouse  BSA  Cell Signaling Technology  1:1000 
HIF1α   mouse  milk  BD Biosciences  1:250 
Hsc70  mouse  milk  Santa Cruz Biotechnology 
Ltd., Heidelberg, Germany 
1:1000 
NDRG1  rabbit  BSA  Cell Signaling Technology  1:1000 
p70 S6K  rabbit  BSA  Cell Signaling Technology  1:1000 
P-Akt (Thr308)   rabbit  BSA  Cell Signaling Technology  1:1000 
P-Akt (Ser473)   rabbit  BSA  Cell Signaling Technology  1:1000 
P-AMPK (Thr172)  rabbit  BSA  Cell Signaling Technology  1:1000 
P-eEF2 (Thr56)  rabbit  BSA  Cell Signaling Technology  1:1000 
P-eIF2α (Ser51)  rabbit  BSA  Cell Signaling Technology  1:1000 
P-ERK1/2 
(Thr202/Tyr204) 
rabbit  BSA  Cell Signaling Technology  1:1000 
P-NDRG1 
(Thr346) 
rabbit  BSA  Cell Signaling Technology  1:1000 
P-p70 S6K 
(Thr389) 
rabbit  BSA  Cell Signaling Technology  1:1000 
PTEN  goat  milk  Santa Cruz Biotechnology 
Ltd. 
1:200 
Tuberin  mouse  milk  Santa Cruz Biotechnology 
Ltd. 
1:200 
Secondary 
antibody 
Species 
raised in 
Blocking 
step 
 
Supplier 
 
Dilution 
goat  rabbit  milk  Dako, Stockport, UK  1:5000 
mouse  sheep  milk  GE Healthcare UK Ltd., 
Buckinghamshire, UK 
1:5000 
rabbit  donkey  milk  GE Healthcare UK Ltd.  1:5000 
Table 2.4: List of antibodies used for western blotting. 
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2.5 HDAC  inhibition  assay 
 
Cells were seeded at a density of 1000 cells per well of a 96 well plate in complete 
DMEM (81 µl) and incubated overnight at 37ºC/10% (v/v) CO2. The following day cells 
were treated in the absence or presence of watercress-derived compounds. A DMSO 
solvent control was carried out and known HDAC inhibitors trichostatin A (TSA; Sigma) 
(Yoshida et al., 1990) or suberoylanilide hydroxamic acid (SAHA; Enzo Life Sciences 
Ltd., Exeter, UK) (Richon et al., 1998) were used as positive controls. A blank 
containing all reagents but no cells was also analysed. Stock solutions were diluted in 
DMSO to give 100x final concentrations before 4 μl of each was added to complete 
DMEM (36 μl) in a dilution plate. 9 μl of the serially diluted compound was added to 
each well. This way every well has the same concentration of DMSO. Cells were 
incubated for 16 h. 10 μl of either 2 mM BOC-lys(ac)-AMC (Bachem, Weil am Rhein, 
Germany) or 2 mM control, BOC-lys-AMC (Bachem), was added to each well and cells 
incubated for a further 1 h. Lysis buffer/developer mix (100 μl; see Section 2.11) was 
added to each well and incubated for 16 h before fluorescence (excitation 355 nm, 
emission 460 nm) was measured on Varioskan Flash plate reader. See Figure 2.1 for 
schematic of the mechanism. 
2.6  Luciferase reporter assay 
 
2.6.1 Plasmid  transformation 
 
0.5 μl of each plasmid was added to 50 μl competent JM109 bacterial cells (kind gift of 
Patrick Duriez, Cr-UK Protein Core Facility, Southampton, UK) including a negative 
control (no addition) and incubated on ice for 30 min. The bacteria were then heat 
shocked for 60 seconds at 42°C and immediately cooled on ice for 2 min. L Broth (450 
μl; LB) warmed to 37ºC was added and the tubes were agitated at 200 rpm for 45 min 
in an incubating shaker (37ºC). 50 μl was spread on LB agar plates containing 50 
ug/ml ampicillin (Sigma) and incubated at 37°C overnight. A single colony from each 
positive plate was picked using a sterile pipette tip and placed in a 50 ml centrifuge 
tube containing LB (5 ml) supplemented with 50 ug/ml ampicillin and placed in an 
incubating shaker overnight (200 rpm at 37°C). The following day 400 μl from the 
culture was removed and placed in 1 L conical flask along with 200 ml LB and 200 μl 
ampicillin, and returned to an incubating shaker overnight (200 rpm at 37°C). 
Maxipreps were prepared using a Hi Speed
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Figure 2.1: Schematic of the mechanism behind the HDAC inhibition assay.  
(a) In the absence of a HDAC inhibitor the BOC-lys(ac)-AMC compound is 
deacetylated by HDACs in the cells. This allows the trypsin in the lysis buffer to cleave 
the bond between the now unprotected lysine and the AMC fluorescent fluorophore, 
releasing it. The fluorophore gives off a fluorescent signal. (b) In the presence of a 
HDAC inhibitor the cells are prevented from deacetylating the BOC-lys(ac)-AMC 
compound, so the lysine remains acetylated. The trypsin is unable to cleave the 
fluorophore and subsequently there is a reduction in fluorescent signal. HDAC, histone 
deacetylase; Lys, lysine; Ac, acetyl group; AMC, 7-amino-4-methylcoumarin; HDACi, 
histone deacetylase inhibitor. 
AMC  BOC-lys + 
BOC-lys(ac )-AMC  
BOC-lys-AMC  
Trypsin 
HDAC 
Step 1: HDACs remove acetyl  
             group from substrate. 
Step 2: Bond between lysine and  
             AMC is cleaved by trypsin. 
AMC fluorophore is free to 
fluoresce. 
a) 
HDAC  HDACi 
BOC-lys(ac)-AMC  
BOC-lys(ac)-AMC  
BOC-lys(ac)-AMC  
Trypsin 
Step 1: Activity of HDACs is  
             inhibited and the substrate            
             remains acetylated. 
Step 2: Bond between lysine and  
             AMC is protected by the  
             acetyl group and trypsin is  
             unable to cleave it. 
AMC fluorophore remains  
attached and does not fluoresce. 
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UK) as per manufacturer’s instructions. Plasmid DNA was quantified on a NanoDrop 
1000 Spectrophotometer (Thermo Fisher Scientific) and stored at + 4°C. 
 
2.6.2  Transfecting cell lines 
 
Cells were seeded at a density of 3x10
6 cells per 10 cm culture dish (Greiner Bio-One 
Ltd.)  in complete DMEM (15 ml) and incubated overnight at 37°C/10% (v/v) CO2. The 
following day cells were transfected with either the HIF-dependent luciferase reporter 
construct pGL2-TK-HRE (Rapisarda et al., 2002) (a kind gift of Giovanni Melillo, 
Tumour Hypoxia Laboratory, NCI, USA) or a control pGL3-promotor (Promega).   
Transfection mixtures containing 6 ml serum free DMEM, 4 µg desired plasmid DNA 
and 90 µl TransFast™
 Transfection Reagent (Promega) were incubated for 12 min at 
room temperature and mixed intermittently. Media was removed from cells and 
replaced with the transfection mixture. Cells were incubated for a further 2 h at 
37°C/10% (v/v) CO2 after which the transfection mixtures were removed and replaced 
with complete DMEM (15 ml). Cells were incubated overnight at 37°C/10% (v/v) CO2. 
 
2.6.3  Treating the cells 
 
Transfected cells were recovered and plated in white 96 well plates (PerkinElmer Ltd., 
Cambridge, UK) at a density of 2000 cells per well in complete DMEM (50 μl).  Cells 
were incubated for 5 h to allow cells to adhere before being treated with increasing 
concentrations of crude watercress extract, and distilled water as a control. Cells were 
cultivated with or without hypoxia mimetic DFO for 24 h at 37°C/10% (v/v) CO2.   
 
When analysing the effect on antioxidant response element (ARE) activity, stably 
transfected MCF-7 derived reporter cells, AREc32, were used. In this instance cells 
were simply plated in white 96 well plates at a density of 5000 cells per well in 
complete DMEM (50 μl) and left overnight to adhere. The following day the cells were 
treated with increasing concentrations of PEITC or crude watercress extract, and either 
DMSO or distilled water as solvent controls respectively for 24 h at 37°C/10% (v/v) 
CO2. 
 
2.6.4  Bright Glo assay 
 
Luciferase activity was measured after 24 h. Bright -Glo™ (100 µl; Promega) was 
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plate reader where the plates were shaken for 2 min and incubated at 37°C for 12 min. 
Luminescence was then measured.   
 
2.7 Quantitative-reverse  transcription-polymerase chain 
reaction (Q-RT-PCR) 
 
2.7.1  Total RNA extraction 
 
MCF7 cells were seeded at a density of 1x10
6 cells in 60 mm culture plates in 
complete DMEM (5 ml) and incubated at 37ºC/10% (v/v) CO2 overnight to adhere. The 
following day cells were treated in duplicate with PEITC or DMSO as a solvent control, 
or were left untreated. Cells were cultured in a hypoxia chamber for 16 h before being 
harvested. On ice, media was decanted and discarded and the cells were rinsed with 
ice cold PBS (1 ml). More ice cold PBS (1 ml) was added and the cells were scraped 
with a plastic cell scraper and collected in a 1.5 ml microcentrifuge tube.  
 
Cells were centrifuged at 4ºC and 3000 rpm for 1 min in a Heraeus
® Biofuge
® fresco 
microfuge (860 g) and the supernatant decanted and discarded. The cell pellet was 
resuspended in TRIZOL (1 ml; Invitrogen, Paisley, UK) and incubated at room 
temperature for 5 min. Samples were further centrifuged at 4ºC and 13000 rpm for 15 
min in a Heraeus
® Biofuge
® fresco microfuge (16100 g) and the supernatant 
transferred to a fresh 1.5 ml microcentrifuge tube. Phenol chloroform (200 μl; Applied 
Biosystems, CA, USA) was added to each sample before they were vortexed 
vigorously for 15 seconds and incubated at room temperature for 3 min. Samples were 
again centrifuged 4ºC and 13000 rpm for 15 min in a Heraeus
® Biofuge
® fresco 
microfuge (16100 g) to separate the mixture into a lower phenol-chloroform phase, an 
interphase, and a colourless upper aqueous phase. RNA remains exclusively in the 
aqueous phase. The upper aqueous phase was carefully transferred into a fresh 1.5 ml 
microcentrifuge tube without disturbing the interface. Isopropanol (500 μl) was added 
to precipitate the RNA and the samples were incubated at room temperature for 10 min 
before being centrifuged at 4ºC and 13000 rpm for 15 min in a Heraeus
® Biofuge
® 
fresco microfuge (16100 g). The supernatant was decanted and discarded and the 
pellets washed with 75% (v/v) ethanol (1 ml) by vortexing samples and centrifuging at 
4ºC and 7500 rpm for 15 min in a Heraeus
® Biofuge
® fresco microfuge (5360 g) and 
again discarding the supernatant. The remaining RNA pellet was partially air-dried for 
5-10 min and dissolved in nuclease free water (20 µl; Promega). RNA was quantified                                                                                        Chapter 2: Materials and methods 
61 
on NanoDrop 1000 Spectrophotometer and all samples had an A260/A280 ratio > 2.0 
confirming the purity of the samples. 
 
2.7.2  Generation of cDNA by reverse transcriptase  
 
1 μg total RNA was added to 1 μl oligo (dT) primer (500 μg/ml; Promega) and made up 
to 15 μl with nuclease-free water (Promega). Samples were vortexed and spun briefly 
at 13000 rpm in a Heraeus
® Biofuge
® fresco microfuge (16100 g) before being 
incubated at 70ºC for 5 min. 5 μl M-MLV RT 5x buffer (see Section 2.11), 1.25 μl of 10 
mM dNTP mix, 0.625 μl RNasin (40 U/μl), 1 μl M-MLV reverse transcriptase enzyme 
(200 U/μl) and 2.125 μl nuclease-free water were added to each sample. Samples 
were again vortexed and spun briefly at 13000 rpm in a Heraeus
® Biofuge
® fresco 
microfuge before being incubated at 42ºC for 60 min and 95ºC for 5 min. 75 μl 
nuclease-free water was added to make the final volume 100 μl and the samples 
stored at -20ºC. 
 
2.7.3 Q-PCR 
 
Q-PCR was performed in 20 μl reactions containing 10μl Taqman
® Universal 2x PCR 
Master Mix (P/N 4304437 contains AmpliTaq Gold DNA Polymerase, AmpErase UNG, 
dNTPs with dUTP, Passive Reference, and optimized buffer components; Applied 
Biosystems), 1 µl of the Taqman
® Gene Expression Assay of interest (Applied 
Biosystems), 5 μl cDNA and 4 μl nuclease free water. Expression assays used for this 
study were; BNIP3 (Hs00969293_mH), VEGF-A (Hs00173626_m1), CAIX 
(Hs00154208_m1), GLUT1 (Hs00892681_m1) and β-actin (Hs99999903_m1). All 
reactions were performed in duplicate. PCR plates were spun briefly up to 1000 rpm in 
a Sorvall
® Legend RT bench top centrifuge (200 g) before PCR was performed using 
the ABI PRISM 7500 Sequence Detection System (Applied Biosystems) according to 
the following thermal cycle protocol: 94°C 10 min followed by 40 cycles of denaturation 
at 94°C for 15 s and annealing/extension at 60°C for 1 min. Control reactions with no 
cDNA were run on each plate for each Taqman
® Gene Expression Assay used and no 
amplification was detected in any control reaction. All expression values were 
normalised using expression of β-actin as a control. 
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2.8  Metabolic radiolabelling experiments 
 
2.8.1 Metabolic  radiolabelling   
 
Cells were seeded at a density of 1x10
6 cells per well in a 6 well dish (Greiner Bio-One 
Ltd.) in complete DMEM (2 ml) and incubated overnight to adhere. The following day 
cells were washed three times in warm DMEM (1 ml) lacking L-glutamine, L-cysteine 
and L-methionine (MP Biomedicals, Illkirch, France) before being incubated in DMEM 
(1 ml) without L-glutamine, L-cysteine and L-methionine supplemented with 10% (v/v) 
dialysed FBS and 2 mM glutamine for 1 h. Cells were pretreated for 1 h in the absence 
or presence of crude watercress extract, PEITC, 0.3% DMSO (equivalent to the 
highest volume of PEITC) or 10 μg/ml cycloheximide (CHX; Sigma) before the cells 
were radioactively labelled. In one experiment cells were also treated with 25 nM of the 
mTORC1 inhibitor rapamycin (Sigma). CHX is an inhibitor of general protein synthesis 
(Baliga et al., 1969) and acts as a positive control. In experiments where CoCl2 was 
used to mimic hypoxia, 100 μM was added at the same time as PEITC.  0.75 MBq per 
ml TRAN35S - LABEL
™ No - Thaw Metabolic Labelling Reagent (MP Biomedicals) with 
specific activity >37.0 TBq/mmol was added to each well and the cells incubated for 2 
h at 37°C/10% (v/v) CO2. Future experiments were performed using the same amount 
of [
35S]methionine and [
35S]cysteine. 
 
2.8.2 Immunoprecipitation 
 
Following S
35 metabolic cell labelling (see Section 2.8.1), media was decanted and 
discarded and the cells washed with ice cold PBS (1 ml) on ice. 1x RIPA buffer (800 μl) 
with a 1:100 dilution of protease inhibitor cocktail and phosphatase inhibitor cocktail 1 
was added and intermittently pipetted up and down to lyse all the cells. Lysates were 
transferred to a 1.5 ml microcentrifuge tube and left on ice for 15 min. Samples were 
centrifuged at 4ºC and 13000 rpm in a Heraeus
® Biofuge
® fresco bench top centrifuge 
(16100 g) for 10 min and the supernatant removed and aliquoted into a fresh 
microcentrifuge tube. Samples were incubated with 1 μg anti-HIF1α (BD Biosciences) 
overnight at 4ºC on a suspension mixer. Meanwhile G-coupled Sepharose beads (GE 
Healthcare UK Ltd.), were washed in 1x RIPA buffer (3x 1 ml) before being 
resuspended in twice their volume of 1x RIPA buffer and stored at 4ºC overnight. The 
following day G-coupled Sepharose beads (100 μl of 2x slurry) were added to each 
sample and incubated for 4 h at 4ºC on a suspension mixer. Beads were washed in 1x                                                                                        Chapter 2: Materials and methods 
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RIPA buffer (4x 500 μl) and resuspended in 30 µl 3x SDS Sample Buffer Red 
supplemented with 0.1 M DTT before being stored at -20ºC. 
 
2.8.3  SDS-PAGE and phosphor imaging 
 
See Section 2.4.3 for making Tris-HCl gels. Gels were placed in a BioRad Mini-
PROTEAN 3 Cell and surrounded with approximately 500 ml 1x running buffer.  The 
samples along with the protein marker were heated at 95ºC for 5 min before being 
spun briefly up to 13000 rpm in a Heraeus
® Biofuge
® fresco microfuge (16100 g). The 
protein marker (5 µl) was loaded into the first well and samples (15 µl) loaded into 
subsequent wells. The gel was resolved at 150 V for a minimum of 60 min before being 
removed and washed in 75% (v/v) ethanol (10 ml; Thermo Fisher Scientific) for 15 min 
at room temperature to fix it. The gel was dried for approximately 1 h in a BioRad 
GelAir Dryer according to the manufacturer’s instructions with Saran™ wrap the size of 
the gel between the first layer of BioRad GelAir Cellophane Support and the gel for 
easy removal of the cellophane at the end of drying. The gel was placed in a BioRad 
Exposure Cassette-K for 24 h, face up against a Kodak storage phosphor screen 
(BioRad Laboratories). The Kodak storage phosphor screen was scanned by the 
BioRad Personal Molecular Imager
® FX and analysed by BioRad Quantity One 
Software. 
 
2.8.4 Trichloroacetic  acid  precipitation 
 
Following S
35 metabolic cell labelling (see Section 2.8.1), media was decanted and 
discarded and the cells washed with ice cold PBS (1 ml) on ice. Ice cold PBS (1 ml) 
was then added and the cells were detached with a plastic cell scrapper and collected 
in a 1.5 ml microcentrifuge tube.  This protocol was carried out for all cell lines with the 
exception of TSC2+/+TP53-/- and TSC2-/-TP53-/- MEFs. In this case, cells were 
scraped on ice in their media before the whole volume was transferred to a 15 ml 
centrifuge tube and centrifuged at 4ºC and 1500 rpm in a Sorvall
® Legend RT bench 
top centrifuge (500 g) for 5 min. The supernatant was discarded and the cell pellet 
resuspended in ice-cold PBS (1 ml) before being transferred to a 1.5 ml 
microcentrifuge tube. Cells were centrifuged at 4ºC and 1500 rpm in a Sorvall
® Legend 
RT bench top centrifuge (500 g) for 5 min and were again washed in ice-cold PBS (1 
ml).  
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Cell pellets were resuspended in distilled H2O (100 μl) by vortexing. 50 μl of 3 mg/ml 
methionine (Sigma) and 3 mg/ml cysteine (Sigma) in 1 M NaOH (diluted from 10 M 
stock; Thermo Fisher Scientific) was added and the tubes incubated at 37°C for 15 
min. 25% (w/v) trichloroacetic acid (100 μl; TCA; Sigma) was added to each tube 
before being cooled on ice. The resultant precipitate was collected on 25 mm glass 
microfibre filters (Whatman) using a sample manifold and the filters washed with 10% 
(w/v) TCA (3x 1 ml) and 95% (v/v) ethanol (2x 1 ml). The filter paper was air dried 
before being placed in a scintillation tube and covered with scintillation fluid (4 ml). 
Radioactivity was analysed on a WALLAC 1409 liquid scintillation counter (Perkin 
Elmer).  
 
2.9  Statistical Analysis  
 
All error bars represent ± the standard deviation of the mean for that data set. Data 
was analysed using the software package GraphPad Prism 4. The statistical 
significance of any differences was analysed using paired t-test. Asterisks on graphs 
are used to denote the following: * P < 0.05; **P < 0.01; ***P< 0.005. 
 
2.10 Field  trials 
 
Three field trials were carried out at either Vitacress’ Fobdown farm in Alresford or 
Vitacress’ Doddings farm in Bere Regis in August 2009, September 2010 and April 
2011. In general, watercress seeds were germinated in polytunnels on a thin layer of 
soil and transplanted into gravel lined concrete beds supplied with a constant flow of 
spring water from a bore hole. Seedling density and base application of fertiliser, 
containing 7.5% N (CaNO3), 12% P2O4, 7.5% K2O, 4.5% MgO + SO3, followed by a 
second application once the plant roots had established themselves in the bed, were 
kept in accordance to Vitacress’ standard practice. Growing period varied between the 
trials from 4-8 weeks, depending on weather, and the watercress was considered 
ready to harvest when leaf size reached approximately 3 cm in diameter. Samples of 
approximately 100 g were cut using scissors from each of the top, middle and bottom 
sections of the beds to allow for biological repeats and ensure any effect seen applied 
to the entire bed. Samples were collected in freezer bags and immediately put on ice, 
before being snap frozen in liquid nitrogen and stored at -80°C on return to the 
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During the trials growing conditions were altered by cutting off spring water supply to 
the bed and the addition of sulfur-rich fertilisers. Microthiol
® Special, which contains 
80% w/w sulfur, was purchased from Fargro Ltd. (Littlehampton, UK) and was applied 
to the watercress as a foliar spray. Palm Brand sulfur powder, which is 99.8% sulfur, 
was also purchased from Fargro Ltd. and was added as a base application prior to 
transplanting the watercress seedlings. SoluPotasse, containing 55.8% SO4, 50.9% 
K2O and 0.6% Cl, and citric acid anhydrous (used to increase nutrient uptake) were 
purchased from Solufeed Ltd. (West Sussex, UK) and applied as a top dressing to the 
watercress. 
 
For the second and third field trials, fresh samples from each of the beds were sent to 
Natural Resource Management Ltd. (NRM; Berkshire, UK) for chemical analysis of 
total sulfur content. 
 
2.11  Media and solutions  
 
Complete Dulbecco’s modified Eagle’s medium (DMEM) 
500 ml DMEM  
50 ml FBS 
2 mM L-glutamine 
50 U/ml Penicillin 
50 U/ml Streptomycin 
(For culture of all cell lines) 
 
Serum free DMEM 
500 ml DMEM 
2 mM L-glutamine 
50 U/ml Penicillin 
50 U/ml Streptomycin 
 
Roswell Park Memorial Institute 1640 (RPMI) 
500 ml RPMI 
 
Phosphate buffered saline (PBS) 
137 mM NaCl  
2.7 mM KCl                                                                                         Chapter 2: Materials and methods 
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4.3 mM Na2HPO4  
1.47 mM KH2PO4 
Adjust to a final pH of 7.4.  
 
5x Radioimmunoprecipitation assay (RIPA) buffer 
250 mM Tris-HCl (pH 8.0) 
750 mM NaCl 
5% (v/v) Igepal CA-630 
2.5% (w/v) Deoxycholate (DOC)  
0.5% (w/v) Sodium dodecylsulfate (SDS)  
 
Protease inhibitor cocktail (Sigma) 
2 mM AEBSF  
1 mM EDTA  
130 µM Bestatin  
14 µM E-64  
1 µM Leupeptin  
0.3 µM Aprotinin  
 
3x SDS sample buffer red (Cell Signaling Technology) 
187.5 mM Tris-HCl (pH 6.8 at 25°C) 
6% (w/v) SDS 
30% (v/v) glycerol  
0.03% (w/v) phenol red 
 
10x Running buffer 
250 mM Tris-base 
1.92 M glycine 
1% (w/v) SDS 
 
Transfer buffer 
25 mM Tris-base 
192 mM glycine 
0.1% (w/v) SDS 
25% (v/v) ethanol 
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10x TBS (Tris-buffered saline) 
100 mM Tris-HCl (pH 8.0) 
1.5 M NaCl 
 
TBS-Tween 
10 mM Tris-HCl (pH 8.0) 
150 mM NaCl 
0.1% (v/v) Tween-20 
 
Stripping buffer 
25 mM glycine (pH 2.0)  
1% (w/v) SDS 
 
Lysis buffer/developer mix 
25 mM Tris-HCl (pH 8.0) 
70 mM NaCl 
1.3 mM KCl 
1 mM MgCl2 
0.5% (v/v) Igepal CA-630 
Just before use add: 
2 mg/ml Trypsin (Sigma) 
10 μM TSA 
 
M-MLV RT 5x buffer (Promega) 
250 mM Tris-HCl (pH 8.3 at 25°C) 
375 mM KCl 
15 mM MgCl2  
50 mM DTT  
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3.1 Introduction 
 
The long term goal of this project was to determine whether it was possible to 
manipulate the growth environment of watercress to improve its potential anticancer 
activities. An important first step in this process was to identify approaches suitable for 
the accurate quantitation of anticancer effects. Therefore, the aim of the work 
described in this chapter was to select assays to assess the in vitro anticancer effects 
of watercress-derived compounds. Once assays have been identified, subsequent 
studies would then use these assays to assess the effects of watercress extracts from 
crops grown under different cultivation conditions. 
 
This initial study focused on specific watercress-derived compounds, rather than 
watercress extracts. This approach was adopted before moving on to more complex 
proof-of-principle studies using extracts. Three specific watercress-derived 
compounds, PEITC, I3C and quercetin (see Figure 3.1 for compound structures) were 
selected for these studies. These compounds were selected because they have been 
shown to exert anticancer effects in a range of assays and were known to be present 
at high levels in watercress extracts. The assays selected for analysis included (i) 
inhibition of cell growth, (ii) inhibition of PI3K/Akt signalling, (iii) inhibition of HDAC 
activity and (iv) activation of Nrf2. Watercress compounds have been shown to inhibit 
the growth of various cancer cell lines (Chinni et al., 2001; Lee et al., 2009; Zhang et 
al., 2003b) and PEITC has previously been shown to inhibit PI3K signalling and HDAC 
activity, and to activate Nrf2 (Bonnesen et al., 2001; Myzak et al., 2006; Satyan et al., 
2006). Human MCF7 breast cancer cells were used for the majority of experiments, 
although some studies were also performed in SK-BR-3 cells to determine potential 
effects within distinct subtypes of breast cancer. 
 
3.2 Results 
 
3.2.1  Effect of PEITC, I3C and quercetin on the growth inhibition of 
breast cancer cell lines 
 
The MTS assay was used as a quick and simple way to measure growth inhibition by 
means of metabolic activity following treatment with PEITC, I3C or quercetin. In this 
context the term growth inhibition refers to the number of cells although it should be                                                                                                  Chapter 3: Assay selection 
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Figure 3.1: Structure of watercress-derived compounds.  
(a) phenethyl isothiocyanate (PEITC), (b) indole-3-carbinol (I3C), (c) quercetin. 
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noted that the MTS assay in fact assesses metabolic activity and this is not an 
absolute measure of cell number. Changes to number of mitochondria can also alter 
metabolic activity. However, all plates were routinely checked under a microscope to 
confirm that the observed decrease in MTS reduction also correlated with reduced cell 
number.  MCF7 and SK-BR-3 breast cancer cell lines were treated with the 
watercress-derived compounds for 6 days prior to the MTS assay. Representative 
growth inhibition data in the form of survival curves are shown for PEITC, I3C and 
quercetin in Figure 3.2, Figure 3.3, and Figure 3.4 respectively. 
 
All compounds inhibited the growth of MCF7 and SK-BR-3 cells in a dose-dependent 
manner. Compounds provided simple sigmoidal dose response curves, allowing for 
robust curve-fitting and reproducible determination of relative IC50 values using the 
Prism software (Table 3.1). PEITC was found to be the most potent of the watercress-
derived compounds in both MCF7 and SK-BR-3 cells, although MCF7 cells appear to 
be approximately 2.5-fold more sensitive to PEITC than SK-BR-3 cells. In contrast 
there was no statistically significant difference in IC50 values for either I3C or quercetin 
between the cell lines.  
 
  
IC50/µM Value (mean ± SD)  Watercress-derived 
compound 
MCF7  SK-BR-3 
PEITC  10.6 ± 1.4  27.0 ± 6.7*** 
I3C  104.7 ± 25.6  77.3 ± 25.0 
Quercetin  51.1 ± 11.7  133.9 ± 96.7 
Table 3.1: IC50 values of PEITC, I3C and quercetin in MCF7 and SK-BR-3 cells.  
IC50 values represent mean values ± standard deviation (SD) from at least five 
experiments performed in triplicate. Statistically significant differences in IC50 values for 
the compounds between the two cell lines are indicated (*** p<0.005). 
 
 
3.2.2 Molecular  assays 
 
3.2.2.1 Effect of PEITC, I3C and quercetin on PI3K/Akt pathway  
 
HER2 is a member of the epidermal growth factor receptor (EGFR) family that when 
activated initiates a signal via the PI3K/Akt pathway that results in cell proliferation. 
HER2 has been found to be overexpressed in many cancers, and this overexpression                                                                                                  Chapter 3: Assay selection 
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Figure 3.2: Effect of PEITC on growth inhibition of MCF7 and SK-BR-3 cells.  
Representative growth inhibition experiments of (a) MCF7 and (b) SK-BR-3 cell lines. 
Cells were treated with various concentrations of PEITC ( ), DMSO ( ) equivalent to 
the highest volume of PEITC and 0.5 μM STS as a positive control ( ). After six days 
metabolic activity was determined by MTS assay using the CellTiter 96
® AQueous One 
Solution reagent. Data shown are derived from means of triplicate wells (± SD).  
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Figure 3.3: Effect of I3C on growth inhibition of MCF7 and SK-BR-3 cells. 
Representative growth inhibition experiments of (a) MCF7 and (b) SK-BR-3 cell lines. 
Cells were treated with various concentrations of I3C ( ), DMSO ( ) equivalent to the 
highest volume of I3C and 0.5 μM STS as a positive control ( ). After six days 
metabolic activity was determined by MTS assay using the CellTiter 96
® AQueous One 
Solution reagent. Data shown are derived from means of triplicate wells (± SD). 
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Figure 3.4: Effect of quercetin on growth inhibition of MCF7 and SK-BR-3 cells.  
Representative growth inhibition experiments of (a) MCF7 and (b) SK-BR-3 cell lines. 
Cells were treated with various concentrations of quercetin ( ), DMSO ( ) equivalent to 
the highest volume of quercetin and 0.5 μM STS as a positive control ( ). After six days 
metabolic activity was determined by MTS assay using the CellTiter 96
® AQueous One 
Solution reagent. Data shown are derived from means of triplicate wells (± SD). 
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is consistent with poor clinical outcome (Slamon et al., 1987; Slamon et al., 1989). This 
pathway was chosen to be investigated as it represents a key cancer pathway, 
especially in certain breast cancer subtypes, and quercetin has been previously shown 
to reduce HER2 expression (Kim et al., 2005).  
 
Akt phosphorylation was used as a measure of the effect of watercress-derived 
compounds on HER2. The activation of HER2 triggers a signal cascade involving 
recruitment of Akt to the cell membrane and its subsequent phosphorylation.  Akt is 
phosphorylated at multiple sites, at threonine 308 (Thr308) by PDK1 (Alessi et al., 
1997) and at serine 473 (Ser473) by mTORC2 (Sarbassov et al., 2005). It has been 
shown that the monoclonal antibody Herceptin inhibits HER2 induced proliferation and 
this correlates with reduced Akt phosphorylation at Thr308 and Ser473 (Longva et al., 
2005; Tseng et al., 2006). Herceptin is only effective in cancers where HER2 is 
overexpressed (Vogel et al., 2002) and as a result the SK-BR-3 breast cancer cell line 
was used initially in this experiment as these cells overexpress HER2. Cells were 
incubated in the presence or absence of PEITC, I3C or quercetin for 2 h and Akt 
phosphorylation at both Thr308 and Ser473 analysed by western blot (Figure 3.5 and 
3.6). Blots were stripped and reprobed for β-actin and total Akt to demonstrate equal 
loading and that changes in Akt phosphorylation occurred independent of changes to 
total Akt protein levels. It should be noted that sometimes there are two bands 
detected when probing for phospho-Akt (Thr308). The faster migrating band may be 
Akt 2 isoform that has a Mw of 56 kDa compared to 60 kDa of Akt 1 and 3.  
 
Quercetin induced a statistically significant decrease in phosphorylation of Akt at 
Ser473 at both concentrations tested, but had no effect on phosphorylation at Thr308. 
There appeared to be a trend towards increased phosphorylation of both sites in 
PEITC-treated cells, although this did not reach statistical significance. There was no 
effect of I3C on either Akt phosphorylation site. 
 
As receptors other than HER2 can lead to Akt phosphorylation the effect of watercress-
derived compounds on Akt phosphorylation was also investigated in MCF7 cells 
(Figure 3.7 and 3.8). Similar to SK-BR-3 cells, quercetin has no effect on Thr308 
phosphorylation but caused a statistically significant reduction in Akt Ser473 
phosphorylation. There was no change observed following I3C treatment. Similar to 
SK-BR-3 cells, PEITC increased Akt phosphorylation at both Thr308 and Ser473 and, 
in MCF7 cells, this did reach statistical significant at all concentrations tested. Taken 
together the data demonstrate that watercress compounds do modulate Akt                                                                                                  Chapter 3: Assay selection 
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Figure 3.5: Effect of PEITC, I3C and quercetin on Akt phosphorylation in SK-BR-3 
cells.  
SK-BR-3 cells were treated with indicated concentrations (µM) of PEITC, I3C, or 
quercetin (Qn), DMSO (equivalent to the highest volume), or left untreated (UT) for 2 h. 
20 µg of whole cell lysate was subjected to SDS-page and analysed by western blot for 
either phospho-Akt (Thr308) or phospho-Akt (Ser473) then stripped and reprobed for 
total Akt (60 kDa) and β-actin (42 kDa). Western blots are representative of three 
independent experiments, the results of which are combined in the densitometry graph 
(Figure 3.6). 
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Figure 3.6: Densitometry of effect of PEITC, I3C and quercetin on Akt 
phosphorylation in SK-BR-3 cells western blot.  
SK-BR-3 cells were treated with indicated concentrations (µM) of PEITC, I3C, or 
quercetin (Qn), DMSO (equivalent to the highest volume), or left untreated (UT) for 2 h. 
Whole cell lysate was subjected to SDS-page and analysed by western blot for either 
phospho-Akt (Thr308) or phospho-Akt (Ser473) then stripped and reprobed for total 
Akt. Band area from three independent experiments were analysed by ImageJ 
software and mean band area of (a) P-Akt (308) or (b) P-Akt (473) relative to total Akt 
are shown (± SD). Statistically significant differences between UT and the treatments 
are indicated (*** p<0.005). All other comparisons were not statistically significant. 
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Figure 3.7: Effect of PEITC, I3C and quercetin on Akt phosphorylation in MCF7 
cells.  
MCF7 cells were treated with indicated concentrations (µM) of PEITC, I3C, or 
quercetin (Qn), DMSO (equivalent to the highest volume), or left untreated (UT) for 2 h. 
20 µg of whole cell lysate was subjected to SDS-page and analysed by western blot for 
either phospho-Akt (Thr308) or phospho-Akt (Ser473) then stripped and reprobed for 
total Akt (60 kDa) and β-actin (42 kDa). Western blots are representative of three 
independent experiments, the results of which are combined in the densitometry graph 
(Figure 3.8). 
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Figure 3.8: Densitometry of effect of PEITC, I3C and quercetin on Akt 
phosphorylation in MCF7 cells western blot.  
MCF7 cells were treated with indicated concentrations (µM) of PEITC, I3C, or 
quercetin (Qn), DMSO (equivalent to the highest volume), or left untreated (UT) for 2 h. 
Whole cell lysate was subjected to SDS-page and analysed by western blot for either 
phospho-Akt (Thr308) or phospho-Akt (Ser473) then stripped and reprobed for total 
Akt. Band area from three independent experiments were analysed by ImageJ 
software and mean band area of (a) P-Akt (308) or (b) P-Akt (473) relative to total Akt 
are shown (± SD). Statistically significant differences between UT and the treatments 
are indicated (* p<0.05; ** p<0.01; *** p<0.005). All other comparisons were not 
statistically significant. 
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phosphorylation in breast cancer cell lines. However, different compounds either 
increase or decrease phosphorylation. Overall there appears to be little difference in 
the effect of watercress derived compounds between the two cell lines suggesting that 
these responses are independent of HER2. Although as only two cell lines were looked 
at this would require further validation.   
 
3.2.2.2 Effect of PEITC, I3C and quercetin on HDAC inhibition 
 
Altered gene expression patterns due to modified chromatin organisation are found in 
many cancers. Epigenetic modifications such as the level of histone acetylation, which 
is determined by the balance between the activity of histone acetyltransferases (HATs) 
and histone deacetylases (HDACs), are responsible for remodeling chromatin into a 
transcriptionally active or inactive state (Ropero and Esteller, 2007). In particular, 
HDAC inhibitors are emerging as a promising new tool in the treatment of cancer. They 
offer the possibility to reverse the repression of various genes that are involved with 
apoptosis and cell cycle regulation such as Bax and p21. The assay to determine 
HDAC inhibition activity in the watercress-derived compounds was selected as there is 
some evidence that conjugates of ITCs act as HDAC inhibitors (Myzak et al., 2004). 
This HDAC inhibition coincides with increased global acetylation at histone H3 and H4, 
as well as specific acetylation at the p21 promoter. To examine if PEITC, I3C and 
quercetin act as HDAC inhibitors MCF7 cells were treated in the absence or presence 
of each compound for 16 h before the addition of a HDAC substrate, BOC-lys(ac)-
AMC, for a further hour. 
 
Cells were subsequently lysed and incubated overnight before fluorescence was 
determined on a plate reader.  If the BOC-lys(ac)-AMC compound is able to be 
deacetylated by the cells then when the lysis buffer is added the trypsin in it is able to 
cleave the bond between the now unprotected lysine and the AMC fluorescent 
fluorophore, thus releasing it and allowing it to give off a fluorescent signal. However, if 
the compounds act as HDAC inhibitors and prevent the cells from deacetylating the 
BOC-lys(ac)-AMC compound, then the lysine will remain acetylated. The trypsin will 
then be unable to cleave the fluorophore and subsequently there will be a reduction in 
fluorescent signal.   
 
The known HDAC inhibitor Trichostatin A (TSA) (Yoshida et al., 1990) was used as a 
positive control and shows complete loss of fluorescence at all concentrations tested                                                                                                  Chapter 3: Assay selection 
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(Figure 3.9). With regards to the watercress-derived compounds there was very little 
change in fluorescence following either PEITC or I3C treatment, although there was a 
dose dependent decrease in fluorescence when the cells were treated with quercetin 
with an IC50 of 100.2 µM.  
 
It was important to determine whether quercetin acted as a true HDAC inhibitor, or 
whether it interfered with trypsin cleavage in the second phase of the assay (i.e. was a 
false positive). To investigate this, non-acetylated BOC-lys-AMC was added to 
quercetin treated cells alongside the BOC-lys(ac)-AMC reagent. If quercetin was a 
bona fide HDAC inhibitor than it would have no effect on the fluorescence of the non-
acetylated reagent as it is not a HDAC substrate. In this experiment another known 
HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) (Richon et al., 1998) was used 
as a positive control and demonstrated a dose-dependent loss of fluorescence (Figure 
3.10).  While a decrease in fluorescence was again observed in cells treated with 
quercetin and BOC-lys(ac)-AMC, a similar reduction in fluorescence was detected in 
cells treated with the non-acetylated reagent. Therefore, quercetin is not a true HDAC 
inhibitor but produced a false positive result by interfering with trypsin’s ability to cleave 
the bond between the deacetylated lysine and the AMC fluorescent fluorophore.  
 
3.2.2.3 Effect of PEITC on Nrf2 activity 
 
One of the key targets for xenobiotics and phytochemicals is the Nrf2 transcription 
factor. Activation of Nrf2 induces a battery of target genes involved in antioxidant 
protection. This is important not just for protecting cells from oxidative/electrophilic 
damage, but also the chemopreventive actions of compounds such as PEITC. I 
therefore analysed the effect of PEITC on Nrf2 activity. Nrf2 activity was analysed 
using AREc32 cells, a stable MCF-7 derived reporter cell-line containing a luciferase 
construct controlled by multiple copies of the antioxidant response element (ARE) 
(Wang et al., 2006). AREc32 cells were incubated in the presence of PEITC for 24 h 
before luciferase was assayed. PEITC caused a dose-dependent increase in ARE-
driven gene expression that was statistically significant at all doses tested (Figure 
3.11). In previous studies, effective concentrations have been considered as the 
concentration of compound that doubled induction of luciferase gene activity (CD) 
(Wang et al., 2006). In my hands, 2.5 µM PEITC resulted in over a 2-fold increase in 
Nrf2 activity.                                                                                                 Chapter 3: Assay selection 
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Figure 3.9: Effect of watercress-derived compounds on HDAC inhibition.  
MCF7 cells were treated in the absence or presence of either PEITC ( ), I3C ( ), or 
quercetin ( ) for 16 h before the BOC-lys(ac)-AMC reagent was added for 1 h. Lysis 
buffer was added and the cells were incubated overnight before fluorescence was read 
on a 96-well plate reader. Known HDAC inhibitor TSA ( ) was used as a positive 
control and   represents untreated. Data shown are derived from means of triplicate 
wells ± SD. 
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Figure 3.10 Effect of quercetin on HDAC inhibition.  
MCF7 cells were treated in the absence or presence of quercetin for 16 h before either 
the BOC-lys(ac)-AMC reagent ( ) or non-acetylated control BOC-lys-AMC ( ) was 
added for 1 h. Lysis buffer was added and the cells were incubated overnight before 
fluorescence was read on a 96-well plate reader. Known HDAC inhibitor SAHA ( ) was 
used as a positive control.   and   represent untreated with either the BOC-lys(ac)-
AMC or BOC-lys-AMC respectively. Data shown are derived from means of triplicate 
wells ± SD. 
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Figure 3.11: Effect of PEITC on ARE-driven expression.  
MCF7 cells stably transfected with ARE were treated with the indicated concentrations 
of PEITC ( ) or equivalent volume of DMSO as a control ( ) for 24 h and then 
luciferase activity determined. Data shown is mean (± SD) of three independent 
experiments. Statistically significant differences between DMSO and PEITC treated 
cells are indicated (* p<0.05; ** p<0.01).                                                                                                Chapter 3: Assay selection 
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3.3 Discussion 
 
The aim of the work described in this chapter was to identify assays that could be used 
for the subsequent analysis of the in vitro anticancer effects of watercress extracts. 
Based on published literature, I selected four assays to investigate, (i) growth 
inhibition, (ii) inhibition of PI3K/Akt signalling, (iii) HDAC activity and (iv) Nrf2 activity. 
 
3.3.1 Growth  inhibition 
 
Growth inhibition appeared to be an appropriate assay to monitor the activity of 
watercress-derived compounds. The MTS assay is rapid and simple, and can be 
performed in 96 well plates allowing determination of IC50 values with good 
reproducibility. All compounds inhibited the growth of both MCF7 and SK-BR-3 cells in 
a dose-dependent manner. This is consistent with previous studies demonstrating that 
all three compounds inhibited the growth of a variety of human cancer cells grown in 
culture and within a similar concentration range (Chinni et al., 2001; Lee et al., 2009; 
Zhang et al., 2003b). Overall, PEITC was the most potent compound tested. There 
was relatively little difference in the response of the two cell lines to the compounds, 
and only for PEITC were responses statistically different, with MCF7 cells being 
approximately 2.5-fold more sensitive.  
 
It is not clear why MCF7 cells are more sensitive to growth inhibition by PEITC. MCF7 
cells have wild type p53 whereas SK-BR-3 cells contain mutant p53. Some studies 
have suggested that PEITC has similar effects in wild type and mutant p53 containing 
colon cancer cells (Pappa et al., 2006). However, other studies have shown that 
PEITC induced greater apoptosis in mouse epidermal JB6 p53 -/- cells compared to 
corresponding p53 +/+ cells (Huang et al., 1998). Therefore, the role of p53 in the 
differential responses of MCF7 and SK-BR-3 cells is unclear.  Recent studies in the 
laboratory suggest that MCF7 cells have relatively high basal levels of oxidative stress 
compared to other breast cancer cell lines (Sharaifah Syed Alwi, Breeze Cavell, 
Graham Packham, unpublished). Heightened basal ROS may explain why these cells 
are more susceptible to further PEITC-induced ROS accumulation. 
 
The mechanisms of PEITC induced growth inhibition are not clear. Due to the indirect 
nature of the MTS assay, decreased signals may be due to decreased cell division 
and/or increased apoptosis. Decreased metabolism could also contribute to reduced                                                                                                 Chapter 3: Assay selection 
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MTS reduction. However, visual inspection of the plates confirmed that reduced MTS 
signals were associated with reduced cell numbers. Further studies in the group have 
shown that PEITC induces a G2/M arrest and high levels of apoptosis in MCF7 cells, 
and this could be studied further in SK-BR-3 cells using PI/cell cycle analysis and 
annexin V staining, respectively.  
 
The molecular mechanisms that mediate cell death/cell cycle arrest in response to 
watercress compounds are likely to be complex. As described in the introduction, 
PEITC has been shown to induce G2/M and S phase arrest via downregulation of 
CDK1, cyclin B and cyclin A (Hwang and Lee, 2010; Wu et al., 2011; Xiao et al., 2004), 
in addition to inducing apoptosis via both the intrinsic and extrinsic pathways (Satyan 
et al., 2006; Tang and Zhang, 2005). 
 
By contrast, I3C has consistently been shown to induce G1 cell cycle arrest in several 
different cancer cell lines, although the specific factors involved varied (Rogan, 2006). 
In MCF7 cells I3C has been reported to downregulate CDK6 expression by disrupting 
the binding of transcription factor SP1 to its promoter region, and inhibit CDK2 activity 
by altering the composition of the CDK2 protein complex to a larger less active form, 
both essential in the progression of G1 phase. I3C has also been recently shown to 
promote the degradation of phosphatase Cdc25A, required for dephosphorylation and 
activation of CDK2, in a panel of breast cancer cell lines (Wu et al., 2010b). With 
regards to apoptosis, it appears I3C may act to suppress the activation of nuclear 
transcription factor (NF-κB), which regulates a wide range of genes involved in 
apoptosis including Bcl-2 and Bcl-xL (Ahmad et al., 2011). This could be the result of 
the inactivation of Akt, an upstream regulator of NF-κB, as I3C treatment has been 
associated with a reduction in Akt activity (Rahman et al., 2004).  
 
Quercetin has been shown to inhibit cell cycle progression through the G2/M or G1/S 
transition. In the SK-BR-3 breast cancer cell line quercetin was shown to cause cell 
cycle arrest at G1 and this was associated with an increase in p21 expression and 
hypophosphorylation of retinoblastoma tumour suppressor protein (Rb). p21 is a CDK 
inhibitor and is proposed to inhibit cyclin-CDK activity required for phosphorylation of 
Rb. Unphosphorylated Rb sequesters transcription factor E2F1 preventing it from 
promoting expression of genes essential for cell cycle progression from G1 to S phase. 
However, in the same study quercetin was also shown to downregulate cyclin B and 
CDK1 in SK-BR-3 cells which are required for G2/M cell cycle progression (Jeong et 
al., 2009). Quercetin can also inhibit phosphorylation of Akt which is thought to result in                                                                                                 Chapter 3: Assay selection 
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apoptosis by causing dissociation of Bax from Bcl-xL (Lee et al., 2008), and upregulate 
death receptor 5 (DR5) expression in prostate cancer DU-145 cells, sensitising them to 
TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis (Jung et al., 2010). 
 
3.3.2  PI3K/Akt signalling  
 
Several previous studies have shown that PEITC, I3C and quercetin modulate Akt 
phosphorylation and for the most part this was confirmed in my experiments using 
HER2 overexpressing SK-BR-3 cells. Although HER2 is an important activator of Akt in 
SK-BR-3 cells, the effects of the compounds may be independent of any specific affect 
on HER2 signalling, since similar results were obtained in MCF7 cells which lack HER2 
overexpression, and a wide range of signalling pathways have been shown to activate 
PI3K/Akt signalling. Despite the observed effects, analysis of Akt phosphorylation did 
not appear to be a suitable assay to monitor effects of watercress extracts. First, the 
assay was very time-consuming and quantitation limited by the semiquantitative nature 
of immunoblotting. Second, different compounds either increased or decreased Akt 
phosphorylation making it likely that effects of watercress extracts would be highly 
complex. 
 
Loss of Akt phosphorylation in response to quercetin has been observed in multiple 
cell lines and is associated with quercetin-induced apoptosis (Kim and Lee, 2007; Lee 
et al., 2008; Sun et al., 2010). The majority of these studies look only at Akt 
phosphorylation at Ser473, and this is consistent with my findings that quercetin 
inhibits phosphorylation at this site. Kim and Lee (2007) did observe inhibition of Akt 
phosphorylation at both Thr308 and Ser473 sites following treatment with 200 μM 
quercetin for 4 h in human prostate adenocarcinoma DU-145 cells. However, in MCF7 
and SK-BR-3 breast cancer cells I found quercetin had no effect on Thr308 Akt 
phosphorylation. Consequently, the effect of quercetin on Akt phosphorylation, 
particularly at Thr308, may be cell type specific. 
 
It is widely reported that PEITC inhibits Akt activation and this is believed to contribute 
to its anticancer activity (Gao et al., 2011; Satyan et al., 2006; Xiao and Singh, 2007). 
In contrast, I found Akt phosphorylation at both Thr308 and Ser473 sites was 
enhanced in response to PEITC. However, it was recently shown that while PEITC did 
cause a decrease in Akt phosphorylation in multiple myeloma MM.1S cells at later time 
points (12 h), this followed an initial increase in Akt phosphorylation (2 h) (Jakubikova 
et al., 2011). Therefore, the increase in Akt phosphorylation I observe after 2 h may                                                                                                 Chapter 3: Assay selection 
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also only be transient. It has been previously reported that I3C can inhibit Akt 
phosphorylation in breast cancer and prostate cancer cell lines after 24-48 h 
treatments (Chinni and Sarkar, 2002; Rahman et al., 2004). While I did not observe 
any effect of I3C on Akt phosphorylation this may be due to the shorter time point (2 h) 
selected for this study.  
 
3.3.3 HDAC  activity 
 
PEITC, I3C and quercetin were examined for HDAC inhibition activity in a cell-based 
assay using MCF7 cells.  Wang et al. (2007) have previously shown by both a cell-free 
assay and through the analysis of PEITC treated LNCap AD prostate cancer cell 
lysates, that as little as 5 μM PEITC is able to inhibit HDAC activity. In contrast to this, I 
observed no inhibition of HDAC activity following treatment with PEITC. Similar results 
were obtained with I3C. Quercetin did appear to be a potential HDAC inhibitor. 
However, subsequent control experiments demonstrated that this apparent activity was 
in fact likely to be due to inhibition of trypsin activity. Several flavonoids including 
quercetin have previously been shown to act as trypsin inhibitors through binding with 
the S
1 region of trypsin via various electrostatic interactions that include at least one 
hydrogen bond (Jedinak et al., 2006; Maliar et al., 2004; Zhang et al., 2009). It is not 
clear why I did not observe HDAC inhibition with PEITC, but this may reflect the 
relatively short time point selected for these studies. Longer exposure may be required 
to allow accumulation of the PEITC-metabolites which are thought to be the active 
components for HDAC inhibition. Regardless, the HDAC assay was not considered to 
be suitable for analysis of watercress extracts. It was expensive and time-consuming to 
perform and clearly susceptible to false positive results. 
 
3.3.4 Nrf2  activity 
 
The effect of PEITC on Nrf2 activity was determined using a stable MCF7 derived 
reporter cell line containing a luciferase construct controlled by multiple copies of the 
ARE. As discussed in the introduction, PEITC has been shown to induce the 
expression of phase II drug metabolising enzymes via the ARE present in the promoter 
regions of these genes, and this is believed to be responsible for inhibition of 
carcinogen-induced tumourigenesis in rodents by PEITC.  I confirmed that PEITC 
increased Nrf2-dependent transcription in a dose-dependent manner, with a 
concentration of 2.5 µM required to double the induction of gene expression. This is in 
agreement with other studies that demonstrated 1.7 µM and 2 µM PEITC caused 2-fold                                                                                                 Chapter 3: Assay selection 
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increase in the induction of Nrf2-dependent transcription using a chloramphenicol 
acetyltransferase (CAT) and luciferase reporter construct respectively (Bonnesen et 
al., 2001; Xu et al., 2006b).  Overall, the Nrf2 activity assay was considered suitable for 
subsequent analysis of watercress extracts since it was straightforward to perform and 
the assay produced quantitative data. Moreover, in contrast to Akt and HDAC, where 
the significance of any regulation remains poorly understood, it is clear that Nrf2 
activation is a key mediator of chemopreventive activities.  
 
I did not perform any studies with I3C as previous studies have shown it to be a 
relatively weak inducer of ARE-driven gene expression, instead inducing expression of 
phase I and phase II drug metabolising enzymes via xenobiotic response elements 
(XREs) (Bonnesen et al., 2001). In this case, transcriptional regulation is mediated by 
the aryl hydrocarbon receptor (AhR). Similarly, quercetin has also been reported to be 
a ligand for the AhR (Ciolino et al., 1999).  
 
 
 
Chapter 4
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4.1 Introduction 
 
In addition to identifying assays suitable for analysis of watercress extracts, it is also 
important to discover more about how watercress-derived phytochemicals interfere 
with the growth of cancer cells. In this chapter I investigated the effects of PEITC on 
hypoxia inducible factors (HIFs), oxygen sensitive transcription factors that activate 
genes involved in the regulation of angiogenesis and cell survival. Overexpression of 
HIF has been found in many human cancers including breast cancer (Zhong et al., 
1999) and is often associated with resistance to cancer therapies such as 
chemotherapy.  This work focused on PEITC since several isothiocyanates, including 
PEITC, have already been shown to inhibit angiogenesis (Xiao and Singh, 2007)  
which is linked to inhibition of HIF1α expression (Yao et al., 2008). Furthermore, work 
in this laboratory has demonstrated that PEITC can inhibit HIF transcriptional activity 
(Wang et al., 2009).  
 
4.2 Results 
 
4.2.1  Effect of PEITC on the expression of HIF target genes 
 
It has been previously found in this laboratory that PEITC inhibits the activity of HIF as 
shown by using a hypoxia-dependent construct in a luciferase reporter assay (Wang et 
al., 2009). As HIFs are transcription factors it would be expected that a decrease in 
activity would result in decreased expression of HIF target genes. Therefore, the effect 
of PEITC on the expression of various target genes was examined. Four well known 
target genes were chosen that represent a range of processes effected by HIF; BNIP3 
(Bcl2/adenovirus E1B 19kDa interacting protein 3) involved in cell survival (Sowter et 
al., 2001), CAIX (carbonic anhydrase IX) involved in pH regulation (Wykoff et al., 
2000), GLUT1 (glucose transporter 1) involved in glucose metabolism (Airley et al., 
2001), and VEGF-A (vascular endothelial growth factor A) involved in angiogenesis 
(Forsythe et al., 1996). 
 
MCF7 cells were exposed to hypoxia for 16 h in the absence or presence of PEITC 
and the expression of the target genes analysed by Q-RT-PCR. All the target genes 
investigated were induced by hypoxia and demonstrated dose-dependent inhibition by 
PEITC that was statistically significant (Figure 4.1). CAIX was most strongly induced by 
hypoxia, showing a 50-fold increase in mRNA expression, and displayed statistically                                                                                     Chapter 4: Hypoxia inducible factor  
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significant inhibition by PEITC at all concentrations tested (Figure 4.1b). In comparison, 
mRNA expression of BNIP3, GLUT-1 and VEGFA was induced only 3-6 fold, and 
higher concentrations of PEITC were required to inhibit this expression. It has 
previously been reported that the promoter activity of CAIX is highly dependent on 
hypoxia and expression is very low under normoxic conditions giving a possible 
explanation for the increased sensitivity observed (Wykoff et al., 2000). Therefore, in 
addition to effects in artificial reporter assays, PEITC also decreases the expression of 
endogenous HIF-regulated target genes. 
 
4.2.2  Effect of PEITC on HIF1α accumulation 
 
To explore the mechanism by which PEITC inhibits HIF-dependent transcription the 
effect of PEITC on HIF1α accumulation in cells cultured under hypoxic conditions was 
investigated. MCF7 cells were placed in a hypoxia chamber for 5 h in the presence or 
absence of PEITC before being harvested and analysed by western blot (Figure 4.2). 
As expected, increased HIF1α expression was observed in cells exposed to hypoxia. 
However, treatment with 10 µM PEITC greatly reduced the levels of HIF1α, and at 15 
µM and 20 µM PEITC this reduction was statistically significant. Therefore, PEITC 
prevents the accumulation of HIF1α in hypoxia-treated cells. 
 
4.2.3  Effect of PEITC on mTOR 
 
Previous work in this laboratory has shown that inhibition of HIF activity by PEITC 
occurs independently of changes in the level of HIF1α mRNA as well as the activity of 
prolyl hydroxylases, the pVHL and the proteasome, which are all required for the rapid 
degradation of HIF1α in normoxia (Wang et al., 2009). It was therefore possible that 
PEITC inhibited the translation of HIF1α mRNA. Inhibition of HIF1α mRNA translation 
has previously been linked to impaired activity of the mammalian target of rapamycin 
complex 1 (mTORC1) (Bernardi et al., 2006). This forms part of a negative feedback 
loop to decrease HIF1α accumulation during prolonged hypoxia, as mTORC1 activity 
is suppressed in response to hypoxia through both HIF dependent and independent 
mechanisms (Arsham et al., 2003). Mouse embryonic fibroblasts (MEFs) lacking 
TSC2, which forms half of the heterodimeric negative regulator of mTORC1, TSC1/2, 
were unable to suppress mTORC1 activity in response to hypoxia and this was 
associated with increased HIF1α accumulation (Brugarolas et al., 2004). Furthermore, 
it has already been reported that HIF1α translation is reduced following treatment with                                                                                      Chapter 4: Hypoxia inducible factor  
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Figure 4.1: Effect of PEITC on expression of endogenous HIF target genes.  
MCF7 cells were left untreated as a control or incubated in hypoxic conditions for 16 h 
in the presence or absence of the indicated concentrations of PEITC (µM), or DMSO 
(equivalent volume to 26 µM PEITC). Expression of (a) BNIP3, (b) CAIX, (c) GLUT1 
and (d) VEGFA were analysed by Q-RT-PCR. Data are mean of duplicate 
determinations, normalised to expression of β-actin. Relative expression in untreated 
cells was set to 1.0. Statistically significant differences between DMSO and PEITC 
treated cells are indicated (* p<0.05; ** p<0.01; *** p<0.005). All other comparisons 
were not statistically significant different. 
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Figure 4.2: Effect of PEITC on HIF1α accumulation.  
MCF7 cells were incubated in hypoxic conditions for 5 h in the absence (UT) or 
presence of the indicated concentrations of PEITC (µM), or DMSO (equivalent to 20 
µM PEITC). 20 µg of whole cell lysate was subjected to SDS-page and analysed by 
western blot for HIF1α (120 kDa). Equal loading was determined by probing for β-actin 
(42 kDa). Western blot is representative of three independent experiments and all 
results are combined in the densitometry graph (± SD). Statistically significant 
differences between UT and the treatments are indicated (* p<0.05; *** p<0.005). All 
other comparisons were not statistically significant. 
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the mTORC1 antagonist, rapamycin (Thomas et al., 2006). 
 
I analysed the phosphorylation status of downstream substrates to investigate the 
effects of PEITC on mTORC1 kinase activity. The best known substrates of mTORC1 
are the eIF4E binding proteins (4E-BPs) and 70 kDa protein kinases (p70 S6K), both of 
which are involved in the control of mRNA translation. The 4E-BP family, of which 4E-
BP1 is the most prominent, are key negative regulators of the eukaryotic initiation 
factor 4F (eIF4F) complex required for cap-dependent translation. Hypophosphorylated 
4E-BP1 binds strongly to eIF4E, the cap-binding protein of eIF4F, thus preventing the 
assembly of this complex (Cormier et al., 2003). It was discovered that mRNAs with 
complex secondary structures within their 5’-untranslated region (5’UTR) were 
preferentially upregulated following overexpression of eIF4E (Koromilas et al., 1992). 
This subset of mRNAs may be more sensitive to changes in eIF4E, the limiting eIF4F 
factor, as they are particularly dependent on mRNA unwinding by the eIF4A 
component. Interestingly, HIF1α possess a highly structured 5’UTR and therefore 
could be particularly sensitive to 4E-BP1 sequestering eIF4E (Iyer et al., 1998).     
 
Phosphorylation of the other main mTORC1 substrate, p70 S6K, at Thr389 provides an 
excellent indicator of mTORC1 activity and was therefore looked at alongside 4E-BP1. 
Targets of p70 S6K, include the S6 ribosomal protein, which forms part of the 40S 
ribosomal subunit, eukaryotic initiation factor 4B (eIF4B) (Raught et al., 2004) and 
programmed cell death protein 4 (Pdcd4) (Dorrello et al., 2006), which respectively 
enhance and impair mRNA helicase eIF4A, and the eukaryotic elongation factor 2 
kinase (eEF2K), which inhibits eEF2 (Wang et al., 2001).  
 
MCF7 cells were treated with PEITC for 3 h and analysed by western blot (Figure 4.3). 
Consistent with the idea that PEITC inhibits mTORC1 activity, treatment of cells with 
PEITC resulted in reduced phosphorylation of p70 S6K. Phosphorylation of 4E-BP1 is 
a complex process involving multiple sites of modification (Thr37, Thr46, Thr70, and 
Ser65). This is consistent with the multiple slower-migrating isoforms of 4E-BP1 that 
were detected on a total 4E-BP1 blot. Similar to p70 S6K, treatment with PEITC 
reduced the levels of 4E-BP1 phosphorylation, as demonstrated by greater 
electroporetic mobility. The reduction in p70 S6K and 4E-BP1 phosphorylation was 
statistically significant in cells treated with 15 or 20 µM PEITC. Therefore, PEITC 
inhibits mTORC1 activity.                                                                                     Chapter 4: Hypoxia inducible factor  
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Figure 4.3: Effect of PEITC on mTORC1 signalling in MCF7 cells.  
MCF7 cells were treated with indicated concentrations of PEITC or DMSO 
(equivalent to 20 µM PEITC) for 3 h. 25 µg of whole cell lysate was subjected to 
SDS-page and analysed by western blot for phospho-p70 S6K (Thr389; 70 kDa) 
and total 4E-BP1 (15-20 kDa; as indicated, multiple bands represent different 
phospho-forms) then stripped and re-probed for total p70 S6K. Equal loading was 
determined by probing for β-actin (42 kDa). The blot is representative of three 
independent experiments and the results from all three are combined in the 
densitometry graphs (± SD). Statistically significant differences between UT and 
the treatments are indicated (* p<0.05; *** p<0.005). All other comparisons were 
not statistically significant.                                                                                     Chapter 4: Hypoxia inducible factor  
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To further investigate the effect of PEITC on mTORC1 activity a time course was 
carried out (Figure 4.4). mTORC1 activity was assessed by loss of p70 S6K 
phosphorylation as this seemed to be a clearer readout than 4E-BP1 phosphorylation. 
A noticeable reduction of p70 S6K phosphorylation was observed after only 30 min 
PEITC treatment, with almost total dephosphorylation seen at 1 h. This decrease in 
phospho-p70 S6K is maintained for at least 8 h indicating prolonged inhibition of 
mTORC1 by PEITC.  
 
4.2.4  Where in the mTORC1 pathway does PEITC act? 
 
It is clear PEITC inhibits the activity of mTORC1 as demonstrated by the reduced 
phosphorylation of p70 S6K and 4E-BP1, but how is this achieved? mTORC1 is 
regulated by multiple pathways that sense whether or not conditions are favorable for 
cell growth and proliferation, such as nutrient availability, cellular energy levels, oxygen 
levels and the presence growth factors, which then activate or inhibit mTORC1 
accordingly. In this section I investigated the effects of PEITC on various modulators of 
mTORC1 activity, including the PI3K/Akt pathway, ERK pathway, and 5’ adenosine 
monophosphate-activated kinase (AMPK).  
 
4.2.4.1 Effect of PEITC on PI3K/Akt pathway  
 
One of the ways growth factors can stimulate mTORC1 is through activation of the 
PI3K/Akt pathway. Akt has been shown to phosphorylate TSC2 at multiple sites 
although two in particular, Ser939 and Ser981, seem to be important in the binding of 
14-3-3 proteins which are proposed to sequester TSC2 to the cytosol and away from 
membrane associated TSC1 (Cai et al., 2006). In addition, Akt can phosphorylate 
PRAS40, which is known to associate with the mTORC1 complex (Haar et al., 2007). 
Although, as discussed in the introduction, the functional role of this is not fully 
understood (Rapley et al., 2011). 
 
PTEN reverses the action of PI3K by dephosphorylating PIP3, negatively regulating the 
PI3K/Akt pathway. As previously discussed one potential mechanism of action by 
PEITC is through protein thiocarbamoylation. The active site of PTEN contains several 
key cysteine residues that when oxidised form a disulphide bond, resulting in the 
inactivation of PTEN (Lee et al., 2002). Consequently, PTEN is a potential candidate 
for direct covalent modification by PEITC. Heterozygous and homozygous null PTEN                                                                                      Chapter 4: Hypoxia inducible factor  
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Figure 4.4: Time course of PEITC-induced inhibition of p70 S6K phosphorylation.  
MCF7 cells were treated with 20 µM of PEITC or DMSO (equivalent to 20 µM PEITC) 
for the indicated time points. 25 µg of whole cell lysate was subjected to SDS-page 
and analysed by western blot for phospho-p70 S6K (Thr389; 70 kDa) then stripped and 
re-probed for total p70 S6K. Equal loading was determined by probing for β-actin (42 
kDa). 
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MEFs along with wild type control were used to determine whether the effects of 
PEITC were dependent on PTEN. After PTEN status in each of the MEFs was 
confirmed (Figure 4.5), the homozygous null PTEN and wild type MEFs were treated 
with PEITC for 3 h and analysed by western blot to determine whether inhibition of 
mTORC1 activity by PEITC was reversed in the PTEN null cells (Figure 4.6). 
Treatment of PEITC caused a dose-dependent decrease of phospho-p70 S6K and 
band shift of 4E-BP1 to less phosphorylated forms in the wild type cells, confirming 
what was seen in the MCF7 cell line. However, PEITC also inhibited phosphorylation of 
these mTORC1 substrates in the PTEN null MEFs. Thus, PTEN status does not 
appear to influence effects of PEITC on mTORC1 activity.   
 
Furthermore, I have previously shown in Chapter 3 that PEITC treatment (2 h) did not 
inhibit Akt phosphorylation in MCF7 and SK-BR-3 cells (Figure 3.5 and 3.7), both of 
which have wild type PTEN (Li et al., 1998). In fact Akt phosphorylation appears to be 
enhanced by PEITC at both of its phosphorylation sites, suggesting that PEITC does 
not act through the PI3K/Akt pathway to inhibit mTORC1 activity.     
 
4.2.4.2 Effect of PEITC on ERK1/2 
 
In addition to the PI3K/Akt pathway, growth factors relay signals to TSC1/2 to positively 
regulate mTORC1 via activation of the classical MAPK pathway. Both ERK1/2 and 
downstream target p90RSK have been shown to phosphorylate TSC2 (Ma et al., 2005; 
Roux et al., 2004). These ERK1/2 and p90RSK directed phospho-sites are distinct 
from each other, but those linked to p90RSK overlap with some of the proposed Akt 
phosphorylation sites (Huang and Manning, 2008). Furthermore, it has been 
demonstrated that p90RSK may regulate mTORC1 more directly through 
phosphorylation of Raptor (Carrière et al., 2008).   
 
In order to determine whether PEITC acts via the classical MAPK cascade to inhibit 
mTORC1, MCF7 cells were treated with PEITC for 3 h before being analysed by 
western blot for phospho-ERK1/2 (Figure 4.7). Although decreased ERK1/2 
phosphorylation has been associated with reduced mTORC1 activity, ERK1/2 
phosphorylation actually increased in PEITC treated cells. This increase was 
reproducible but did not reach statistical significance due to variation between 
individual experiments. Thus, it is unlikely that PEITC acts on mTORC1 via ERK1/2. 
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Figure 4.5: Confirmation of homozygous and heterozygous PTEN deficient 
MEFs.  
30 µg of whole cell lysate from each of the MEF genotypes was subjected to SDS-
page and analysed by western blot for PTEN (55 kDa). Equal loading was determined 
by probing for β-actin (42 kDa). 
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Figure 4.6: Effect of PEITC on mTORC1 signalling in PTEN null and wild type 
MEFs.  
PTEN +/+ and -/- MEFs were treated with indicated concentrations of PEITC or DMSO 
(equivalent to 20 µM PEITC) for 3 h. 25 µg of whole cell lysate was subjected to SDS-
page and analysed by western blot for phospho-p70 S6K (Thr389; 70 kDa) and total 
4E-BP1 (15-20 kDa; as indicated, multiple bands represent different phospho-forms) 
then stripped and re-probed for total p70 S6K. Equal loading was determined by 
probing for β-actin (42 kDa).   
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Figure 4.7: Effect of PEITC on phosphorylation of ERK1/2.  
MCF7 cells were treated with indicated concentrations of PEITC or DMSO (equivalent 
to 20 µM PEITC) for 3 h. 25 µg of whole cell lysate was subjected to SDS-page and 
analysed by western blot for phospho-ERK1/2 (Thr202/Tyr204; 42/44 kDa) and then 
stripped and re-probed for total ERK1/2. Equal loading was determined by probing for 
Hsc70 (70 kDa). The blot is representative of three independent experiments and the 
results from all three are combined in the densitometry graphs (± SD). Statistically 
significant differences between UT and the treatments are indicated (* p<0.05). All 
other comparisons were not statistically significant.                                                                                    Chapter 4: Hypoxia inducible factor  
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4.2.4.3 Effect of PEITC on AMPK 
 
5’ adenosine monophosphate-activated kinase (AMPK) acts as an energy sensor by 
responding to changes in 5’ adenosine monophosphate (AMP)/ 5’ adenosine 
triphosphate (ATP) ratio. Phosphorylation of Thr172 by serine/threonine kinase 11 
(STK11, also known as LKB1) is required for AMPK activation. It is thought that when 
ATP levels decline and AMP levels rise, the binding of AMP to AMPK facilitates this 
phosphorylation by LKB1 (Hardie et al., 2006). Activated AMPK has been shown to 
phosphorylate residues Thr1227 and Ser1345 on TSC2, however unlike 
phosphorylation by Akt, ERK1/2 and p90RSK, this is associated with enhanced 
TSC1/2 activity and subsequent inhibition of mTORC1 (Inoki et al., 2003b). 
Phosphorylation of Ser1345 by AMPK has been proposed to prime TSC2 for further 
phosphorylation and activation by glycogen synthase kinase 3 (GSK3), which is 
negatively regulated by the Wnt pathway (Inoki et al., 2006). Furthermore, AMPK has 
also been shown to phosphorylate Raptor, which is believed to inactivate mTORC1 by 
stimulating the binding of 14-3-3 proteins (Gwinn et al., 2008).   
 
To establish if PEITC impairs mTORC1 activity by activating AMPK, MCF7 cells were 
treated with PEITC for 3 h before being analysed by western blot for phospho-AMPK 
(Figure 4.8). There was no effect of PEITC treatment on Thr172 phosphorylation of 
AMPK. Therefore, it does not seem PEITC acts through AMPK to inhibit mTORC1. 
 
4.2.4.4 Does mTORC1 inactivation by PEITC require TSC1/2? 
 
TSC2 null and wild type MEFs (also deficient for p53) were used to determine whether 
PEITC-induced inhibition of mTORC1 activity was dependent on TSC1/2 (Zhang et al., 
2003a). Following verification of TSC2 status in each of the MEFs (Figure 4.9), the 
response of the two cell lines to serum starvation was also investigated. Serum 
contains growth factors that stimulate mTORC1, and serum withdrawal has been 
shown to impair mTORC1 activity in a TSC1/2-dependent manner (Zhang et al., 
2003a). TSC2 null and wild type MEFs were cultured in the absence of serum for 24 h 
before serum was reintroduced to control cells for 2 h. Phosphorylation of mTORC1 
substrates were analysed by western blot (Figure 4.10). As discussed, growth factors 
in the serum are believed to activate mTORC1 activity via phosphorylation and 
inhibition of TSC1/2, resulting in loss of its inhibitory influence on mTORC1. Serum  
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Figure 4.8: The effect of PEITC on phosphorylation of AMPK.  
MCF7 cells were treated with indicated concentrations of PEITC or DMSO (equivalent 
to 20 µM PEITC) for 3 h. 25 µg of whole cell lysate was subjected to SDS-page and 
analysed by western blot for phospho-AMPK (Thr172; 62 kDa) and then stripped and 
re-probed for total AMPK. Equal loading was determined by probing for β-actin (42 
kDa). Lack of positive data meant the experiment was only performed once. 
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Figure 4.9: Confirmation of TSC2+/+TP53-/- and TSC2-/-TP53-/- MEFs. 
TSC2+/+TP53-/- and TSC2-/-TP53-/- MEFs were serum starved for 24 h before media 
with the absence or presence of serum was added for 2 h.  40 µg of whole cell lysate 
was subjected to SDS-page and analysed by western blot for tuberin (TSC2; 200 kDa). 
Equal loading was determined by probing for Hsc70 (70 kDa). 
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Figure 4.10: Effect of serum on mTORC1 signalling in TSC2 null and wild type 
MEFs.  
TSC2+/+TP53-/- ( ) and TSC2-/-TP53-/- ( ) MEFs were serum starved for 24 h before 
media with the absence or presence of serum was added for 2 h. 25 µg of whole cell 
lysate was subjected to SDS-page and analysed by western blot for phospho-p70 S6K 
(Thr389; 70 kDa) and total 4E-BP1 (15-20 kDa; as indicated, multiple bands represent 
different phospho-forms) then stripped and re-probed for total p70 S6K. Equal loading 
was determined by probing for β-actin (42 kDa). The blot is representative of three 
independent experiments and the results from all three are combined in the 
densitometry graphs (± SD). Statistically significant differences between UT and the 
treatments are indicated (* p<0.05; ** p<0.05; *** p<0.005), and between the same 
treatment in the different cell lines (# p<0.05). All other comparisons were not 
statistically significant.                                                                                     Chapter 4: Hypoxia inducible factor  
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starvation should therefore restore TSC1/2 activity which in turn will inhibit mTORC1. 
As expected, wild type MEFs were sensitive to serum starvation with a decrease in 
phospho-p70 S6K and increase in 4E-BP1 electroporetic mobility observed. In MEFs 
deficient for TSC2, mTORC1 activity should be unrestrained and therefore resistant to 
inhibition by serum starvation. Indeed, in the TSC2 null MEFs there was no change in 
p70 S6K or 4E-BP1 phosphorylation following serum starvation. The TSC2 null MEFs 
also had higher basal phosphorylation of p70 S6K and 4EBP1, which would be 
expected in cells were mTORC1 is uninhibited by TSC2. However, I also observed 
lower overall levels of 4E-BP1 protein in the TSC2 null MEFs compared to the wild 
type MEFs. It has previously been reported that both the cell lines have similar levels 
of total 4E-BP1, so the reason for this difference is unclear (Smith et al., 2005). 
 
Subsequent experiments with the TSC2 null and wild type MEFs were carried out in 
the presence of serum. MEFs of either genotype were treated with PEITC for 3 h and 
analysed by western blot to determine whether TSC1/2 is required for mTORC1 
inhibition by PEITC (Figure 4.11). PEITC caused a statistically significantly dose-
dependent decrease in the phosphorylation of p70 S6K and 4E-BP1 (as indicated by 
the band shift) in the wild type MEFs which was not seen in the TSC2 null cells.  
Therefore, PEITC-induced inhibition of mTORC1 activity is dependent on TSC1/2. 
 
4.2.5  Effect of PEITC on mTORC2 
 
mTORC1 can negatively regulate mTORC2 activity via phosphorylation of Rictor by 
p70 S6K (Julien et al., 2010). Furthermore, mTORC1 inhibition can cause an increase 
in phosphorylation of Akt on Ser473, a target for mTORC2. Supposedly as a 
consequence of the lost inhibitory influence of p70 S6K (Breuleux et al., 2009). 
Therefore, the effect of PEITC on mTORC2 was also investigated. One of the main 
functions of mTORC2 is to phosphorylate Akt on Ser473, which along with 
phosphorylation on Thr308 by PDK1 is required for full Akt activation (Sarbassov et al., 
2005). Another substrate for mTORC2 is the serum- and glucocorticoid-induced protein 
kinase 1 (SGK1). N-myc downstream regulated gene 1 (NDRG1) is a downstream 
target of SGK1 and while its function is not well understood it has been shown to be a 
good indicator of mTORC2 activity (García-martínez and Alessi, 2008).  
 
The effect of PEITC on the phosphorylation of downstream targets of mTORC2, 
Ser473 on Akt, and SGK1 substrate, NDRG1 were analysed in the TSC2 null and                                                                                      Chapter 4: Hypoxia inducible factor  
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Figure 4.11: Effect of PEITC on mTORC1 signalling in TSC2 null and wild type 
MEFs.  
TSC2+/+TP53-/- ( ) and TSC2-/-TP53-/- ( ) MEFs were treated with indicated 
concentrations of PEITC or DMSO (equivalent to 20 µM PEITC) for 3 h. 25 µg of whole 
cell lysate was subjected to SDS-page and analysed by western blot for phospho-p70 
S6K (Thr389; 70 kDa) and total 4E-BP1 (15-20 kDa; as indicated, multiple bands 
represent different phospho-forms) then stripped and re-probed for total p70 S6K. 
Equal loading was determined by probing for β-actin (42 kDa). The blot is 
representative of three independent experiments and the results from all three are 
combined in the densitometry graphs (± SD). Statistically significant differences 
between UT and the treatments are indicated (* p<0.05; ** p<0.05; *** p<0.005), and 
between the same treatment in the different cell lines (
# p<0.05). All other comparisons 
were not statistically significant.                                                                                     Chapter 4: Hypoxia inducible factor  
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wild type MEFs (Figure 4.12). As previously reported by Huang et al. (2009), I found 
TSC2 null MEFs have low basal levels of phosphorylated Akt (Ser473) and NDRG1 in 
comparison to their wild type counterparts. In response to PEITC treatment a dose-
dependent increase in Akt Ser473 and NDRG1 phosphorylation is observed in the wild 
type MEFs. This corresponds with the decrease in mTORC1 activity I have seen in 
previous experiments. However, PEITC also seems to induce mTORC2 activity in the 
TSC2 null MEFs (albeit from a lower basal level) even though mTORC1 activity is 
unaffected by PEITC in these cells. 
 
4.2.6  Effect of PEITC on growth inhibition in the MEF cell lines  
 
Since PEITC-dependent regulation of mTORC1 was dependent on the presence of 
TSC2, I investigated whether TSC2 also influenced the growth inhibitory response to 
PEITC. To assess the role of TSC2 in PEITC-induced growth inhibition, TSC2 null and 
wild type MEFs were treated with PEITC for four days prior to cell number being 
determined by the MTS assay (Figure 4.13). TSC2 null cells were less sensitive to 
PEITC-mediated growth inhibition relative to control cells. Although the difference in 
sensitivity of the two lines was small (IC50 4.7 µM versus 7.9 µM), this difference was 
statistically significant. Therefore, similar to mTORC1 regulation, TSC2 is required for 
optimal growth inhibition in response to PEITC. 
 
Similar experiments were performed using PTEN-deficient cells (Figure 4.14). There is 
a trend for heterozygous and homozygous null PTEN MEFs to be more resistant to 
PEITC-induced growth inhibition then the wild type cells, and in all experiments IC50 
values were higher in the former two cell lines compared to the latter. However, the 
difference between the IC50 values of the wild type and PTEN-deficient cell lines varied 
considerably from 0.5-fold higher to 3-fold higher. As a result of this high standard 
deviation differences in IC50 values, they were not statistically significant. There was no 
discernable trend between the heterozygous and homozygous null MEFs. 
 
4.2.7  Effect of PEITC on translation of HIF1α mRNA 
 
The observation that PEITC decreased mTORC1 activity is consistent with the idea 
that PEITC inhibits the translation of HIF1α mRNA. To directly test whether PEITC 
effects HIF1α mRNA translation, MCF7 cells were metabolically labelled with 
[
35S]Met/Cys and HIF1α immunoprecipitated (Figure 4.15). To enhance the sensitivity                                                                                      Chapter 4: Hypoxia inducible factor  
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Figure 4.12: Effect of PEITC on mTORC2 signalling in TSC2 null and wild type 
MEFs.  
TSC2+/+TP53-/-and TSC2-/-TP53-/- MEFs were treated with indicated concentrations 
of PEITC or DMSO (equivalent to 20 µM PEITC) for 3 h. 25 µg of whole cell lysate was 
subjected to SDS-page and analysed by western blot for phospho-Akt (Ser473; 60 
kDa) as well as phospho-NDRG1 (Thr346; 46, 48 kDa) then stripped and re-probed for 
total equivalents. Equal loading was determined by probing for Hsc70 (70 kDa). 
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Figure 4.13: Effect of PEITC on growth inhibition of TSC2 null and wild type 
MEFs. 
Representative growth inhibition experiments. TSC2+/+TP53-/- ( ) or TSC2-/-TP53-/-  
( ) MEFs were treated with various concentrations of PEITC, DMSO ( ) equivalent to 
the highest dose of PEITC and 0.5 μM STS as a positive control ( ). After four days 
metabolic activity was determined by MTS assay using the CellTiter 96
® AQueous One 
Solution reagent. Data shown are derived from means of triplicate wells (± SD). Table 
showing IC50 values represent mean values ± SD from three experiments performed in 
triplicate. A statistically significant difference between IC50 values for TSC2 null and 
wild type MEFs is indicated (* p<0.05). 
 
 
IC50/µM Value (mean ± SD)   
TSC2+/+TP53-/-  TSC2-/-TP53-/- 
PEITC  4.7 ± 1.3  7.9 ± 0.8*                                                                                     Chapter 4: Hypoxia inducible factor  
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Figure 4.14: Effect of PEITC on growth inhibition of PTEN knockout and wild type 
MEFs. 
Representative growth inhibition experiments. PTEN +/+ ( ), PTEN +/- ( ) and PTEN -/- 
( ) MEFs were treated with various concentrations of PEITC, DMSO ( ) equivalent to 
the highest dose of PEITC and 0.5 μM STS as a positive control ( ). After four days 
metabolic activity was determined by MTS assay using the CellTiter 96
® AQueous One 
Solution reagent. Data shown are derived from means of triplicate wells (± SD). Table 
showing IC50 values represent mean values ± SD from five experiments performed in 
triplicate. 
 
 
 
 
 
 
 
 
 
 
 
IC50/µM Value (mean ± SD)   
PTEN +/+  PTEN +/-  PTEN -/- 
PEITC  5.4 ± 1.3  13.0 ± 4.9  10.9 ± 5.4                                                                                     Chapter 4: Hypoxia inducible factor  
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Figure 4.15: Effect of PEITC on the translation of HIF1α mRNA.   
MCF7 cells were pretreated with 100 µM cobalt chloride (CoCl2), a hypoxia mimetic, 
and then incubated in the absence (UT) or presence of indicated concentrations of 
PEITC, DMSO (equivalent to 20 µM PEITC), or 10 µg/ml cycloheximide (CHX) as a 
positive control for 1 h. 100 µCi/ml of [
35S]Met/Cys protein labelling mix was added for 
2 h. Cells were lysed and immunoprecipitated for HIF1α protein (120 kDa). 
Immunoprecipitated proteins were separated on SDS-PAGE, gel dried and phosphor 
imaging used to detect radioactive bands. Gel image is representative of three 
independent experiments with all results combined in the densitometry graph (± SD). 
Statistically significant differences between UT and the treatments are indicated (* 
p<0.05; ** p<0.01; *** p<0.005). All other comparisons were not statistically significant.                                                                                    Chapter 4: Hypoxia inducible factor  
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of the assay, cells were pretreated with hypoxia mimetic cobalt chloride (CoCl2), which 
acts to prevent binding of pVHL to HIF1α and its subsequent degradation. Consistent 
with this, addition of CoCl2 increased the apparent metabolic labelling of HIF1α. 
Translation of HIF1α was inhibited by PEITC in a dose-dependent manner and was 
statistically significant at concentrations of 5 µM and above. Concentrations of 10 µM 
PEITC and above resulted in almost total loss of radioactive HIF1α, similar to the 
control translation inhibitor cycloheximide. 
 
4.3 Discussion 
 
It has been previously found in this laboratory that PEITC inhibited the activity of HIF 
as shown by using a hypoxia-dependent construct in a luciferase reporter assay (Wang 
et al., 2009). I have further demonstrated that PEITC is able to inhibit the expression of 
a variety of endogenous HIF target genes, as well as inhibit HIF1α accumulation in 
hypoxia treated cells. Therefore, I conclude that PEITC is a potent inhibitor of HIF 
expression. 
 
Work in this laboratory has also shown PEITC can inhibit HIF1α accumulation in the 
pVHL-deficient RCC4 renal carcinoma cell line, which is unable to degrade HIFα 
proteins via the canonical pVHL pathway and as a result constituently expresses 
HIF1α in normoxia. Furthermore, it was demonstrated that inhibition of HIF 
accumulation by PEITC occurred independently of the proteasome, and treatment with 
PEITC had no effect on the expression of HIF1α mRNA (Wang et al., 2009).  This 
suggests that PEITC-induced inhibition of HIF expression does not occur via 
suppression of HIF transcription or by interfering with the degradation pathway. It is 
therefore proposed that PEITC acts at the level of mRNA translation. Inhibition of 
HIF1α mRNA translation has previously been linked to impaired activity of mTORC1 
(Bernardi et al., 2006). Phosphorylation of 4E-BP1 by mTORC1 decreases its affinity to 
eIF4E, the rate limiting component of the eIF4F complex, enabling cap-dependent 
translation. Possibly due to a greater need for mRNA unwinding by the eIF4A 
component, mRNAs with complex secondary structures within their 5’UTR are more 
sensitive to changes in eIF4E (Koromilas et al., 1992). HIF1α possess a highly 
structured 5’UTR (Iyer et al., 1998) and therefore the effect of PEITC on mTORC1 
activity was investigated. It was discovered that PEITC did inhibit mTORC1 activity as 
assessed by loss of substrate phosphorylation, p70 S6K and 4E-BP1. Consistent with 
my findings, PEITC has also been shown to inhibit 4E-BP1 phosphorylation at both                                                                                     Chapter 4: Hypoxia inducible factor  
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Thr70 and Ser65 sites in colorectal cancer HCT-116 cells and prostate cancer PC3 
cells (Hu et al., 2007). Hu et al. (2007) also demonstrated that PEITC preferentially 
inhibited cap-dependent translation as assessed by luciferase reporter constructs with 
and without a stem-loop secondary structure introduced into the 5’ UTR.  
 
In trying to unravel where in the mTORC1 pathway PEITC acts, it was found PEITC 
was unable to impair mTORC1 activity in TSC2 null MEFs, indicating that PEITC-
induced inhibition of mTORC1 is dependent on TSC1/2 activity. TSC1/2 integrates 
several regulatory pathways to control mTOR in response to various cellular stresses 
and growth factors, and these were also investigated. Akt phosphorylates and inhibits 
TSC2 in response to growth factors via PI3K pathway leading to enhanced mTORC1 
activity. This pathway is negatively regulated by PTEN. PTEN is subject to redox 
regulation and therefore presents an attractive target for direct protein modification by 
PEITC. However, using PTEN null MEFs it was found PEITC was able to suppress 
mTORC1 activity regardless of PTEN status. Furthermore, PEITC treatment did not 
inhibit Akt phosphorylation at either Thr308 or Ser473 sites, and was in fact found to be 
increased in both MCF7 and SK-BR-3 breast cancer cell lines. Activation of mTORC1 
via phosphorylation and inhibition of TSC2 in response to growth factors also occurs 
via the classical MAPK pathway involving ERK and p90RSK. Phosphorylation of ERK 
at Tyr202/Thr204 that corresponds to its activity is not inhibited by PEITC, and as with 
Akt, actually results in an increase in ERK phosphorylation at these sites. 
Phosphorylated AMPK, which activates TSC1/2 and consequently inhibits mTORC1 in 
response to ATP depletion, was also unaffected by PEITC treatment. 
 
mTORC1 activity can also be inhibited by regulated in development and DNA damage 
response 1 (REDD1; also known as RTP801), which is transcriptionally upregulated in 
response to a variety of cellular stresses including hypoxia (Shoshani et al., 2002) and 
ER stress (Jin et al., 2009; Whitney et al., 2009). How exactly REDD1 suppresses 
mTORC1 has not been fully elucidated but studies carried out with TSC2 null MEFs 
suggest it is upstream of TSC1/2 (Brugarolas et al., 2004). One theory is that REDD1 
functions to bind to and sequester inhibitory 14-3-3 proteins that interact with TSC2 
following its phosphorylation by Akt. When bound, the 14-3-3 proteins are thought to 
destabilise the interaction between TSC1 and 2 removing its inhibition on mTORC1 
(DeYoung et al., 2008). However, the rapid inhibition of p70 S6K phosphorylation by 
PEITC (30 min) likely discounts REDD1 as the target for PEITC-induced inhibition of                                                                                     Chapter 4: Hypoxia inducible factor  
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mTORC1, as per Balgi et al. (2011), considering de novo transcription of REDD1 takes 
considerably longer.  
 
These findings suggest that PEITC either acts on TSC1/2 itself or upstream of TSC1/2 
on an as of yet unknown regulator of mTORC1. A recent study has demonstrated that 
mTORC1 activity can also be impaired in response to acidic pH and that this is 
mediated via TSC1/2. Inhibition of mTORC1 activity was associated with a decrease in 
MEK and downstream ERK activity however, this had if anything only a modest effect 
on mTORC1 inhibition by acidification (Balgi et al., 2011). Similar to my study, Balgi et 
al. (2011) found no evidence that any of the other pathways known to regulate 
mTORC1 through TSC1/2 were involved. Therefore, it is likely that there is at least one 
unidentified regulator of mTORC1 that acts as a pH sensor.  
 
The anticancer effects of PEITC and other isothiocyanates are thought to target 
multiple aspects of tumour progression, including chemoprevention, induction of 
apoptosis and suppression of angiogenesis. However, knowledge of the upstream 
triggering events is limited. It is likely that generation of ROS and direct covalent 
modification of target proteins, particularly those with thiol containing cysteines, play a 
role.   
 
Sarbassov and Sabatini (2005) demonstrated that cysteine oxidants, diamide and 
phenylarsine oxide (PAO), stimulated mTORC1 activity even during nutrient 
withdrawal, and this was associated with an instability of the mTOR-Raptor interaction. 
Interestingly, the mTOR-Rictor interaction was unaffected by cysteine oxidants. 
Furthermore, the reducing agent BAL (British anti-Lewisite, or 2,3-dimercapto-1-
propanol) was found to inhibit mTORC1 activity. As already mentioned mTOR has 
several conserved cysteine residues that make it a potential target for redox regulation 
(Dames et al., 2005). However, as PEITC-induced inhibition of mTORC1 is dependent 
on TSC2 it does not seem that direct modification of mTOR is involved. Recently it was 
discovered that cysteine oxidants increased levels of Rheb-GTP and that redox 
regulation of mTORC1 by both cysteine oxidants and reducing agents was also 
dependent on TSC1/2. Similar to PEITC, mTORC1 activity, as assessed by 
phosphorylation of p70 S6K, was unaffected by treatment with either PAO or BAL in 
TSC2 null MEFs (Yoshida et al., 2011).  
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There is clearly a role for redox in the regulation of mTORC1, therefore the ability of 
PEITC to conjugate with protein cysteinyl thiols may be important in its effect on 
mTORC1 activity. However, as ROS acts like PAO to oxidise cysteines it is unlikely 
that ROS generation contributes to the observed inhibition of mTORC1 activity 
following PEITC treatment. Although, it should be noted despite initially acting as a pro-
oxidant, PEITC can also act indirectly as an anti-oxidant, by inducing Nrf2-mediated 
antioxidant gene expression.   
 
Furthermore, while it is known Akt, ERK/p90RSK and AMPK phosphorylate TSC2 at 
diverse sites, it is unclear how this can result in either the inhibition or stimulation of 
TSC1/2. It has been suggested that 14-3-3 proteins recognise Akt-directed 
phosphorylation sites on TSC2, and cause translocation of TSC2 to the cytosol and 
away from TSC1, disrupting the complex (Cai et al., 2006). Indeed, it is thought that 
REDD1 impairs mTORC1 by removing these 14-3-3 proteins and restoring the 
inhibitory influence of TSC1/2 (DeYoung et al., 2008).  
 
There are seven mammalian isoforms of 14-3-3 proteins that form hetero- or 
homodimers and bind to phospho-serine/phospho-threonine residues on a wide range 
of proteins. Binding can obstruct interaction of the target protein with essential partner 
proteins or substrates, or induce a conformational change to affect its stability or 
activity (Morrison, 2009). REDD1 does contain a serine residue (Ser137) within a 
consensus 14-3-3 binding motif, however this motif is not conserved and mutations to 
several key residues including the Ser137 did not affect REDD1-induced inhibition of 
mTORC1 (Vega-Rubin-de-Celis et al., 2010). As it is unclear exactly if or how REDD1 
binds 14-3-3 proteins, another protein may well exist that interacts with REDD1 and 
relays a signal to activate TSC1/2 that could be influenced by PEITC. It should be 
noted that 14-3-3 proteins can bind phospho-serine/phospho-threonine residues 
outside of recognised motifs and even in a phosphorylation-independent manner. 
However, another reservation on the proposed mechanism of 14-3-3 sequestration by 
REDD1 is that considering the abundance of 14-3-3 proteins and they’re interaction 
with over 100 different proteins how is it possible REDD1 achieves specificity and 
sequesters enough to be effective (Vega-Rubin-de-Celis et al., 2010; Wang and Proud, 
2010). It has been found that binding of 14-3-3 proteins to one partner, CD81, is 
prevented by redox sensitive palmitoylation of several of its cysteine residues (Clark et 
al., 2004). Perhaps binding of 14-3-3 proteins to TSC2 can also be redox regulated. 
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As recently reviewed by Wang and Proud (2010) there is much about mTORC1 
signalling that is still unknown and it may be that PEITC could be used as a probe to 
explore this pathway further. 
 
I have previously discussed the available literature on the effect of PEITC on Akt 
phosphorylation in Chapter 3. However, now in the context of mTOR, it is possible an 
increase in Akt phosphorylation is a consequence of PEITC-induced inhibition of 
mTORC1. In a negative feedback loop, mTORC1 and its substrate p70 S6K can 
phosphorylate insulin receptor substrate 1 (IRS1), reducing its stability (Shah and 
Hunter, 2006; Tzatsos and Kandror, 2006). As IRS1 is required for insulin and insulin-
growth factor 1 (IGF1) mediated activation of PI3K, stimulation by these growth factors 
no longer leads to recruitment of Akt to the cell membrane and phosphorylation by 
PDK1 and mTORC2. mTORC1 has also been shown to impair Akt phosphorylation by 
decreasing transcription of platelet derived growth factor receptor (PDGFR), that 
activates PI3K in response to a number of different growth factors (Zhang et al., 2007).  
The recent discovery that growth factor receptor-bound protein 10 (Grb10) is a 
substrate for mTORC1 highlights that the mTORC1-mediated negative feedback 
mechanism on growth factor induced stimulation is multifaceted.  Grb10 binds to and 
negatively regulates the insulin and IGF1 receptors, it is proposed phosphorylation of 
Grb10 by mTORC1 increases its activity by promoting protein stability (Hsu et al., 
2011).  Furthermore, p70 S6K has been found to directly phosphorylate mTORC2 
specific component Rictor, an action that seemingly impairs mTORC2-mediated 
phosphorylation of Akt (Julien et al., 2010).  Thus, suppression of mTORC1 and 
removal of these inhibitory influences may result in the increased Akt phosphorylation 
seen following PEITC treatment.  
 
In addition, mTORC1 inhibition has been shown to activate ERK in a mechanism that 
is dependent on PI3K and involves activation of the classical MAPK cascade 
(Carracedo et al., 2008). Therefore, the increase in ERK phosphorylation I see in 
MCF7 cells is possibly also a consequence of PEITC-induced inhibition of mTORC1. 
An increase in ERK phosphorylation following PEITC treatment has been previously 
reported in human prostate and bladder carcinoma cell lines and is associated with 
PEITC-induced apoptosis and Nrf2 mediated ARE activity (Pullar et al., 2004; Xiao and 
Singh, 2002; Xu et al., 2006a; Xu et al., 2006b). However, the effect of PEITC on ERK 
phosphorylation seems to be cell type specific as PEITC has been shown to inhibit 
ERK phosphorylation in human cervical and ovarian cancer cell lines (Huong et al.,                                                                                     Chapter 4: Hypoxia inducible factor  
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2011; Satyan et al., 2006). Specifically Huong et al. (2011) reported loss of ERK 
phosphorylation resulted in upregulation of death receptors 4 and 5 (DR4 and DR5) 
causing PEITC-induced apoptosis.   
 
Consistent with the view mTORC1 inhibition enhances upstream signalling to 
mTORC2 due to the loss of p70 S6K-IRS1 negative feedback, I observed a dose-
dependent increase in Akt Ser473 and NDRG1 phosphorylation in wild type MEFs. 
This corresponded with the decrease in p70 S6K phosphorylation I have seen in 
previous experiments. Furthermore, I found that basal phosphorylation of mTORC2 
downstream effectors, Akt and NDRG1, was greatly impaired in TSC2 null MEFs 
where mTORC1 activity is unrestrained. Indeed, loss of mTORC2 activity in TSC2 null 
MEFs has been reported previously (Huang et al., 2008; Huang et al., 2009). Although, 
the authors attributed this observation to a direct effect of TSC2 on mTORC2, 
independent of its Rheb GAP activity. Despite this, I found PEITC treatment still 
caused a dose-dependent increase in mTORC2 activity in these cells. As I have 
previously shown, PEITC has a limited effect on mTORC1 activity in the TSC2 null 
MEFs, this increase in mTORC2 activity can not be attributed to a relief in p70 S6K-
mediated inhibition. Little is known about the regulation of mTORC2. However, it 
seems that while PEITC inhibits mTORC1 activity in a TSC2-dependent manner, it can 
also activate mTORC2 in a way that is independent of its effect on mTORC1 and does 
not require TSC2. This also indicates that elevated Akt phosphorylation in response to 
PEITC can not simply be attributed to loss of mTORC1 negative feedback loops as 
discussed earlier.        
 
The growth inhibitory action of PEITC has been well documented and I have 
demonstrated it myself in Chapter 3. mTORC1 inhibitor rapamycin has been shown to 
inhibit cell proliferation by arresting cell cycle progression at the G1/S boundary 
(Terada et al., 1993).  In particular, inhibition of cell proliferation due to loss of 
mTORC1 activity is dependent on 4E-BPs which when hypophosphorylated 
sequesters eIF4E, required for cap-dependent translation (Dowling et al., 2010). 
Overexpression of eIF4E has been shown to protect HCT-116 cells from PEITC-
induced growth inhibition, suggesting that growth inhibition by PEITC may in part be 
due to impaired protein synthesis (Hu et al., 2007). These effects are unlikely to be 
attributed to reduced HIF activity as these experiments were performed in normoxia. 
However, other studies have demonstrated overexpression of eIF4E preferentially 
increased translation of proteins involved in cell survival (Bcl-XL) and proliferation 
(cyclin D1), which may confer some protection from PEITC-mediated growth inhibition                                                                                     Chapter 4: Hypoxia inducible factor  
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(Li et al., 2003; Rosenwald et al., 1995). I found that TSC2 null MEFs which were 
resistant to mTORC1 inhibition by PEITC were slightly less sensitive to PEITC-induced 
growth inhibition compared to their wild type counterparts. Although, as this effect was 
only modest there are likely multiple mechanisms by which PEITC inhibits growth 
inhibition. Indeed, loss of one or both PTEN alleles also seemed to have a modest 
effect on PEITC-mediated growth inhibition, despite there being no effect of PTEN 
status on the ability of PEITC to suppress mTORC1 activity.      
 
I have proposed that PEITC-induced inhibition of HIF1α protein accumulation is the 
result of impaired translation of HIF1α mRNA and that this is a consequence of 
reduced mTORC1 activity. Through 
35S-metabolic cell labelling I was able to directly 
look at translation and found that PEITC does appear to inhibit protein synthesis of 
HIF1α. Indeed, a downregulation in hypoxia induced HIF1α expression and VEGF 
production in human prostate cancer and tongue squamous cancer cell lines by the 
isothiocyanate SFN also appeared to be due to inhibition of HIF1α/ HIF2α mRNA 
translation (Yao et al., 2008). Although, there may also be a role for PEITC in 
modulating transcription, as while SFN was also shown to decrease HIF1α 
accumulation and VEGF production in HUMEC-1 cells this was associated with a 
reduction of HIF1α mRNA (Bertl et al., 2006). The effects of PEITC on translation are 
likely to be complex. Previous work in my laboratory has shown that PEITC also 
inhibits HIF2α protein accumulation in MCF7 cells (Wang et al., 2009), despite the 
absence of complex secondary structures within the 5’UTR of HIF2α mRNA. 
Furthermore, expression of HIF2α is unaffected by mTORC1 inhibitor rapamycin (Bhatt 
et al., 2008). It is possible PEITC affects global protein synthesis via inhibition of cap-
dependent translation, but that a small subset of mRNAs with highly structured 5’-
UTRs are particularly sensitive to decreased efficiency of translation. 
 
     
  
 
 
 
Chapter 5
 
The effect of PEITC on 
total mRNA translation 
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5.1 Introduction 
 
Following on from the discovery described in Chapter 4 that PEITC decreases HIF1α 
mRNA translation the effect of PEITC on total mRNA translation was investigated. 
Increased protein synthesis is an inevitable consequence of carcinogenesis, with 
uncontrolled cell growth and proliferation being a defining hallmark of cancer (Hanahan 
and Weinberg, 2000). Multiple factors involved in the regulation of translation including 
eukaryotic initiation factor 4E (eIF4E) and 2 (eIF2) have been implicated in 
downstream oncogenic signalling and as a result the translational machinery 
represents a potential target for cancer therapy (Rajasekhar and Holland, 2004).  Work 
described in this chapter demonstrates that PEITC acts as a general inhibitor of protein 
synthesis, and reveals that in addition to mTORC1, PEITC influences other key 
translational regulators.  
 
5.2 Results 
 
5.2.1  Effect of PEITC on total mRNA translation 
 
To determine the effect of PEITC on total mRNA translation, global protein synthesis 
was analysed following PEITC treatment. Treated MCF7 cells were metabolically 
labelled with [
35S]Met/Cys and trichloroacetic acid (TCA) was used to precipitate the 
protein prior to quantitation of incorporation using a scintillation counter (Figure 5.1). 
Similar to HIF1α synthesis, PEITC resulted in a dose-dependent inhibition of total 
protein synthesis with 7.5 µM PEITC resulting in a statistically significant reduction. 
Furthermore, 10 µM PEITC decreased mRNA translation to the same extent as CHX, a 
general inhibitor of protein synthesis, suggesting that PEITC has an equivalent 
universal effect on translation. 
 
5.2.2  The role of mTORC1 pathway in PEITC-induced inhibition of total 
mRNA translation 
 
In Chapter 4 I established that PEITC inhibited the activity of mTORC1 as assessed by 
a decrease in 4E-BP1 and p70 S6K phosphorylation. As discussed, the exact role of 
p70 S6K in translation is not well defined, but 4E-BP1 is known to sequester cap-
binding protein eIF4E, which is required to form the eIF4F complex in cap-dependent 
translation. However, it seems that only a small subset of proteins are sensitive to                                                                                               Chapter 5: Total mRNA translation 
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Figure 5.1: The effect of PEITC on total mRNA translation.  
MCF7 cells were incubated in the absence (UT) or presence of indicated 
concentrations of PEITC, DMSO (equivalent to 20 µM PEITC), or 10 µg/ml 
cycloheximide (CHX) as a positive control for 1 h. 100 µCi/ml of [
35S]Met/Cys protein 
labelling mix was added for 2 h. Cells were harvested and protein extracted using TCA 
precipitation. Radioactivity was measured on a scintillation counter. Experiments were 
performed in duplicate and normalised to UT, graph shows means from three 
independent experiments ± SD. Statistically significant differences between UT and the 
treatments are indicated (* p<0.05). All other comparisons were not statistically 
significant. 
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changes in eIF4E, therefore it is unlikely that loss of mTORC1 activity can account for 
the almost complete inhibition of global protein synthesis by PEITC (Koromilas et al., 
1992). Indeed, treatment of wild type MEFs with mTORC1 inhibitor rapamycin only 
suppressed global protein synthesis by approximately 50% (Figure 5.2). Although, it 
should be noted that while not all functions of mTORC1 are inhibited by rapamycin, 
phosphorylation of p70 S6K and 4E-BP1 at site Ser65 are rapamycin-sensitive (Wang 
et al., 2005).  
 
To further explore the potential role of impaired mTORC1 activity in PEITC-induced 
inhibition of total mRNA translation, global protein synthesis was analysed in the TSC2 
null and wild type MEFs (Figure 5.3). I have previously shown that a statistically 
significant decrease in 4E-BP1 and p70 S6K phosphorylation is observed following 
PEITC treatment in the wild type TSC2 MEFs, but that this inhibition is lost in the TSC2 
deficient MEFs when mTORC1 is no longer under the regulatory influence of TSC1/2 
(Figure 4.6). If the effect of PEITC on total mRNA translation was a result of this 
inhibition of mTORC1 activity I would expect the TSC2 null MEFs to be less sensitive. 
However, global protein synthesis is equally inhibited by PEITC in both the MEF 
genotypes. 
 
5.2.3  Effect of PEITC on key translational proteins 
 
As inhibition of total mRNA translation by PEITC occurs regardless of a decrease in 
mTORC1 activity, I investigated the effect of PEITC on several other key proteins 
involved in general protein synthesis, eukaryotic initiation factor 2 (eIF2) and eukaryotic 
elongation factor 2 (eEF2). Phosphorylation of eIF2α subunit at Ser51, or eEF2 at 
Thr56 impairs the function of these proteins, inhibiting translation. 
 
MCF7 cells were treated with increasing concentrations of PEITC for 3 h and analysed 
by western blot (Figure 5.4).  PEITC caused a statistically significant dose-dependent 
increase in eIF2α phosphorylation. However, there was no change in eEF2 
phosphorylation. 
 
To further investigate the effect of PEITC on eIF2α I used MEFs that were 
homozygous for a mutation of eIF2α at amino acid reside 51. This serine to alanine 
conversion renders eIF2α unphosphorylatable at this critical regulatory residue. Mutant 
(eIF2α AA) and wild type (eIF2α SS) MEFs were treated with PEITC for 3 h and 
analysed by western blot for phosphorylation of the translational modulators eIF2α and                                                                                               Chapter 5: Total mRNA translation 
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Figure 5.2: The effect of rapamycin on global mRNA translation in wild type 
MEFs.  
Wild type MEFs were incubated in the absence (UT) or presence of 25 nM rapamycin 
or 10 µg/ml cycloheximide (CHX) as a positive control for 1 h. 100 µCi/ml of 
[
35S]Met/Cys protein labelling mix was added for 2 h. Cells were harvested and protein 
extracted using TCA precipitation. Radioactivity was measured on a scintillation 
counter. Experiment was performed once in duplicate and normalised to UT.  
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Figure 5.3: The effect of PEITC on global mRNA translation in TSC2 null and wild 
type MEFs.  
TSC2+/+TP53-/- ( ) and TSC2-/-TP53-/- ( ) MEFs were incubated in the absence (UT) 
or presence of indicated concentrations of PEITC, DMSO (equivalent to 20 µM PEITC), 
or 10 µg/ml cycloheximide (CHX) as a positive control for 1 h. 100 µCi/ml of 
[
35S]Met/Cys protein labelling mix was added for 2 h. Cells were harvested and protein 
extracted using TCA precipitation. Radioactivity was measured on a scintillation 
counter. Experiments were performed in duplicate and normalised to UT, graph shows 
means from three independent experiments ± SD. Statistically significant differences 
between UT and the treatments are indicated (* p<0.05; *** p<0.005). All other 
comparisons were not statistically significant.                                                                                              Chapter 5: Total mRNA translation 
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Figure 5.4: The effect of PEITC on key translational proteins in MCF7 cells.  
MCF7 cells were treated with indicated concentrations of PEITC or DMSO (equivalent 
to 20 µM PEITC) for 3 h. 25 µg of whole cell lysate was subjected to SDS-page and 
analysed by western blot for phospho-eEF2 (Thr56; 95 kDa) and phospho-eIF2α 
(Ser51; 38 kDa) then stripped and re-probed for total equivalents. Equal loading was 
determined by probing for β-actin (42 kDa). The blot is representative of three 
independent experiments and the results from all three are combined in the 
densitometry graphs (± SD). Statistically significant differences between UT and the 
treatments are indicated (* p<0.05; *** p<0.005). All other comparisons were not 
statistically significant.                                                                                              Chapter 5: Total mRNA translation 
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eEF2, as well as indicators of mTORC1 activity, p70 S6K and 4E-BP1 phosphorylation 
(Figure 5.5). Confirming observations from MCF7 cells, PEITC caused a dose-
dependent increase in eIF2α phosphorylation in the eIF2α SS wild type MEFs, but as 
expected not in the unphosphorylatable eIF2α AA MEFs. This phosphorylation 
occurred independently of changes in mTORC1 activity as loss of 4E-BP1 and p70 
S6K phosphorylation is seen in both cell lines. In contrast to MCF7 cells, the basal 
levels of eEF2 phosphorylation were extremely low but eEF2 phosphorylation 
increased in a dose-dependent manner in PEITC treated cells. 
 
5.2.4  Role of eIF2α phosphorylation in PEITC-induced inhibition of total 
mRNA translation 
 
In order to establish the importance of eIF2α phosphorylation in PEITC-induced 
inhibition of total mRNA translation, global protein synthesis was analysed in the wild 
type eIF2α SS and eIF2α AA MEFs (Figure 5.6).  The inability of eIF2α to become 
phosphorylated did render eIF2 AA MEFs less sensitive than the wild type MEFs to 
PEITC-induced inhibition of total mRNA translation. However, at higher concentrations 
of PEITC global protein synthesis was statistically significantly inhibited in both cell 
lines. 
 
5.2.5  Role of eIF2α Phosphorylation in PEITC-Induced Growth Inhibition  
 
To examine the role of eIF2α phosphorylation in PEITC-induced growth inhibition, the 
sensitivity of wild type and eIF2α AA MEFs to various concentrations of PEITC was 
examined. MEFs were treated with PEITC for four days before relative cell number 
was measured by the MTS assay. Representative growth inhibition data in the form of 
survival curves and mean IC50 values are shown in Figure 5.7. MEFs of both 
genotypes demonstrated dose-dependent growth inhibition following PEITC treatment, 
but interestingly the wild type MEFs retained significantly higher cell numbers, giving 
rise to an IC50 value two-fold higher, than the MEFs with unphosphorylatable eIF2α. 
 
5.2.6  Effect of PEITC on eEF2 phosphorylation 
 
I have observed that while PEITC has no effect on phosphorylation of eEF2 in human 
breast cancer MCF7 cells (Figure 5.4), PEITC caused a dose-dependent increase in 
phospho-eEF2 in both the eIF2α SS and AA MEFs (Figure 5.5). To determine whether                                                                                               Chapter 5: Total mRNA translation 
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Figure 5.5: The effect of PEITC on key translational proteins in eIF2α SS and 
eIF2α AA MEFs. 
MEFs were treated with indicated concentrations of PEITC or DMSO (equivalent to 20 
µM PEITC) for 3 h. 25 µg of whole cell lysate was subjected to SDS-page and 
analysed by western blot for phospho-eEF2 (Thr56; 95 kDa), phospho-p70 S6K 
(Thr389; 70 kDa), phospho-eIF2α (Ser51; 38 kDa) and total 4E-BP1 (15-20 kDa; as 
indicated, multiple bands represent different phospho-forms) then stripped and re-
probed for total equivalents. Equal loading was determined by probing for β-actin (42 
kDa).  
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Figure 5.6: The effect of PEITC on global mRNA translation in eIF2α SS and 
eIF2α AA MEFs.  
eIF2α SS ( ) and eIF2α AA ( ) MEFs were incubated in the absence (UT) or presence 
of indicated concentrations of PEITC, DMSO (equivalent to 20 µM PEITC), or 10 µg/ml 
cycloheximide (CHX) as a positive control for 1 h. 100 µCi/ml of [
35S]Met/Cys protein 
labelling mix was added for 2 h. Cells were harvested and protein extracted using TCA 
precipitation. Radioactivity was measured on a scintillation counter. Experiments were 
performed in duplicate and normalised to UT, graph shows means from three 
independent experiments ± SD. Statistically significant differences between UT and the 
treatments are indicated (* p<0.05; ** p<0.01; *** p<0.005), and between the same 
treatment in the different cell lines (# p<0.05; ## p<0.01). All other comparisons were 
not statistically significant. 
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Figure 5.7: PEITC-induced growth inhibition of eIF2α SS and eIF2α AA MEFs.  
eIF2α SS ( ) and eIF2α AA ( ) MEFs were treated with various concentrations of 
PEITC, DMSO ( ) equivalent to the highest dose of PEITC and 0.5 μM STS as a 
positive control ( ). After four days metabolic activity was determined by MTS assay 
using the CellTiter 96
® AQueous One Solution reagent. Graph is representative and 
shows data derived from means of triplicate wells (± SD). Table showing IC50 values 
represent mean values ± SD from four experiments performed in triplicate. A 
statistically significant difference between IC50 values for eIF2α SS and AA MEFs is 
indicated (** p<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC50/µM Value (mean ± SD)   
eIF2α SS  eIF2α AA 
PEITC  9.3 ± 1.4  4.8 ± 0.7**                                                                                              Chapter 5: Total mRNA translation 
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PEITC could also induce phosphorylation of eEF2 in the other MEFs used within this 
study, they were also treated with PEITC for 3 h and analysed by western blot for 
phospho-eEF2 (Figure 5.8). Similar to the eIF2α MEFs, the PTEN MEFs of both 
genotypes seem to have low basal levels of eEF2 phosphorylation which increases in 
response to treatment with PEITC. On the other hand, basal eEF2 phosphorylation 
appears to be higher in both genotypes of the TSC2 MEFs and PEITC does not have 
any effect.  
 
Furthermore, as the response to PEITC is consistent between the wild type and 
genetically modified counterpart of each of the MEFs, the effect of PEITC on eEF2 
phosphorylation must be independent of PTEN, TSC2 and eIF2α phosphorylation. It 
should be noted that the concentrations of PEITC treatments between the PTEN and 
TSC2 MEFs are slightly different as to correlate with the range of concentrations 
previously tested in each of the cell lines. However, in both the PTEN and eIF2α 
MEFs, an increase in eEF2 phosphorylation is clearly evident at 10 µM PEITC 
treatment, while no change is observed at this concentration in the TSC2 MEFs. 
 
5.3 Discussion 
 
Following on from the discovery in Chapter 4 that PEITC inhibits translation of HIF1α 
mRNA in MCF7 cells, I investigated the effect of PEITC on global inhibition of protein 
synthesis in these cells and found that PEITC seems to have a general inhibitory effect 
on mRNA translation. However, it seemed unlikely that PEITC-induced inhibition of 
mTORC1 activity was responsible, as mTORC1 inhibitor rapamycin only suppressed 
global protein synthesis by approximately 50% in wild type MEFs. This is consistent 
with previous studies, which using various mTOR inhibitors demonstrated mTORC1 
only has a modest effect on total mRNA translation (Jefferies et al., 1994; Thoreen et 
al., 2009). Indeed, global protein synthesis in TSC null MEFs, which I have shown in 
Chapter 4 to be resistant to PEITC-induced suppression of mTORC1 activity, was 
inhibited by PEITC to a similar extent as their wild type counterparts. In an attempt to 
elucidate how PEITC was inhibiting total mRNA translation, I investigated the effect of 
PEITC on two other key regulators of protein synthesis, eIF2α and eEF2, in MCF7 
cells. While there was no effect of PEITC on eEF2 phosphorylation, eIF2α 
phosphorylation was significantly increased. Using MEFs that were homozygous for a 
mutation of eIF2α Ser51 to unphosphorylatable alanine (eIF2α AA), I confirmed that 
while PEITC caused a dose-dependent increase in eIF2α phosphorylation in the eIF2α 
SS wild type MEFs, it was unable to in the eIF2α AA MEFs. Furthermore, this                                                                                               Chapter 5: Total mRNA translation 
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Figure 5.8: Effect of PEITC on phosphorylation of eEF2 in different MEFs. 
(a) PTEN wild type (+/+) and deficient (-/-), or (b) TSC2 wild type (+/+TP53-/-) and 
deficient (-/-TP53-/-) MEFs cells were treated with indicated concentrations of PEITC 
or DMSO (equivalent to 20 µM PEITC) for 3 h. 25 µg of whole cell lysate was 
subjected to SDS-page and analysed by western blot for phospho-eEF2 (Thr56; 95 
kDa) then stripped and re-probed for total eEF2. Equal loading was determined by 
probing for β-actin (42 kDa). Lysates used for blot (a) are the same as those shown in 
Figure 4.6.   
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phosphorylation occurred independently of changes in mTORC1 activity as loss of 4E-
BP1 and p70 S6K phosphorylation is seen in both cell lines. However, in contrast to 
what was observed in MCF7 cells, PEITC caused a dose-dependent increase in eEF2 
phosphorylation in both the eIF2α MEF genotypes. This difference will be discussed 
later. Importantly, I have shown that eIF2α phosphorylation does seem to contribute to 
PEITC-induced inhibition of total mRNA translation as the unphosphorylatable eIF2 AA 
MEFs were less sensitive than the wild type MEFs to inhibition of global protein 
synthesis by PEITC. Although, at higher concentrations of PEITC global protein 
synthesis was statistically significantly inhibited in both eIF2α MEF genotypes 
suggesting that other mechanisms are involved. 
   
eIF2 is a heterotrimeric protein, and when bound to GTP recruits Met-tRNAi and 
transfers it to the 40S ribosomal subunit in a process that requires hydrolysis of GTP 
and release of eIF2-GDP.  For continued initiation of translation and protein synthesis, 
eIF2 needs to exchange GDP for GTP and this is facilitated by the GEF eIF2B. 
However, phosphorylation of Ser51 on the α subunit of eIF2 stabilises the interaction 
between eIF2B and GDP bound eIF2, preventing nucleotide exchange (Webb and 
Proud, 1997). In mammals, eIF2α is known to be phosphorylated by four distinct 
kinases in response to a variety of environmental and cellular stresses; heme-
regulated inhibitor (HRI), protein kinase RNA-dependent (PKR), PKR-like ER 
(endoplasmic reticulum) kinase (PERK), and nutrient-regulated general control non-
depressible 2 (GCN2) (Wek et al., 2006).  
 
HRI kinase is abundantly expressed in erythroid tissues and was initially identified to 
phosphorylate eIF2α in response to heme deficiency, matching synthesis of globulin 
proteins with heme availability (Han et al., 2001). A single heme molecule directly 
interacts with HRI kinase through a cysteine residue in the C-terminal kinase domain 
and a histidine residue in the N-terminal domain, inhibiting HRI kinase activity when 
heme is abundant (Miksanova et al., 2006). However, oxidative stress induced by 
arsenite and heat stress has also been demonstrated to activate HRI kinase in 
erythroid cells, and although the exact mechanism remains unclear it seems to be 
independent of heme (Lu et al., 2001). In addition, HRI kinase is expressed in non-
erythroid cells (Berlanga et al., 1998), and using HRI knockout MEFs was shown to be 
the principal kinase responsible for eIF2α phosphorylation induced by 26S proteasome 
inhibition in these cells (Yerlikaya et al., 2008).  
                                                                                             Chapter 5: Total mRNA translation 
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PKR plays a role in the antiviral defence mechanism, phosphorylating eIF2α to prevent 
translation of viral mRNA. Expression of PKR is upregulated by interferon and 
enzymatic activation occurs by binding of double stranded RNA (dsRNA) that 
accumulates during viral infection. PKR contains two dsRNA motifs that when are 
bound to dsRNA promotes homodimerisation and subsequent autophosphorylation to 
activate PKR (Cole, 2007). However, PKR can also be activated in the absence of viral 
infection, independent of dsRNA, by heterodimerisation with PKR-associated activator 
(PACT). Phosphorylation of PACT can be triggered by a variety of cellular stresses 
including oxidative stress, ER stress and serum deprivation, and leads to increased 
affinity for PKR (Patel et al., 2000; Singh et al., 2009a).  
 
PERK is an ER transmembrane kinase that phosphorylates eIF2α in response to a 
buildup of misfolded proteins in the ER (Harding et al., 2000). This forms part of the 
unfolded protein response (UPR), halting protein synthesis to prevent further burden 
on the chaperones required for proper folding of newly synthesised membrane and 
secretory proteins. PERK is maintained in an inactive form through binding with ER 
chaperone Grp78/BiP. However, accumulation of unfolded proteins sequesters 
Grp78/BiP away from PERK, activating the eIF2α kinase by allowing homodimerisation 
and autophosphorylation.  Changes to the luminal ER environment by altering redox 
state or calcium levels, or disruption to posttranslational modification such as N-linked 
glycosylation can all impair proper protein folding and lead to a buildup of misfolded 
proteins (Lai et al., 2007).  
 
GCN2 phosphorylates eIF2α in response to amino acid deprivation, coordinating 
protein synthesis with amino acid availability (Zhang et al., 2002). GCN2 possess a 
domain homologous to histidyl-tRNA synthetases (HisRS) enzyme and is believed to 
be activated by binding of uncharged tRNA molecules that increase in concentration 
during amino acid starvation. However, GCN2 has also been shown to be involved in 
eIF2α phosphorylation in response to UV irradiation and proteasome inhibition (Deng 
et al., 2002; Jiang and Wek, 2005). 
 
Considering the redundancy of these kinases to many of the cellular stresses and the 
pleiotrophic effects of PEITC, it is likely that PEITC activates several if not all the eIF2α 
kinases. Perhaps the most obvious means of PEITC to cause eIF2α phosphorylation is 
through oxidative stress, as it is known depletion of ROS-scavenger, glutathione 
(GSH), by PEITC leads to increased intracellular concentrations of ROS (Trachootham                                                                                             Chapter 5: Total mRNA translation 
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et al., 2006). The exact mechanism by which oxidative stress causes activation of the 
eIF2α kinases HRI and PKR is unknown, however, as with modulation of other redox 
sensitive proteins it is likely to involve oxidation of key cysteine residues that alter 
protein activity. Indeed, a cysteine residue is required to coordinate heme to HRI 
kinase and thiol oxidation may disrupt this interaction, removing the inhibitory influence 
of heme (Miksanova et al., 2006). The presence of key regulatory cysteines means it is 
also possible that PEITC activates HRI through direct protein modification. 
Furthermore, conjugation of PEITC to protein cysteinyl thiols in the ER may prevent 
proper formation of disulphide bridges, resulting in an accumulation of misfolded 
proteins and activation of PERK.                                                                                                          
 
Both HRI and GCN2 have also been implicated in eIF2α phosphorylation in response 
to proteasome inhibition in MEFs, and 26S proteasome inhibitors MG132 and 
bortezomib have further been shown to induce phosphorylation of eIF2α in murine 
B16F10 melonama and 4T1 breast cancer cell lines (Yerlikaya and Dokudur, 2010). It 
has recently been shown that PEITC can inhibit both 20S and 26S proteasome activity 
in multiple myeloma cells (Mi et al., 2011a). This inhibition occurs independently of 
ROS generation or ITC-induced protein aggregation therefore, the authors propose 
that PEITC inhibits the proteasome through direct binding. Consequently it is possible 
PEITC thiocarbamoylation indirectly activates eIF2α kinases via the 26S proteasome.  
 
In addition to inhibiting general protein synthesis, eIF2α phosphorylation selectively 
induces translation of a subset of mRNAs that both promote cell survival, through 
adaptation to stress, and induce apoptosis (Harding et al., 2003). Coincident signalling 
pathways activated alongside eIF2α phosphorylation in response to cellular stresses 
can also contribute to cell survival and apoptosis. Seemingly, the ultimate fate of the 
cell depends on the balance between the cytoprotective and pro-apoptotic pathways, 
and these can be influenced by the intensity, duration and type of stress (Muaddi et al., 
2010; Rutkowski et al., 2006; Scheuner et al., 2006). I found that MEFs homozygous 
for an unphosphorylatable form of eIF2α were more sensitive to PEITC-induced growth 
inhibition than their wild type counterparts, suggesting that in this context eIF2α 
confers some protection from PEITC-induced stress.  
 
eEF2 is required for the translocation of the peptidyl chain along the ribosome from A 
to P site during elongation and is negatively regulated through eEF2 kinase directed 
phosphorylation, which prevents eEF2 from binding to the ribosome (Carlberg et al.,                                                                                             Chapter 5: Total mRNA translation 
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1990). eEF2K is a calcium/calmodulin (CAM)-dependent kinase also regulated by 
multiple phosphorylation sites which have both activatory and inhibitory influences. 
Several mTOR-dependent eEF2K phosphorylation sites have been identified that in 
response to insulin inhibit eEF2K thereby decreasing eEF2 phosphorylation and 
promoting mRNA translation. mTORC1 substrate p70 S6K directly phosphorylates 
eEF2K at Ser366, impairing its activity particularly at low calcium concentrations. This 
site can also be phosphorylated by downstream ERK target, p90RSK (Wang et al., 
2001). Cdc2/cyclin B has been shown to phosphorylate eEF2K at Ser 359 in a manner 
that is consistent with being regulated by mTORC1, although exactly how mTORC1 
controls Cdc2/cyclin B is unknown (Smith and Proud, 2008). Phosphorylation at Ser78 
inhibits the binding of calmodulin to eEF2K and is sensitive to rapamycin, although the 
kinase responsible has yet to be identified (Browne and Proud, 2004). On the other 
hand, phosphorylation of Ser398 by AMPK promotes eEF2K activity, inhibiting the 
energy consuming process of elongation when ATP levels are low (Browne et al., 
2004), and phosphorylation of Ser500 (Ser499 in rabbit reticulocytes) by cAMP-
dependent protein kinase (PKA) allows calcium-independent activation of eEF2 (Diggle 
et al., 2001).  
 
Despite PEITC inhibiting p70 S6K phosphorylation, in human MCF7 breast cancer 
cells, there does not appear to be any effect of PEITC on eEF2 phosphorylation. In 
Chapter 4 I demonstrated that PEITC enhanced phosphorylation of upstream p90RSK 
activator, ERK, and therefore it is possible that this compensates for the loss of p70 
S6K activity. While several other mTOR-dependent eEF2K phosphorylation sites have 
also been identified and PEITC does affect mTORC1 activity, as shown by loss of 4E-
BP1 and p70 S6K phosphorylation, it is possible that not all functions are inhibited.  
Surprisingly, when eEF2 phosphorylation was analysed in the eIF2α SS and eIF2α AA 
MEFs, PEITC resulted in a dose-dependent increase in phospho-eEF2 in both MEF 
genotypes. The effect of ERK phosphorylation was not examined in these cells, but as 
with MCF7 cells, PEITC similarly inhibited p70 S6K phosphorylation in both the wild 
type and unphosphorylatable eIF2α MEFs. Interestingly, the MEFs seemed to display 
lower basal levels of eEF2 phosphorylation than the MCF7 cells, which may be a 
consequence of different intracellular levels of calcium. As mentioned, phosphorylation 
by p70 S6K affects eEF2K activity particularly at low calcium concentrations and may 
explain why loss of p70 S6K phosphorylation relieves eEF2K inhibition, increasing 
eEF2 phosphorylation in the MEFs but not the MCF7 cells. I also examined the effect 
of PEITC on eEF2 phosphorylation in the other MEFs used in this study. Similar to the                                                                                             Chapter 5: Total mRNA translation 
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eIF2α MEFs, the PTEN MEFs of both genotypes had low basal levels of eEF2 
phosphorylation which increased with PEITC treatment. However, basal eEF2 
phosphorylation appears to be higher in both genotypes of the TSC2 MEFs and PEITC 
does not have any effect. Notably, unlike the other MEFs, the TSC2 MEFs are also 
knockout for p53. 
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6.1 Introduction 
 
An important aim of this project was to determine whether it was possible to enhance 
the in vitro anticancer activity of watercress. Based on results described in Chapter 3, 
growth inhibition and activation of Nrf2-dependent transcription were selected as 
candidate assays for in vitro analysis of crude watercress extracts and in this chapter, I 
describe a series of proof-of-principle experiments using these assays. The goals of 
these experiments were to (i) optimise methods for preparation of watercress extracts, 
(ii) determine the suitability of the assays for the analysis of crude watercress extracts, 
and (iii) to gain any insight into whether different watercress crops might possess 
distinct in vitro anticancer properties, as a precursor to direct agronomic experiments. 
 
Two varieties of watercress were selected for these proof-of-principle experiments. 
First, the commercially available ’regular’ green watercress from the Vitacress seed 
and second, an American ‘red’ variety of watercress (Figure 6.1).  Apart from the 
obvious difference in colour and the fact that red watercress is sterile little is known 
about the differences between these two varieties. Although, red watercress may have 
similar origins to brown watercress which up until the Second World War was 
commercially cultivated alongside the ’regular’ green watercress.  
 
6.2 Results 
 
6.2.1 Preparation  of watercress extracts 
 
Before I could assess the in vitro anticancer activity of crude watercress extract it was 
necessary to optimise preparation of the extract. Previous studies investigating the in 
vitro anticancer potential of watercress prepared extracts by homogenising samples in 
a commercial juice processor (Boyd et al., 2006; Kassie et al., 2003). Cell debris was 
subsequently removed by centrifugation. This technique is not quantitative and 
therefore unsuitable for comparing between different watercress samples. The method 
obtained from colleagues in Biological Sciences, University of Southampton, UK 
involved grinding snap frozen samples to a fine powder in a pestle and mortar. Ground 
watercress was then decanted into a QIAshredder homogeniser (Qiagen) consisting of 
a mini-spin column and a collection tube. The sample was centrifuged to collect the 
extract. While this technique is quantifiable the grinding of samples is time-consuming. 
To determine whether grinding is necessary I compared crude watercress extracts                               Chapter 6: Proof-of-principle 
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a) b)
Figure 6.1: Images of the two different watercress varieties tested.  
(a) Green watercress, (b) red watercress. 
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prepared using the QIAshredder method from either ground or whole snap frozen 
material in the MTS growth inhibition assay. I found no difference in IC50 values 
between the two samples (Figure 6.2). Snap freezing the sample seems sufficient to 
break open the plant cell walls and allow myrosinase to catalyse the conversion of 
glucosinolates to isothiocyanates. Therefore, in future experiments I used whole 
watercress. Another limitation to using the QIAshredder method was that due to its size 
only 1 g of sample could be prepared, producing approximately 500 µl crude 
watercress extract. Sterile filtering of the extract further reduced sample volume. 
Essentially the QIAshredder homogeniser consists of a column with a filter, sat within a 
collection tube. To create a larger version that could process more watercress, I placed 
a 20 ml syringe (BD Biosciences) that had had the plunger removed and a circular 25 
mm glass microfibre filter (Whatman) inserted in the bottom, inside a 50 ml centrifuge 
tube. Like with the QIAshredder homogenizer, centrifugation allowed for collection of 
crude watercress extract. Crude watercress extracts prepared using either the 
QIAshredder or syringe method were compared in the MTS growth inhibition assay. 
There was no discernable difference in IC50 values between the two samples (Figure 
6.3). As a result, the syringe method was used for the preparation of subsequent crude 
watercress extracts.   
        
I also compared the effect of crude watercress extracts prepared from either leaves or 
stems on growth inhibition in MCF7 cells. Interestingly, extracts from the leaves of 
watercress exhibited approximately 2.5-fold more in vitro anticancer activity than that 
from the stems (Figure 6.4). It is important the watercress extracts come from both the 
leaf and stem to be representative of what an individual may consume however, in 
order to avoid differences in leaf/stem ratio skewing results crude watercress extracts 
for future experiments were prepared from equal parts leaf and stem. 
 
6.2.2  Effect of crude watercress extract from different varieties of 
watercress on the growth inhibition of MCF7 cells  
 
I have already demonstrated that the MTS growth inhibition assay is suitable for the 
analysis of a crude watercress extract; however, I also wanted to investigate whether 
different varieties of watercress possess distinct in vitro anticancer properties. To 
compare the growth inhibitory activity of different varieties of watercress, MCF7 breast 
cancer cells were treated with crude watercress extract from either the green or red 
variety. Extracts from both varieties inhibited the growth of MCF7 cells, but crude 
watercress extract from red watercress was nearly 10-fold more potent than that from                              Chapter 6: Proof-of-principle 
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Figure 6.2: Comparison of the ability of crude watercress extract prepared from 
either ground or whole sample to inhibit the growth of MCF7 cells. 
Representative growth inhibition experiments. Cells were treated with various 
concentrations of crude watercress extract prepared from ground ( ) or whole ( ) 
frozen samples of green watercress, PEITC for use as a standard ( ) or 0.5 μM STS as 
a positive control ( ). Note on the graph the units for PEITC and STS are M. After six 
days metabolic activity was determined by MTS assay using the CellTiter 96
® AQueous 
One Solution reagent. Data shown are derived from means of duplicate wells (± SD). 
Table showing IC50 values represent mean values ± SD from three experiments.  
 
 
IC50 Value (mean ± SD) 
Ground  Whole  PEITC 
36.7 µl/ml ± 18.3  43.8 μl/ml ± 13.7  12.3 μM ± 2.1                              Chapter 6: Proof-of-principle 
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Figure 6.3: Comparison of the ability of crude watercress extract prepared by the 
QIAshredder or syringe technique to inhibit the growth of MCF7 cells. 
Representative growth inhibition experiments. Cells were treated with various 
concentrations of crude watercress extract from green watercress prepared by the 
QIAshreder ( ) or syringe ( ) technique, PEITC for use as a standard ( ) or 0.5 μM STS 
as a positive control ( ). Note on the graph the units for PEITC and STS are M. After 
six days metabolic activity was determined by MTS assay using the CellTiter 96
® 
AQueous One Solution reagent. Data shown are derived from means of duplicate wells 
(± SD). Table showing IC50 values represent mean values ± SD from three 
experiments. 
 
 
 
IC50 Value (mean ± SD) 
QIAshredder  Syringe  PEITC 
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Figure 6.4: Comparison of the ability of crude watercress extract from either the 
leaf or stem of green watercress to inhibit the growth of MCF7 cells. 
Representative growth inhibition experiments. Cells were treated with various 
concentrations of crude watercress extract from the leaf ( ) or stem ( ) of green 
watercress, PEITC for use as a standard ( ) or 0.5 μM STS as a positive control ( ). 
Note on the graph the units for PEITC and STS are M. After six days metabolic activity 
was determined by MTS assay using the CellTiter 96
® AQueous One Solution reagent. 
Data shown are derived from means of duplicate wells (± SD). Table showing IC50 
values represent mean values ± SD from three experiments. A statistically significant 
difference between IC50 values for crude watercress extracts derived from the leaf and 
stem is indicated (* p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC50 Value (mean ± SD) 
Leaf  Stem  PEITC 
45.4 µl/ml ± 11.0  16.5 μl/ml ± 5.2*  14.4 μM ± 3.8                              Chapter 6: Proof-of-principle 
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green watercress (Figure 6.5). 
 
6.2.3  Effect of crude watercress extract on Nrf2 activity 
 
To investigate effects of watercress extracts on Nrf2 activity, AREc32 cells were 
treated with crude watercress extract from green or red varieties for 24 h before 
luciferase was measured (Figure 6.6). Extracts from the green and red watercress both 
caused a dose-dependent increase in Nrf2-dependent transcription. Similar to 
observations from growth inhibition assays, extract from the red cultivar was 10-fold 
more potent than the green, with a 2-fold increase in Nrf2 activity seen at 0.3125 µM 
and 3.125 µM respectively. 
 
6.2.4  Effect of crude watercress extract on HIF activity 
 
In addition to growth inhibition and Nrf2 activation, I also investigated the effects of 
watercress extracts on other important cancer pathways. In particular, I analysed 
effects on HIF activity and total mRNA translation, shown to be modulated by PEITC in 
previous work (Chapters 4 and 5). 
 
To explore effects on HIF transcriptional activity, MCF7 cells were transiently 
transfected with a luciferase construct containing an upstream hypoxia response 
element (HRE) (Wang et al., 2009). To control for non-specific effects, the activity of 
the SV40-promoter based reporter plasmid pGL3-promoter was also analysed. MCF7 
cells were transfected with the HIF or pGL3-promoter construct and treated with 
increasing amounts of crude watercress extract from the green (Figure 6.7) or red 
(Figure 6.8) varieties, and water as a control. Cells were then exposed to the hypoxia 
mimetic DFO, an iron chelator that inhibits prolyl hydroxylase activity required to target 
HIF for degradation in normoxia.  
 
In both experiments, pretreatment with DFO resulted in strong induction in HIF activity 
with little change observed in the expression of luciferase controlled by the pGL3-
promoter construct. Crude watercress extract from the green variety caused a dose-
dependent decrease in the activity of the HIF reporter construct that is statistically 
significant at 50 µl/ml treatment. There does not seem to be any effect of the green 
watercress extract on the activity of the pGL3-promoter construct. Treatment with 
crude watercress extract from the red variety also resulted in a dose-dependent                               Chapter 6: Proof-of-principle 
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Figure 6.5: Effect of crude watercress extract on the growth of MCF7 cells.  
Representative growth inhibition experiments. Cells were treated with various 
concentrations of crude watercress extract either from the green cultivar ( ) or the red 
cultivar ( ), PEITC for use as a standard ( ) or 0.5 μM STS as a positive control ( ). 
Note on the graph the units for PEITC and STS are M. After six days metabolic activity 
was determined by MTS assay using the CellTiter 96
® AQueous One Solution reagent. 
Data shown are derived from means of duplicate wells (± SD). Table showing IC50 
values represent mean values ± standard deviation from three experiments. A 
statistically significant difference between IC50 values for green and red crude 
watercress extracts is indicated (** p<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC50 Value (mean ± SD) 
Green Wx  Red Wx  PEITC 
34.58 µl/ml ± 9.11  3.25 μl/ml ± 1.77**  17.12 μM ± 4.87    Chapter 6: Proof-of-principle 
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Figure 6.6: Effect of crude watercress extract on ARE-driven expression.  
MCF7 cells stably transfected with ARE were treated with the indicated concentrations 
of crude watercress extract either from (a) green cultivar ( ) or (b) red cultivar ( ) and 
equivalent amounts of H2O as a control ( ) for 24 h and then luciferase activity 
determined. Data shown is mean (± SD) of three independent experiments. Statistically 
significant differences between H2O and watercress treated cells are indicated (* 
p<0.05; ** p<0.01). All other comparisons were not statistically significant.   Chapter 6: Proof-of-principle 
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Figure 6.7: Effect of a crude extract from green watercress on HIF activity.  
MCF7 cells were transfected with (a) pGL2-TK-HRE or (b) control pGL3-promoter 
reporter constructs  and treated with the indicated concentrations of crude watercress 
extract from the green cultivar ( ) or equivalent amounts of H2O as a control ( ) for 24 h 
and then luciferase activity determined. Data shown is mean (± SD) of three 
independent experiments. Statistically significant differences between H2O and 
watercress treated cells are indicated (* p<0.05). All other comparisons were not 
statistically significant. 
    Chapter 6: Proof-of-principle 
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Figure 6.8: Effect of a crude extract from red watercress on HIF activity.  
MCF7 cells were transfected with (a) pGL2-TK-HRE or (b) control pGL3-promoter 
reporter constructs  and treated with the indicated concentrations of crude watercress 
extract from the red cultivar ( ) or equivalent amounts of H2O as a control ( ) for 24 h 
and then luciferase activity determined. Data shown is mean (± SD) of three 
independent experiments. Statistically significant differences between H2O and 
watercress treated cells are indicated (* p<0.05). All other comparisons were not 
statistically significant. 
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decrease in the activity of the HIF reporter construct but at much lower concentrations. 
This is in agreement with the growth inhibition and Nrf2 activity data collected from the 
green and red watercress varieties. However, results were more variable with the red 
watercress extract and the reduction in HIF activity was not statistically significant. In 
addition, extract from the red watercress seemed to reduce activity of the control 
pGL3-promoter construct suggesting there may be non-specific effects. 
 
6.2.5  Effect of crude watercress extract on total mRNA translation 
 
To investigate effects of watercress extracts on total mRNA translation, MCF7 cells 
were treated with crude watercress extract from the green and red varieties. Cells were 
then metabolically labelled with [
35S]Met/Cys and protein synthesis determined 
following TCA precipitation (Figure 6.9). Extracts from both green and red watercress 
caused a dose-dependent decrease in total mRNA translation. However, crude 
watercress extract from the red variety appears to be only 4-fold more potent than that 
from the green variety, as opposed to the 10-fold difference observed in the growth 
inhibition and Nrf2 activity assays. 
 
6.3 Discussion 
 
The goals of this chapter were to optimize preparation of a crude watercress extract, 
determine whether assays developed in previous chapters could be used to analyse 
the in vitro anticancer activity of a crude watercress extract, and investigate whether 
different varieties of watercress might possess distinct in vitro anticancer properties. I 
found that a crude watercress extract can inhibit the growth of MCF7 breast cancer 
cells using the MTS assay and enhance Nrf2 activity as assessed by ARE-driven gene 
expression in a luciferase reporter system. Moreover, I demonstrated that the extract 
from red watercress has more potent in vitro anticancer activity than extracts from the 
green watercress. Therefore, the MTS growth inhibition assay and Nrf2 activity assay 
appear to be suitable to investigate the in vitro anticancer activity of watercress grown 
under different agronomical conditions. I also looked at HIF activity, analysed by a HIF-
dependent construct in a luciferase reporter assay, as a potential means to assess the 
in vitro anticancer activity of crude watercress extract. Crude watercress extract was 
shown to inhibit HIF activity in this assay, and similar to the MTS and Nrf2 activity 
assays showed a difference in the potency of the two varieties of watercress tested. 
However, this assay produced large error bars which meant inhibition of HIF activity     Chapter 6: Proof-of-principle 
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Figure 6.9: Effect of crude watercress extract on total mRNA translation.  
MCF7 cells were incubated in the absence (UT) or presence of indicated 
concentrations of green ( ) or red ( )watercress extract, 20 µM PEITC ( ), or 10 µg/ml 
cycloheximide (CHX) as a positive control for 1 h. 100 µCi/ml of [
35S]Met/Cys protein 
labelling mix was added for 2 h. Cells were harvested and protein extracted using TCA 
precipitation. Radioactivity was measured on a scintillation counter. Experiments were 
performed in duplicate and normalised to UT, graph shows means from three 
independent experiments ± SD. Statistically significant differences between UT and the 
treatments are indicated (* p<0.05; ** p<0.01; *** p<0.005). All other comparisons were 
not statistically significant.  
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was not always statistically significant, and there is also some question as to whether 
crude watercress extract causes non-specific inhibition of the control pGL3-promoter. 
As a result, I decided not to use this assay when determining the in vitro anticancer 
activity of my field trial samples. 
 
Very few studies have actually examined the effect of crude watercress extract on cell 
proliferation. In peripheral blood mononuclear cells (PBMCs) in vitro, 10 µl/ml crude 
watercress extract caused approximately 50% inhibition of metabolic activity while 
having little effect on membrane integrity, suggesting the cells are undergoing 
apoptosis (Hofmann et al., 2009). On the other hand, analysis of cell cycle progression 
following treatment of colorectal carcinoma HepG2 cells with crude watercress extract 
seemed to result in an accumulation in S phase (Boyd et al., 2006). Much of the work 
on crude watercress extract has focused on its effect on drug metabolising enzymes. 
Crude watercress extract has been shown to increase the activity of multiple phase II 
drug metabolising enzymes in vitro, including NQO1 and GST which are under the 
control of AREs (Kassie et al., 2003; Rose et al., 2000). This laboratory has previously 
published data demonstrating the inhibitory effect of crude watercress extract on HIF 
activity in an ARE luciferase system, and showed that consumption of 80 g watercress 
by healthy individuals may be sufficient to cause a transient decrease in 4E-BP1 
phosphorylation in vivo (Syed Alwi et al., 2010). To my knowledge no other groups 
have looked at the effect of watercress or any other cruciferous vegetable on HIF or 
angiogenesis.  
 
Notably, in the MTS and Nrf2 activity assays the crude watercress extract from the red 
variety was found to display considerably more in vitro anticancer activity than that 
from the green variety, being approximately 10-fold more potent. One obvious 
difference between the two varieties is colour. Despite being known as red watercress 
the leaves I tested actually looked more purple in colour, while the green variety of 
watercress was the typical light green colour generally associated with watercress. 
Indeed, the crude watercress extract collected were purple and green respectively. The 
reddy purple colours observed in the red watercress would suggest an increased 
presence of anthocyanins (Mol et al., 1998). It is well known that anthocyanins are 
powerful antioxidants and their presence may be a marker of stress induced changes.  
 
In addition to being antioxidants, there is evidence emerging that anthocyanins and 
their aglycones, anthocyanidins, may also play a more specific anticancer role (Wang 
and Stoner, 2008). Both pure anthocyanins and extracts from anthocyanin rich fruits    Chapter 6: Proof-of-principle 
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and vegetables have been shown to inhibit the growth of a variety of human cancer cell 
lines (Chen et al., 2005; Reddivari et al., 2007; Seeram et al., 2006). This is thought to 
be due to cell cycle arrest in G2/M phase, which is associated with down-regulation of 
a range of cell cycle regulatory proteins, as well as apoptosis initiated via both the 
intrinsic and extrinsic pathways.  It has also been demonstrated that anthocyanins can 
induce the activity of several phase II metabolising enzymes including GST and NQO1 
in rat liver clone 9 cells by promoting ARE-driven gene expression (Shih et al., 2007). 
Anthocyanins have also been reported to possess anti-angiogenic properties. Both the 
anthocyanidin delphinidin and an anthocyanin-rich berry extract were shown to inhibit 
angiogenesis in in vivo models and this was associated with a decrease in VEGF 
expression which is a target for HIF1α (Bagchi et al., 2004; Favot et al., 2003). 
However, it should be noted that these experiments were carried out using much 
higher concentrations of anthocyanins than are likely to be found in red watercress. 
 
If the red watercress does in fact have higher concentrations of anthocyanins than the 
green watercress this may cause the enhanced in vitro anticancer effect observed.   
However, it would be interesting to determine any differences in ITC content between 
the red and green watercress. Anthocyanin presence is an indicator stress and 
therefore other stress-induced changes may have occurred, and these are likely to 
also contribute to the differences in in vitro anticancer activity.  
 
As far as I am aware there has not been any previous data published linking extracts 
from watercress or any other cruciferous vegetable to a decrease in mRNA translation. 
Interestingly, while red crude watercress extract is still more potent than green at 
inhibiting total protein synthesis, the difference in activity is only 4-fold, opposed to the 
10-fold difference observed in the assays looking at growth inhibition and Nrf2 activity. 
It could also be said that crude watercress extract from red watercress is only 5-fold 
more potent than that from the green at inhibiting HIF activity. However, as already 
mentioned there is some difficulty in interpreting the results from this assay.   
 
When assessing the effect of crude watercress extracts on total mRNA translation, 
growth inhibition experiments were carried out alongside using the same extracts. This 
was to confirm that the difference in potency was specific to the effect of watercress on 
total mRNA translation and not an overall decrease in potency due to instability of 
phytochemicals in storage. While storage slightly decreased the potency of the 
watercress samples there was still a relative 10-fold difference between the green and 
red crude watercress extracts in the MTS growth inhibition assay (Appendix 1). These    Chapter 6: Proof-of-principle 
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results suggest that the compound in red watercress responsible for the increased 
growth inhibitory and Nrf2 activity could be different from that responsible for the 
increased inhibition of total mRNA translation. Alternatively, the increased potency in 
the growth inhibition and Nrf2 activity assays could be due to a synergistic effect with 
other phytochemicals, while inhibition of protein translation is caused by a single 
compound acting alone.   
 
One limitation of this study is that I was unable to successfully determine PEITC levels 
in the different watercress samples. Previous studies have highlighted the difficulty in 
measuring breakdown products of glucosinolates due to the volatile nature of many of 
the compounds (Boyd et al., 2006; Rose et al., 2000). However, through use of the 
cyclocondensation assay this problem can be overcome. This method relies on the 
quantitative reaction of ITCs with an excess of 1,2-benzenedithiol to yield the stable 
cyclic-ring product, 1,3-benzodithole-2-thione, and a free amine (Zhang et al., 
1992).The 1,3-benzodithole-2-thione product can then be measured using high-
performance liquid chromatography (HPLC) (Zhang et al., 1996). It should be noted 
that this assay can not distinguish between different isothiocyanates, or their 
conjugation products, therefore the cyclocondensation assay measures total 
isothiocyanates and their metabolites. Nonetheless, this assay could still provide 
valuable insight on whether the differences in in vitro anticancer activity I observed 
were a consequence of altered isothiocyanate content.  
 
In experiments not reported here, aimed at developing the cyclocondensation assay for 
analysis of watercress extracts, I was able to detect 1,3-benzodithole-2-thione in the 
PEITC standard. However, this peak was not seen in the crude watercress extract, 
even when this was spiked with the PEITC standard. The cyclocondensation assay 
has largely been used to determine total ITC content from urinary and plasma samples 
following ingestion of cruciferous vegetables, but crude extracts from broccoli sprouts 
have been analysed by this method (Conaway et al., 2000; Shapiro et al., 2001).  
During my analysis of crude watercress extract an extremely large peak is initially seen 
that was not present in the PEITC standard. This suggests that there is a large amount 
of non-specific binding derived from the watercress extracts that is quickly eluted. The 
non-specific binding may inundate the HPLC column preventing 1,3-benzodithole-2-
thione binding. Differences in the length and diameter of the C18 HPLC column could 
account for why others were still able to achieve 1,3-benzodithole-2-thione binding and 
thus detect ITCs in a crude vegetable extract.  
 
 
 
Chapter 7
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7.1 Introduction 
 
This chapter explores whether it is possible to enhance the in vitro anticancer activity 
of watercress. As described in the introduction, manipulation of both genetics and 
environmental factors provide possible routes to enhance the concentration of 
glucosinolates in crops. Colleagues in Biological Sciences, Southampton University, 
UK are currently establishing a germplasm collection with the view to improve the 
anticancer potential of watercress through selective breeding. Therefore this study will 
investigate the impact of manipulating environmental factors. Altering various aspects 
of the growth environment such as temperature, photoperiod, light quality, sulfur 
fertilisation and water availability have all previously been shown to influence the 
glucosinolate content of cruciferous vegetables. As the changes I make have to be 
suitable for large scale cultivation of watercress in the field, temperature, photoperiod 
and light quality were excluded as variables that could be manipulated. However, 
increasing sulfur fertilisation and withholding water are changes that can be easily 
implemented in the field. Furthermore, it is known that the expression of some plant 
genes follow a circadian rhythm that can be influenced by environmental cues such as 
light and temperature (Schaffer et al., 2001). The fact that glucosinolate content can 
also be affected by these environmental cues suggests that glucosinolate biosynthesis 
may follow a circadian rhythm. ConsequentIy, I investigated whether (i) time of day 
harvest, (ii) increased sulfur fertilisation, and (iii) drought-induced stress, effect the in 
vitro anticancer activity of watercress.   
.   
7.2 Results 
 
7.2.1 First  field  trial 
 
On 6
th August 2009 watercress seedlings were transplanted into three 50 yd
2 gravel 
lined concrete beds at Vitacress’ Fobdown farm in Alresford. To increase sulfur 
fertilisation, Microthiol Special fertiliser, containing 80% w/w sulfur was applied as a 
foliar spray to one of the beds two weeks after planting (Figure 7.1a). In accordance to 
the manufacturer’s guidelines the 50 yd
2 bed was sprayed with 42 g Microthiol Special 
dissolved in 2 L water.  After a further two weeks of growth, the crop was ready to 
harvest (Figure 7.1b). To introduce drought stress, water supply to the second 
watercress bed was cut off at 18:00 h the day before harvesting (see Figure 7.2 for an 
overview of the trial). Typically, harvesting would begin at approximately 07:00-08:00 h    Chapter 7: Field trials 
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Figure 7.1: Images from first field trial. 
(a) Fobdown farm manager, Ron Bainbridge applying a foliar spray of Microthiol 
Special to the sulfur fertilisation bed two weeks after the watercress seedlings were 
transplanted into the bed. (b) Myself harvesting watercress from the control bed four 
weeks after the watercress seedlings were transplanted into the bed.     
 
a) 
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Figure 7.2: Overview of first field trial. 
Three 50 yd
2 gravel lined concrete beds at Vitacress’ Fobdown farm in Alresford, 
supplied with spring water from a bore-hole were transplanted with seedlings. Two 
weeks later sulfur-rich fertiliser Microthiol Special was sprayed onto the watercress in 
the sulfur fertilisation bed. Four weeks later the watercress was ready to harvest. The 
night before harvesting the water supply was cut off to the drought bed. On the day of 
harvest, nine samples from each of the beds were collected, three from each of the 
top, middle and bottom sections of the beds at 6:00 h and then every three hours until 
midnight. Samples were also taken at 6:00 h and 9:00 h the following morning from all 
three beds and at 18:00 h for two days following the first day of harvest from the 
control and drought beds.    
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with exact start and finish time depending on weather and size of order. I decided to 
harvest at first light, which was 6:00 h and then every three hours until midnight, 
repeating the 6:00 h and 9:00 h harvests the following morning to confirm any pattern 
was circadian.  
 
Although there was no rain, shutting off the water supply to the drought bed did not 
completely dry out the bed and there was still water at the 9:00 h harvest on 9
th 
September 2009. Consequently, I decided to continue to take samples from the 
drought and control beds at 18:00 h everyday until the bed had dried out and the 
appearance of watercress no longer met quality standards. Samples were collected at 
18:00 h on the 9
th and 10
th September 2009 when there was still some water in the 
beds. However, on arriving at Fobdown at 18:00 h on 11
th September 2009 I 
discovered that the water supply had erroneously been returned to the bed and as a 
result no further samples were collected.      
 
Initially I compared the in vitro anticancer activity of watercress samples harvested at 
different times throughout the day in the MTS growth inhibition assay (Figure 7.3) and 
Nrf2 activity assay (Figure 7.4). While I carried out experimental repeats on the same 
samples, I also carried out a biological repeat on samples harvested at the same time 
but from a different part of the bed. There was no difference observed in the ability of 
any of the samples to inhibit the growth of MCF7 cells or enhance Nrf2 activity. 
 
As time of day harvest had no effect on in vitro anticancer activity of watercress, when 
examining the effect of sulfur fertilisation only watercress samples harvested at 6:00 h 
and 18:00 h from the control and sulfur treated beds were compared. A single 
treatment of watercress with a foliar spray of Microthiol Special, at an application rate 
of 21 g/L/25 yd
2 two weeks into a four week growing period, had no effect on the ability 
of watercress to inhibit the growth of MCF7 cells (Figure 7.5) or enhance Nrf2 activity 
(Figure 7.6). When comparing the control and drought stressed watercress I also 
analysed samples at 6:00 h and 18:00 h as well as samples harvested at 18:00 h on 
the following two days. Shutting off the water supply to watercress for three days to 
induce drought stress had no effect on the ability of watercress to inhibit the growth of 
MCF7 cells (Figure 7.7) or enhance Nrf2 activity (Figure 7.8). Although, it is important 
to note that the bed was never totally depleted of water, and as water supply was 
erroneously returned to the bed after four days the experiment ended prematurely.            
      Chapter 7: Field trials 
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Figure 7.3: Effect of time of harvest on the ability of crude watercress extract to 
inhibit the growth of MCF7 cells.  
(a) Representative growth inhibition experiment. MCF7 cells were treated with various 
concentrations of crude watercress extract from samples harvested at different times 
throughout the day (06:00 h ( ), 09:00 h ( ), 12:00 h ( ), 15:00 h ( ), 18:00 h ( ), 21:00 
h ( ), 00:00 h ( ), and 06:00 h ( ) and 09:00 h ( ) the following day), PEITC ( ) for use 
as a baseline or 0.5 μM STS ( ) as a positive control. Note on the graph the units for 
PEITC and STS are M. After six days metabolic activity was determined by MTS assay 
using the CellTiter 96
® AQueous One Solution reagent. Data shown are derived from 
means of duplicate wells (± SD).  (b) Mean IC50 values ± SD. Block and hatched bars 
represent biological repeats, each performed in triplicate. 
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Figure 7.4 Effect of time of harvest on the ability of crude watercress extract to 
induce ARE-driven expression.  
MCF7 cells stably transfected with ARE were treated with the indicated concentrations 
of crude watercress extract from samples harvested at different times throughout the 
day (06:00 h ( ), 09:00 h ( ), 12:00 h ( ), 15:00 h ( ), 18:00 h ( ), 21:00 h ( ), 00:00 h    
( ), and 06:00 h ( ) and 09:00 h ( ) the following day), or equivalent amounts of H2O ( ) 
as a control for 24 h and then luciferase activity determined. Data shown is mean (± 
SD) of three independent experiments. (a) and (b) represent biological repeats.   Chapter 7: Field trials 
159 
0
10
20
30
40
50
60
70
80
90
100
PEITC Ctrl MS Ctrl MS
m
e
a
n
 
I
C
5
0
 
v
a
l
u
e
 
(
µ
l
/
m
l
)
-8 -7 -6 -5 -4 -3
-10
0
10
20
30
40
50
60
70
80
90
100
110
log10 concentration (L/ml)
m
e
t
a
b
o
l
i
c
 
a
c
t
i
v
i
t
y
 
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
) a)
b)
06:00 h 18:00 h
 
 
Figure 7.5: Effect of sulfur on the ability of crude watercress extract to inhibit the 
growth of MCF7 cells.  
(a) Representative growth inhibition experiment. MCF7 cells were treated with various 
concentrations of crude watercress extract from control beds (Ctrl) harvested at 06:00 
h ( ) or 18:00 h ( ), Microthiol Special (MS) treated beds at 06:00 h ( ) or 18:00 h ( ), 
PEITC ( ) for use as a baseline or 0.5 μM STS ( ) as a positive control. Note on the 
graph the units for PEITC and STS are M. After six days metabolic activity was 
determined by MTS assay using the CellTiter 96
® AQueous One Solution reagent. Data 
shown are derived from means of duplicate wells (± SD).  (b) Mean IC50 values ± SD. 
Block and hatched bars represent biological repeats, each performed in triplicate. Data 
from the internal PEITC standard and control bed are the same as that used in Figure 
7.7 when looking at the effect of drought-induced stress.    
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Figure 7.6: Effect of sulfur on the ability of crude watercress extract to induce 
ARE-driven expression.  
MCF7 cells stably transfected with ARE were treated with the indicated concentrations 
of crude watercress extract from control beds harvested at 06:00 h ( ) or 18:00 h ( ), 
Microthiol Special (MS) treated beds at 06:00 h ( ) or 18:00 h ( ), or equivalent 
amounts of H2O ( ) as a control for 24 h and then luciferase activity determined. Data 
shown is mean (± SD) of three independent experiments. (a) and (b) represent 
biological repeats. Data from the H2O control and control bed are the same as that 
used in Figure 7.8 when looking at the effect of drought-induced stress.   Chapter 7: Field trials 
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Figure 7.7: Effect of drought on the ability of crude watercress extract to inhibit 
the growth of MCF7 cells.  
(a) Representative growth inhibition experiment. MCF7 cells were treated with various 
concentrations of crude watercress extract from control (Ctrl) beds harvested at 06:00 
h ( ), 18:00 h ( ), 18:00 h 24 h later ( ) or 48 h later ( ), or beds where water supply 
was stopped at 18:00 h the day before (Drht) and harvested at 06:00 h ( ), 18:00 h ( ), 
18:00 h 24 h later ( ) or 48 h later ( ), PEITC ( ) for use as a baseline or 0.5 μM STS     
( ) as a positive control. Note on the graph the units for PEITC and STS are M. After 
six days metabolic activity was determined by MTS assay using the CellTiter 96
® 
AQueous One Solution reagent. Data shown are derived from means of duplicate wells 
(± SD).  (b) Mean IC50 values ± SD. Block and hatched bars represent biological 
repeats, each performed in triplicate. Data from the internal PEITC standard and early 
control bed time points are the same as that used in Figure 7.5 when looking at the 
effect of sulfur fertilisation. 
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Figure 7.8: Effect of drought on the ability of crude watercress extract to induce 
ARE-driven expression.  
MCF7 cells stably transfected with ARE were treated with the indicated concentrations 
of crude watercress extract from control beds harvested at 06:00 h ( ), 18:00 h ( ), 
18:00 h 24 h later ( ) or 48 h later ( ), or beds where water supply was stopped at 
18:00 h the day before and harvested at 06:00 h ( ), 18:00 h ( ), 18:00 h 24 h later ( ) 
or 48 h later ( ), or equivalent amounts of H2O ( ) as a control for 24 h and then 
luciferase activity determined. Data shown is mean (± SD) of three independent 
experiments. (a) and (b) represent biological repeats. Data from the H2O control and 
early control bed time points are the same as that used in Figure 7.6 when looking at 
the effect of sulfur fertilisation.   Chapter 7: Field trials 
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7.2.2  Second field trial  
 
Due to the difficulties encountered in drying out the watercress bed in the first trial and 
existence of potential problems of keeping the crop dry in wet weather, using drought-
induced stress to increase in vitro anticancer activity of watercress was not pursued 
further. Instead, the second field trial focused on developing the method to increase 
sulfur fertilisation. As the trial beds at Fobdown were unavailable, the second field trial 
was carried out at Doddings Farm in Bere Regis on 7
th September 2010. The beds at 
Doddings Farm were larger and only two were available for my use, therefore in order 
to maximise the number of sulfur treatments, one of the beds was transplanted with 50 
yd
2 strips of watercress seedlings, separated by a 25 yd
2 strip. In the separate bed, 
400 g/25yd
2 of Palm Brand sulfur powder, which is 99.8% sulfur, was added as a base 
application prior to transplanting the watercress seedlings (Figure 7.9a and Figure 
7.9b). It was decided to also try the Microthiol Special fertiliser again, but using 
repeated applications as well as higher application rates. Due to the cold weather the 
watercress was growing slowly so 4 weeks after planting one of the beds was sprayed 
with 42 g Microthiol Special dissolved in 2 L water, the same as the first trial, and 
another with 84 g dissolved in 2 L water (Figure 7.9c). Two weeks later this was 
repeated, see Figure 7.10 for an overview of the trial. After a further two weeks of 
growth, the crop was ready to harvest.  
 
Crude watercress extracts from samples exposed to different sulfur fertilisation 
treatments were compared in the MTS growth inhibition assay (Figure 7.11) and Nrf2 
activity assay (Figure 7.12). There was no difference observed in the ability of any of 
the samples to inhibit the growth of MCF7 cells or enhance Nrf2 activity. In order to 
determine whether the applications of sulfur fertilisation were indeed increasing sulfur 
in the watercress, fresh samples from each of the beds were sent to Natural Resource 
Management Ltd. (NRM; Berkshire, UK) for chemical analysis of total sulfur content. 
Unfortunately there was no difference in total sulfur content between the different 
treatments (Figure 7.13). As a result, it was not thought necessary to analyse biological 
repeats. 
 
7.2.3 Third  field  trial 
 
The third field trial was again carried out at Doddings Farm in Bere Regis on 12
th April 
2011. Over two beds, six 25 yd
2 strips of watercress seedlings were transplanted, 
separated by a 25 yd
2 strip (Figure 7.14a). Analysis of the sulfur content of watercress     Chapter 7: Field trials 
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rial. Figure 7.9: Images from second field trial. 
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Figure 7.9: 
Images from 
second field 
trial. (a) Mark 
Newton applying 
a base 
application of 
sulfur powder to 
one of the beds. 
(b) Neal Thorn 
and Marc Miller 
transplanting the 
watercress 
seedlings.  
(c) Mark Newton 
applying a foliar 
spray of 
Microthiol 
Special.  
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Figure 7.10: Overview of second field trial. 
A base application of Palm Brand sulfur powder was applied to one bed prior to transplantation of four 50 yd
2 strips of watercress seedlings in 
gravel lined concrete beds supplied with spring water from a bore-hole at Vitacress’ Doddings farm in Bere Regis. Four weeks later a low and 
high application of sulfur-rich fertiliser Microthiol Special was sprayed onto the watercress. This was repeated Two week later, and the 
watercress was harvested at eight weeks. Samples were taken from each of the top, middle and bottom sections of the beds.   Chapter 7: Field trials 
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Figure 7.11: Effect of different sources of sulfur on the ability of crude 
watercress extract to inhibit the growth of MCF7 cells.  
(a) Representative growth inhibition experiment. MCF7 cells were treated with various 
concentrations of crude watercress extract from control (Ctrl;  ), Palm Brand sulfur 
powder (SP;  ), 21 g/L/25 yd
2 Microthiol Special (Low MS;  ) or 42 g/L/25 yd
2 Microthiol 
Special (High MS;  ) treated beds, PEITC ( ) for use as a baseline or 0.5 μM STS ( ) 
as a positive control. Note on the graph the units for PEITC and STS are M. After six 
days metabolic activity was determined by MTS assay using the CellTiter 96
® AQueous 
One Solution reagent. Data shown are derived from means of duplicate wells (± SD).  
(b) Mean IC50 values ± SD from three independent experiments.       Chapter 7: Field trials 
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Figure 7.12: Effect of different sources of sulfur on the ability of crude 
watercress extract to induce ARE-driven expression.  
MCF7 cells stably transfected with ARE were treated with the indicated concentrations 
of crude watercress extract from control ( ), Palm Brand sulfur powder ( ), 21 g/L/25 
yd
2 Microthiol Special ( ) or 42 g/L/25 yd
2 Microthiol Special ( ) treated beds, or 
equivalent amounts of H2O ( ) as a control for 24 h and then luciferase activity 
determined. Data shown is mean (± SD) of three independent experiments.  
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Figure 7.13: Total sulfur content of sulfur treated beds in the second field trial.  
Fresh samples from control, Palm Brand sulfur powder (SP), 21 g/L/25 yd
2 Microthiol 
Special (Low MS) or 42 g/L/25 yd
2 Microthiol Special (High MS) treated beds were sent 
to Natural Resource Management Ltd. (NRM) for chemical analysis of total sulfur 
content. Data shown is mean (± SD) of two samples, one taken from the middle 
section of the bed and the other from the bottom.  
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samples from the previous trial revealed that sulfur treatments failed to increase sulfur 
concentration. As a result I decided to try sulfur from a different source, added with and 
without citric acid anhydrous (CA) which has been shown to increase nutrient uptake 
(Baldotto et al., 2011). 200 g or 400 g of the sulfur rich fertiliser, SoluPotasse, 
containing 55.8% SO4, 50.9% K2O and 0.6% Cl, was applied as a top dressing to the 
beds in the absence or presence of 25% w/w CA one week after planting the beds 
(Figure 7.14b). As a control, one of the beds was treated with only the highest volume 
of CA. This was repeated every week for four weeks; see Figure 7.15 for an overview 
of the trial. After another weeks growth the crop was ready to harvest (Figure 7.14c).     
 
The in vitro anticancer activity of watercress samples treated with increasing amounts 
of SoluPotasse, in the absence or presence of CA, were compared in the MTS growth 
inhibition assay (Figure 7.16) and Nrf2 activity assay (Figure 7.17). All the watercress 
samples inhibited the growth of MCF7 cells and enhanced Nrf2 activity, but there were 
no difference in their ability to do so. Again, fresh samples from each of the beds were 
sent to Natural Resource Management Ltd. (NRM; Berkshire, UK) for chemical 
analysis of total sulfur content. There was no change in total sulfur content between 
samples taken from the different beds (Figure 7.18).  
 
7.3 Discussion 
 
To investigate whether the in vitro anticancer activity of watercress can be increased 
by altering environmental factors, I introduced drought stress prior to harvesting and 
increased sulfur fertilisation throughout the growing period. In addition I examined 
whether time of day harvest influenced in vitro anticancer activity of watercress.  
 
Circadian rhythms cycle through a 24 h period and are maintained endogenously by 
what is known as the circadian clock. However, these rhythms are synchronised to the 
light/dark cycle by environmental inputs such as light and temperature. In plants, many 
biochemical and physiological processes are regulated by circadian rhythms and 
confer an adaptive advantage (McClung, 2006). For example, the emission of 
attractant volatiles are controlled by circadian rhythms so that they occur when 
pollinators are at their most active (Helsper et al., 1998). The influence of light and 
temperature on glucosinolate concentration in cruciferous vegetables suggests that 
glucosinolate biosynthesis may be regulated by circadian rhythms. However, I found     Chapter 7: Field trials 
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Figure 7.14: Images from third field trial. 
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Figure 7.14: 
Images from 
third field trial. 
(a) Neal Thorn 
and Mark 
Newton 
transplanting the 
watercress 
seedlings.  
(b) Neal Thorn 
applying a top 
dressing of 
SoluPotase in 
the absence or 
prescence of 
citric acid 
anhydrous.  
(c) After five 
weeks growth, 
the watercress 
beds are ready 
to harvest.  
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Figure 7.15: Overview of third field trial. 
Six 25 yd
2 strips of watercress seedlings were transplanted in gravel lined concrete beds supplied with spring water from a bore-hole at 
Vitacress’ Doddings farm in Bere Regis. One week later a low and high application of sulfur-rich fertiliser SoluPotasse in absence or presence of 
25% w/w citric acid anhydrous (CA) was applied as a top dressing to the watercress. This was repeated every week for four weeks, before the 
watercress was harvested at five weeks. Samples were taken from each of the top, middle and bottom sections of the beds. 
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Figure 7.16: Effect of different application rates of sulfur on the ability of crude 
watercress extract to inhibit the growth of MCF7 cells.  
(a) Representative growth inhibition experiment. MCF7 cells were treated with various 
concentrations of crude watercress extract from control (Ctrl;  ), 200 g/25 yd
2 
SoluPotasse (Low SoP;  ) or 400 g/25 yd
2 SoluPotasse (High SoP;  ) treated beds, 
with (solid lines) or without (dashed lines) the addition of citric anhydrous (CA), PEITC 
( ) for use as a baseline or 0.5 μM STS ( ) as a positive control. Note on the graph the 
units for PEITC and STS are M. After six days metabolic activity was determined by 
MTS assay using the CellTiter 96
® AQueous One Solution reagent. Data shown are 
derived from means of duplicate wells (± SD).  (b) Mean IC50 values ± SD from three 
independent experiments.   
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Figure 7.17: Effect of different application rates sulfur on the ability of crude 
watercress extract to induce ARE-driven expression.  
MCF7 cells stably transfected with ARE were treated with the indicated concentrations 
of crude watercress extract from control ( ), 200 g/25 yd
2 SoluPotasse ( ) or 400 g/25 
yd
2 SoluPotasse ( ) treated beds, with (solid bars) or without (hatched bars) the 
addition of citric anhydrous (CA), or equivalent amounts of H2O ( ) as a control for 24 h 
and then luciferase activity determined. Data shown is mean (± SD) of three 
independent experiments.  
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Figure 7.18: Total sulfur content of sulfur treated beds in the third field trial.  
Fresh samples from control, 200 g/25 yd
2 SoluPotasse (Low SoP) or 400 g/25 yd
2 
SoluPotasse (High SoP) treated beds, with or without the addition of citric anhydrous 
(CA) were sent to Natural Resource Management Ltd. (NRM) for chemical analysis of 
total sulfur content. Data shown is mean (± SD) of two samples, one taken from the 
middle section of the bed and the other from the bottom.                  Chapter 7: Field trials 
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no difference in the effect of watercress samples harvested at different times 
throughout the day and night to inhibit the growth of MCF7 cells or enhance Nrf2 
activity. Interestingly, it has been reported that transcription of genes encoding 
enzymes involved in glucosinolate biosynthesis are in fact circadian regulated, peaking 
between 21:00 - 01:00 h (Pan et al., 2009). However, even if glucosinolate 
biosynthesis does follow a circadian rhythm in watercress this does not seem to 
translate to increased in vitro anticancer activity. There might not be a sufficient 
increase in glucosinolate concentration to make a detectable difference in the assays 
used, or despite an increase in glucosinolate concentration there might not be optimal 
conversion to isothiocyanates.   
 
The production of plant secondary metabolites is known to increase in response to 
water stress, specifically the drought-stress induced rise in anthocyanin content in 
grapevine has been shown to be the result of enhanced biosynthesis (Castellarin et al., 
2007). It has previously been shown that water deprivation can also increase 
glucosinolate concentration in cultivated rapeseed (Bouchereau et al., 1996; Jensen et 
al., 1996). Glucosinolate levels may be sensitive to abiotic stress as the production of 
glucosinolates is believed to be adapted as a defence mechanism to biotic stresses, 
making the plant bitter and unpalatable to predators (Rask et al., 2000). However, I 
found shutting off the water supply to watercress for three days to induce drought-
stress had no effect on the ability of the crop to inhibit the growth of MCF7 cells or 
enhance Nrf2 activity. Although, it is important to note that the bed was never totally 
depleted of water, therefore it is unlikely that the watercress was exposed to any 
drought-induced stress. In future, water deficit could be confirmed by analysis of water 
content within the plant.  
 
In initial attempts to increase sulfur fertilisation I used a foliar spray of Microthiol 
Special. This had no effect on the ability of the crude watercress extract to inhibit the 
growth of MCF7 cells or enhance Nrf2 activity. To determine whether this was due to 
an insufficient application of fertiliser in the subsequent trial I increased both 
application rate and concentration of Microthiol Special. I also tried a different source of 
sulfur in the form of Palm brand sulfur that is applied as a base fetiliser prior to 
transplanting seedlings. However, again none of the sulfur treatments had any effect 
on the ability of the crude watercress extract to inhibit the growth of MCF7 cells or 
enhance Nrf2 activity. Chemical analysis of samples by an outside company, NRM, 
revealed that the sulfur treatments failed to increase sulfur concentrations in the 
watercress. As a result, in the final trial I used another source of sulfur in the form of                 Chapter 7: Field trials 
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sulfur-rich fertiliser SoluPotasse at various application rates. This was also added with 
and without citric acid anhydrous, which has been shown to increase nutrient uptake 
(Baldotto et al., 2011). Nonetheless, total sulfur content within the watercress did not 
change following any of the treatments, and there was no change in the ability of the 
crude watercress extract to inhibit the growth of MCF7 cells or enhance Nrf2 activity. 
 
It has been widely reported that increasing sulfur fertilisation can increase 
glucosinolate concentrations in cruciferous vegetables (Falk et al., 2007; Kopsell et al., 
2007; Rosen et al., 2005). This is not wholly unsurprising as glucosinolates are sulfur 
containing compounds. Most of these studies were carried out in controlled growth 
rooms, and of those carried out in the field, the crops were grown in soil. My failure to 
increase sulfur concentrations in watercress is possibly a consequence of the open 
hydroponic system of watercress cultivation, with any nutrients introduced being 
quickly leached away.    
 
However, it should be noted that various attempts by groups to increase glucosinolate 
concentrations in broccoli by sulfur fertilisation have also been largely unsuccessful 
(Aires et al., 2006; Vallejo et al., 2003). This suggests that not all cruciferous 
vegetables may benefit from a fertilisation approach to increase glucosinolate content. 
Although, in the case of the study by Aires et al. (2006), the limited effect of sulfur (and 
nitrogen) fertilisation may be due to a concomitant increase in potassium chloride in 
the fertiliser. The authors suggest that salt-stress is responsible for the low 
glucosinolate levels. However, potassium has also been shown to specifically influence 
glucosinolate concentration. In Arabidopsis Thaliana, a small flowering plant often used 
as a model organism in plant biology, potassium deprivation was shown to increase 
glucosinolate content (Troufflard et al., 2010). As plants deficient in potassium exhibit 
traits that make them more attractive to herbivores, such as elevated sugar levels, it is 
proposed that increased glucosinolate biosynthesis has evolved as a means to 
enhance the plants resistance to attack under such conditions. In addition, while 
nitrogen fertilisation has also been shown to increase some glucosinolates in 
watercress, there is an optimum nitrogen concentration before levels start to decline 
again (Kopsell et al., 2007). This is believed to be due to the additional effect of 
nitrogen to increase tissue biomass. Therefore, as the rate of plant growth overtakes 
the rate of glucosinolate biosynthesis, the glucosinolates become diluted within the 
plant. This is likely to also account for why a study investigating the combined effect of 
nitrogen and sulfur fertilisation in cabbage, reported an increase in nitrogen to sulfur 
ratio decreased glucosinolate content (Rosen et al., 2005).                 Chapter 7: Field trials 
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This data taken together indicates a complex interplay between different minerals to 
influence overall concentrations of glucosinolates within a crop. Therefore, when 
applying fertilisers the impact of each component needs to be considered. 
Furthermore, attempts to increase glucosinolate content via nutrient fertilisation would 
perhaps achieve greater results by identifying an optimum ratio between multiple 
minerals, rather than altering a single mineral. However ultimately, with regards to 
watercress, a method to successfully increase sulfur in the crop has to be established 
before it can be determined whether this translates to increased in vitro anticancer 
activity.     
 
 
 
Chapter 8
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8.1 Summary 
 
To investigate my hypothesis that the in vitro anticancer activity of watercress can be 
enhanced by altering environmental factors, I outlined four aims. The first aim was to 
select assays to assess the in vitro anticancer effects of watercress-derived 
compounds. This was addressed in Chapter 3. Growth inhibition and activation of Nrf2-
dependent transcription were selected as candidate assays for in vitro analysis of 
crude watercress extracts.  
  
The exact mechanism by which PEITC exhibits its anticancer activity is poorly 
understood, and therefore my second aim was to explore the anticancer effects of 
PEITC. Previously in this laboratory Wang et al. (2009) demonstrated that PEITC can 
inhibit HIF activity, therefore in Chapter 4 I investigated the effect of PEITC on HIF. 
The key findings are summarised below: 
 
•  PEITC inhibits the expression of a variety of HIF target genes, as well as HIF1α 
accumulation in hypoxia treated MCF7 cells. 
•  PEITC inhibits mTORC1 activity as assessed by loss of substrate 
phosphorylation (p70 S6K and 4E-BP1). It has previously been shown that 
impaired activity of mTORC1 can effect HIF1α mRNA translation (Bernardi et 
al., 2006). 
•  PEITC-induced inhibition of mTORC1 is dependent on TSC1/2 activity, a 
negative regulator of mTORC1, but PEITC does not seem to work via any of 
the known pathways that control TSC1/2; PI3K/Akt, ERK, AMPK or REDD1.  
•  PEITC-induced inhibition of mTORC1 contributes to its growth inhibitory activity, 
albeit modestly.  
•  PEITC increases the activity of a second mTOR containing complex, mTORC2, 
seemingly independent of TSC1/2 and its effect on mTORC1.  
•  PEITC inhibits protein synthesis of HIF1α as demonstrated by 
35S-metabolic 
cell labelling.     
 
Following on from the discovery in Chapter 4 that PEITC decreases HIF1α mRNA 
translation, in Chapter 5 I investigated the effect of PEITC on total mRNA translation. 
The key findings are summarised below: 
 
•  PEITC inhibits general protein synthesis.     Chapter 8: Final discussion 
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•  PEITC-induced inhibition of total mRNA translation is not a consequence of its 
inhibition of mTORC1 activity. 
•  PEITC increases phosphorylation of key translational modulator, eIF2α, in 
MCF7 cells. 
•  PEITC also increases eIF2α phosphorylation in MEFs, and this occurs 
independently of PEITC-induced inhibition of mTORC1 activity. 
• eIF2α phosphorylation contributes to PEITC-induced inhibition of total mRNA 
translation. 
• eIF2α phosphorylation confers modest protection from PEITC-induced growth 
inhibition.  
•  PEITC increases phosphorylation of another regulator of translation, eEF2, in a 
cell specific manner.  
 
My third aim was to discover whether the assays selected in Chapter 3 were suitable 
for the analysis of a crude watercress extract. I also explored whether different 
watercress crops might possess distinct in vitro anticancer properties, as a precursor to 
direct agronomic experiments. This was addressed in Chapter 6. I demonstrated that a 
crude watercress extract can inhibit the growth of MCF7 breast cancer cells using the 
MTS assay, and enhance Nrf2-dependent transcription in a luciferase reporter assay. 
Moreover, through the analysis of two different varieties of watercress, green and red, I 
established that different watercress crops posses more in vitro anticancer activity than 
others. I also investigated the effect of a crude watercress extract on other important 
cancer pathways, shown to be modulated by PEITC in previous work. Similar to 
PEITC, I found a crude watercress extract inhibited both HIF activity and total protein 
translation. However, due to issues with practicality or assay sensitivity, neither assay 
was used as a means to assess the in vitro anticancer activity of crude watercress 
extracts collected from the field trials. 
 
The final aim, which is ultimately the crux of my hypothesis, was to investigate whether 
altering environmental factors can increase the in vitro anticancer activity of 
watercress. This was addressed in Chapter 7. I found the in vitro anticancer activity of 
crude watercress extract was unaffected by time of day harvest, increased sulfur 
fertilisation, or drought-induced stress. However, experiments were likely unsuccessful 
due to methodology, sulfur treatments failed to increase sulfur concentrations in the 
watercress, and true drought conditions were not achieved.    
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Overall, this study had two main goals, to investigate the mechanisms underlying the 
anticancer activity of PEITC, and to increase the in vitro anticancer activity of 
watercress by manipulating environmental factors.  
 
In exploring the anticancer effects of PEITC I have uncovered a novel role for PEITC in 
inhibiting HIF1α and total protein synthesis, and identified several key regulators of 
these processes, mTORC1 and eIF2α, that are modulated by PEITC. Inhibition of 
mTORC1 activity was found to contribute, albeit modestly, to PEITC-induced growth 
inhibition, while phosphorylation of eIF2α contributes in part to PEITC-induced 
inhibition of total mRNA translation. I also demonstrated that in response to PEITC 
treatment there is an increase in eEF2 phosphorylation, although this effect seems to 
be cell type specific therefore its biological relevance is unknown.  
 
mTORC1 via its substrate 4E-BP1 regulates the availability of cap binding protein 
eIF4E for association with the eIF4F complex at the 5’cap of mRNA to initiate cap-
dependent translation. It has been shown that mRNAs with complex secondary 
structures within their 5’UTR are more sensitive to changes in eIF4E (Koromilas et al., 
1992). As a result, it seems that 4E-BP1 only has translational control over a small 
subset of mRNAs, with many of these being involved in growth, proliferation and 
survival (Mamane et al., 2007). This selective inhibition of translation makes the 
mTORC1 pathway an attractive target for cancer therapy, as cancer cells are more 
dependent on growth and survival signals. Indeed, treatment with the mTORC1 
inhibitor rapamycin only reduces total protein synthesis by approximately 10-15% 
(Jefferies et al., 1994). Although, while rapamycin does inhibit phosphorylation at 
Thr70 and Ser65 sites on 4E-BP1, it does not have any effect on phosphorylation of 
Thr37 and 46, which are believed to act as priming steps for further phosphorylation at 
Thr70 and Ser65. Despite this, Torin1, which inhibits the catalytic kinase activity of 
mTOR and suppresses phosphorylation of 4E-BP1 even at the rapamycin-insensitive 
sites, only reduces total protein synthesis by a maximum of 50% (Thoreen et al., 
2009). mTORC1 can also increase the protein synthesis capacity of cells by 
upregulating specific mRNAs (often 5’TOP mRNAs) such as those encoding ribosomal 
proteins. However, although this function is sensitive to rapamycin, the exact 
mechanism by which mTORC1 increases translation of these mRNAs remains 
unknown (Pende et al., 2004).  
     
I have also demonstrated that PEITC acts as a global inhibitor of protein synthesis, at 
least in part by inducing the phosphorylation of eIF2α. Normal and transformed cells    Chapter 8: Final discussion 
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are likely to be equally sensitive to inhibition of total mRNA translation, and therefore 
this action by PEITC may prove to be toxic. As a result, it is important to appreciate the 
balance between selective and general inhibition of protein synthesis by PEITC. It is 
possible that while PEITC does inhibit global protein synthesis, a small subset of 
mRNAs with highly structured 5’-UTRs are particularly sensitive to decreased 
efficiency of translation. 
 
Furthermore, I also found that PEITC increases the phosphorylation of Akt and ERK. 
These pathways are activated in response to mitogenic signalling and therefore their 
upregulation is often associated with promoting carcinogenesis. Nonetheless, PEITC 
displays many anticarcinogenic activities in vitro and in vivo, therefore the functional 
consequences of enhanced Akt and ERK signalling are unclear. However, it should be 
noted that I only looked at early time points (2-3 h), and the increase in Akt and ERK 
phosphorylation may only be transient, possibly the result of PEITC-induced inhibition 
of mTORC1 and loss of negative feedback loops. An initial increase in Akt 
phosphorylation followed by a more sustained decrease in Akt phosphorylation has 
previously been observed in response to PEITC (Jakubikova et al., 2011). 
 
However, the key question is whether normal dietary intake of cruciferous vegetables 
is sufficient to deliver effective concentrations of ITCs to induce these molecular 
changes in vivo. In fact, a pilot study carried out in this laboratory found that consuming 
a single 80 g portion of watercress was sufficient to cause a transient decrease in 4E-
BP1 phosphorylation in PMBCs (Syed Alwi et al., 2010). Other groups have also 
demonstrated that consumption of cruciferous vegetables can modulate pathways 
associated with anticancer effects of ITCs in vivo. HDAC activity was found to be 
inhibited in PBMCs of healthy human subjects after 3 h of consuming 68 g of SFN-
enriched broccoli sprouts (Myzak et al., 2007). Whereas consumption of 85 g of raw 
watercress once a day for 8 weeks decreased several measures of DNA damage in 
peripheral blood lymphocytes (Gill et al., 2007).  
 
The second goal of this study was to try to generate a watercress cultivar with 
enhanced anticancer activity. Even though I was unsuccessful, the above data is 
encouraging and suggests that efforts to increase glucosinolate concentrations in 
crops could indeed be beneficial. Within this study I found the open hydroponic system 
used in watercress cultivation makes it difficult to increase nutrient availability or 
introduce drought-stress. As a result, altering environmental factors may not be the 
best approach to increase the in vitro anticancer activity of watercress grown on a    Chapter 8: Final discussion 
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large scale. Manipulation of genetics through selective breeding may be a better 
strategy, as used for the development of an ITC-enriched variety of broccoli (Mithen et 
al., 2003). However, enhancing the level of glucosinolates in watercress may reduce 
palatability as these compounds are responsible for the hot bitter taste of cruciferous 
vegetables (Drewnowski and Gomez-Carneros, 2000). Furthermore, while the intention 
is to generate a watercress variety with enhanced anticancer activity by increasing 
glucosinolate concentration, there is the possibility that this could in fact cause adverse 
effects, especially when considering PEITC can inhibit total protein synthesis. 
 
In addition, like 4E-BP1 phosphorylation, the molecular changes identified in this study 
could also be used as biomarkers to assess PEITC bioavailability. In that respect the 
work described in this study is also relevant in the context of clinical trials. There are 
currently two cancer clinical trials evaluating the potential chemopreventive/ 
chemotherapeutic effect of PEITC (http://www.cancer.gov/clinicaltrials). PEITC has 
been found to induce apoptosis in primary chronic lymphocytic leukaemia cells in vitro 
(Trachootham et al., 2008) and consequently a phase I trial (NCT00968461) is planned 
to determine the maximum tolerated dose of oral PEITC in patients with previously 
treated lymphoproliferative disorders. There is also a randomised and placebo-
controlled phase II trial (NCT00691132) in progress to assess the effects of oral PEITC 
in lung cancer in smokers. The primary objective of this trial is to determine the effect 
of PEITC on metabolism of the cigarette smoke procarcinogen 4-(methylnitrosoamino)-
1-(3-pyridyl)-1-butanone (NNK). Secondary objectives include histopathological 
evaluation of lung lesions and analysis of cell cycle and apoptosis biomarkers in 
bronchial tissue. Phosphorylation of p70 S6K and eIF2α may be useful biomarkers to 
monitor PEITC exposure.   
 
8.2  Suggestions for future work 
 
8.2.1  Identifying targets of PEITC  
 
Phosphorylation of eIF2α is mediated by four known kinases that are each stimulated 
by distinct environmental and cellular stresses, HRI, PKR, PERK, and GCN2 (Wek et 
al., 2006). The next step would be to determine if PEITC acts to increase eIF2α 
phosphorylation via any of these four kinases. MEF cell lines each deficient in one of 
the kinases already exist (Yerlikaya et al., 2008) and could be used to establish 
whether loss of a particular kinase prevents eIF2α phosphorylation in response to     Chapter 8: Final discussion 
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PEITC. However, considering the diverse targets of PEITC it likely activates several of 
the eIF2α kinases. As a result, it may be necessary to use small interfering RNAs 
(siRNA) or inhibitors such as hemin (HRI inhibitor) in conjunction with the MEFs, or 
indeed MEFs that are deficient for multiple eIF2α kinases, in order to identify which of 
the kinases are involved.  
 
With regards to identifying how PEITC suppresses mTORC1 activity, this study 
discovered that PEITC-induced inhibition of mTORC1 occurs in a TSC1/2-dependant 
manner. However, PEITC does not seem to work via any of the known pathways that 
control TSC1/2, namely PI3K/Akt, ERK, AMPK or REDD1. It is therefore likely that at 
this time we have gone as far as we can go to dissect this pathway. Furthermore, 
following elucidation of the kinase(s) responsible for PEITC-induced phosphorylation of 
eIF2α, the exact mechanism of their activation by PEITC will remain unknown. The 
ability for PEITC to directly modify proteins is thought to be important in PEITC-
mediated apoptosis and cell cycle arrest, however only a few proteins have been 
shown to be direct targets for ITCs. Perhaps future studies exploring the anticancer 
activity of PEITC, and indeed other ITCs, should employ new strategies to identify 
these molecular targets.   
 
Brown et al. (2009) used immobilised PEITC and affinity purification to identify 
proinflammatory cytokine macrophage migration inhibitory factor (MIF) as a binding 
targets. Lysates were resolved by SDS-PAGE and bands either analysed by 
immunoblotting, or excised and analysed by mass spectrometry. On the other hand, 
tubulin was identified as a direct binding partner for PEITC by treating cells with 
radiolabelled PEITC ([C
14]PEITC). Total protein profiles obtained by coomassie blue 
staining 2D-electrophoresis gels were overlaid with radioactivity patterns of the gels, 
allowing proteins that directly conjugate with PEITC to be identified. Proteins from 
spots of interest can then be identified by mass spectrometry (Mi et al., 2008). Using 
this method Mi et al. (2011b) identified approximately 50 potential binding targets for 
PEITC in human lung cancer A549 cells. However, a limitation of these approaches is 
that they are unable to detect transient dithiocarbamate adducts. In order to examine 
the cysteines modified in Keap-1 by SFN, a stable adduct was achieved by replacing 
the isothiocyanate group of SFN with a sulfoxythiocarbamate moiety (Ahn et al., 2010). 
These sulfoxythiocarbamate analogs are less reactive electrophiles so the adducts 
formed are more stable. However, as they are structurally different from SFN caution 
should be taken when interpreting results. McMahon et al. (2010) employed a biotin 
switch technique to convert unstable cysteine adducts to stable biotin-cysteine     Chapter 8: Final discussion 
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adducts, which could then be pulled out with streptavidin beads.   
 
Breast cancer is a highly heterogeneous disease, with distinct molecular subtypes 
giving rise to differential responses to target therapies. The majority of experiments in 
this study were carried out using only MCF7 cells, particularly those examining the 
novel role of PEITC in inhibiting HIF1α and total protein synthesis, which represent 
only one molecular subclass of breast cancer. Therefore, further work should be 
conducted to determine whether these findings are consistent with other molecular 
subtypes of breast cancer. Any variations in sensitivity between the different subtypes 
may also provide additional insight into the molecular mechanisms behind PEITCs 
mode of action. Furthermore, as mutations in the regulatory pathways of both HIF1α 
and total protein synthesis are not specific to breast cancer, this work could also be 
expanded into cancer cell lines derived from other tissues.   
      
8.2.2  Increasing the anticancer activity of watercress 
 
As already proposed, a selective breeding strategy may be a better than an 
environmental approach to increase the in vitro anticancer activity of watercress grown 
on a large scale. An ITC-enriched variety of broccoli was developed by cross breeding 
commercial broccoli with a wild variety of broccoli containing higher glucosinolate 
concentrations (Mithen et al., 2003).  
 
Similar to the wild broccoli, I found crude watercress extract from the red variety of 
watercress was more potent at inhibiting the growth of MCF7 cells and enhancing Nrf2 
activity than that from the commercial green watercress. It would be interesting to 
determine if this difference in potency was a consequence of a higher glucosinolate 
concentration. Little is known about the genetics of the red variety of watercress, but it 
may have similar origins to brown watercress, a hybrid between Nasturtium officinale 
and a wild watercress, Nasturtium microphyllum. Both are sterile and are characterised 
by purple/brown/red leaves (Stevens, 1983). The sterile nature of these varieties of 
watercress mean they can only be propagated vegetatively and are more susceptible 
to diseases. Indeed, the susceptibility of brown watercress to crook root disease is the 
reason it is no longer cultivated today. Due to disease susceptibility and coarser 
texture of red watercress, which makes it less appealing to the consumer, it might be 
beneficial to identify the genetic traits behind the enhanced in vitro anticancer activity 
of red watercress and introduce these into the genetic background of the commercial 
green watercress. Although as red watercress is sterile conventional cross-breeding    Chapter 8: Final discussion 
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techniques can not be used. The relevant gene or genes would have to be inserted 
artificially via genetic engineering. However, it should be considered that GM crops 
carry negative connotations with the consumer, which may outweigh the perceived 
benefit of enhanced anticancer activity. Subsequently it might be more favorable to 
identify other wild watercress varieties which might display increased in vitro anticancer 
activity but are not sterile so can be bred using conventional techniques.        
 
Experiments carried out during optimisation of crude watercress extract preparation, 
found watercress leaves are slightly more potent than stems at inhibiting the growth of 
MCF7 cells. Increasing the ratio of leaf to stem may therefore may be a beneficial trait 
for selective breeding. This could be achieved by reducing internodal length, the length 
of the stem between each branch of leaves, which incidentally is already part of 
Vitacress’ breeding program as a shorter internodal length makes the crop more 
aesthetically pleasing. Alternatively, plants with a higher number of leaves could be 
selected for. 
 
Furthermore, a limitation to examining crude watercress extracts is that the 
phytochemical concentrations of the ‘juice’ are undefined. As described in Section 6.3, 
total isothiocyanate content of crude watercress extracts could be quantified using a 
cyclocondensation assay. Alternatively, crude watercress extracts could be analysed 
by high-performance liquid chromatography electro-spray mass spectrometry to 
determine the types and concentrations of phytochemicals present. 
 
8.3 Final  comment 
 
In addressing the hypothesis of this study, that the in vitro anticancer activity of 
watercress can be enhanced by altering environmental factors, I have demonstrated 
the in vitro anticancer activity of PEITC and crude watercress extract. In particular, I 
have uncovered a novel role for PEITC in inhibiting HIF1α and total protein synthesis, 
and identified several key regulators of these processes that are modulated by PEITC. 
This work contributes to the understanding of the mechanisms underlying the 
anticancer activity of PEITC. However, in conclusion, manipulating environmental 
factors does not seem to be the best approach to increase the in vitro anticancer 
activity of watercress grown in the field. As I established that a different variety of 
watercress displayed more potent anticancer activity than the commercial variety, in 
the future selective breeding techniques would be better pursued instead.     
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Comparison of the ability of green and red crude watercress extract, used in the 
experiments to analyse protein synthesis, to inhibit the growth of MCF7 cells. 
Representative growth inhibition experiments. Cells were treated with various 
concentrations of crude watercress extract either from the green cultivar ( ) or the red 
cultivar ( ) alongside the experiments analysing protein synthesis (Figure 6.6), PEITC 
for use as a standard ( ) or 0.5 μM STS as a positive control ( ).Note on the graph the 
units for PEITC and STS are M. After six days metabolic activity was determined by 
MTS assay using the CellTiter 96
® AQueous One Solution reagent. Data shown are 
derived from means of duplicate wells (± SD). Table showing IC50 values represent 
mean values ± SD from three experiments. A statistically significant difference between 
IC50 values for green and red crude watercress extracts is indicated (* p<0.05).  
IC50 Value (mean ± SD) 
Green Wx  Red Wx  PEITC 
46.77 µl/ml ± 6.81  5.99 μl/ml ± 4.92*  15.04 μM ± 1.497 